

August 17-20, 2008

Bella Center

Copenhagen, Denmark



24th Annual International Conference On
Pharmacoepidemiology & Therapeutic
Risk Management

ICPE 2008

F I N A L P R O G R A M

Jointly Sponsored By:

- International Society for Pharmacoepidemiology
- International Society for Pharmacovigilance
- University of Southern Denmark

ISPE BOARD OF DIRECTORS & COMMITTEES

ICPE 2008



24th Annual International Conference On
Pharmacoepidemiology & Therapeutic
Risk Management

SCIENTIFIC PROGRAM COMMITTEE

Jesper Hallas, *Chair*

CORE PROGRAM COMMITTEE

M. Miles Braun, FISPE
Corinne de Vries
Mark H. Epstein
Luis Garcia Rodriguez
Jesper Hallas, *Chair*
Kate Lapane, FISPE
Hubert GM Leufkens, FISPE
Yola Moride, FISPE
Susana Perez-Gutthann, FISPE
June Raine
Patricia Saddier
Sebastian Schneeweiss, FISPE
Walter Straus
Robert Vander Stichele
Alexander M. Walker, FISPE

LOCAL HOST COMMITTEE

Morten Anderson
Jens Peter Balling, *Chair*
Helge Gydesen
Jesper Hallas
Christina Madsen
Merete W. Nielsen

DEVELOPMENT COMMITTEE

Annlouise R. Assaf
Dimitri Bennett
Rhonda L. Bohn, FISPE, *Chair*
Andrzej Czarnecki, FISPE
Sonia Hernandez-Diaz, FISPE
David Dore
Nancy A. Dreyer, FISPE
Mark H. Epstein
Barbra King
David E. Lilienfeld, FISPE
Hilal Maradit-Kremers
Serge Novikov
Susan Oliveria
Brian Quilliam
Matthew Reynolds
Cees Schep, FISPE
Soko Setoguchi
Nataliya Volkova
Marianne Uleickas Yood



ISPE BOARD OF DIRECTORS

OFFICERS

Yola Moride, FISPE
President
Miriam CJM Sturkenboom, FISPE
President-Elect
Allen A. Mitchell, FISPE
Immediate Past President
Corinne de Vries
Vice President, Finance
Nancy A. Dreyer, FISPE
Vice President, Finance-Elect
Mark H. Epstein
Executive Secretary

DIRECTORS

Alejandro Arana, FISPE
Ulf Bergman, FISPE
Stella Blackburn
Lynn A. Bosco
Lolkje T. de Jong-van den Berg
Daniel Fife, FISPE
Sonia Hernández-Díaz, FISPE
James D. Lewis
Daniel Mines
Nicholas D. Moore, FISPE
Robert Reynolds
Elena Rivero, FISPE
Kenneth J. Rothman, FISPE
Scott R. Smith
Alexander M. Walker, FISPE
Songlin Xue
Stan A. Edlavitch, *Lifetime Emeritus*

ORGANIZATIONAL AND INSTITUTIONAL MEMBERS

Corporate Benefactors (10-year memberships)

■ Astra Zeneca R & D ■ Pfizer

Members

Pharmaceuticals

■ Bristol-Myers Squibb ■ Roche
■ Merck Research Laboratories ■ Sanofi-Aventis
■ Pfizer ■ Wyeth

Service Provider

■ RTI Health Solutions

Academic Programs

■ Center for Clinical Epidemiology & Biostatistics,
University of Pennsylvania, School of Medicine
■ College of Pharmacy, University of Texas at Austin
■ Drug Safety Research Unit, University of Portsmouth
■ Harvard School of Public Health
■ McGill Pharmacoepidemiology & Research Unit, McGill University
■ Pharmaceutical Health Services Research, University of Maryland,
Baltimore
■ Slone Epidemiology Center, Boston University
■ University of North Carolina at Chapel Hill



ICPE ABSTRACT REVIEWERS

Michael Adena
Erica Agro
Keith Altman
Morten Andersen
Elizabeth Andrews, FISPE
Lawrence Anochie
Faranak Ansari
Alejandro Arana, FISPE
Ariel Arias
H. Michael Arrighi
Janet Arrowsmith-Lowe
Ali Artaman
Quazi Ataher
Agnes Baffoe-Bonnie
Steven Bailey
Jens Peter Balling
Andrew Bate
Annette Beiderbeck
Paul Beninger
Dimitri Bennett
Ulf Bergman, FISPE
Stella Blackburn
Angela Blackwell
William Blumentals
Joseph Blustein
Rhonda L. Bohn, FISPE
Edward A. Bortnichak
Lynn Bosco
Nancy Brandenburg
Miles Braun, FISPE
Kimberly G. Brodovicz
Alan Brookhart
Robert Bwire
Jordi Castellsague
L. Paige Chavers
Scott Chavers
Yan Chen
Lyn Colvin
Suzanne Cook
Michael Cook
Deborah Covington
Suellen Curkendall
Jeffrey Curtis
Andrzej Czarnecki, FISPE
Gerald Dal Pan
Lolkje de Jong-van den Berg
Cynthia De Luise
Corinne de Vries
Wei Dong
Marc Dorais
David Dore
Nancy A. Dreyer, FISPE
Cecile Droz-Perroteau
Stanley Edlavitch
Conference Chair Emeritus

Monique Elseviers
Carol Fairchild
Germano Ferreira
Daniel Fife, FISPE
Michael Fischer
Patricia Fraser
Lourdes Frau, FISPE
Soren Friis
Donnie Funch
Kari Furu
David Gagnon
Luis Garcia Rodriguez
Christiane Gasse
Tobias Gerhard
Andrew Gilbert
Robert Glynn
Jean-Pierre Gregoire, FISPE
Patricia Grossman
Jose Pedro Guerreiro
Joanna F. Haas, FISPE
Gillian Hall, FISPE
Jesper Hallas
Tarek A. Hammad
Niklas Hammar
Joseph Hanlon
Arshadul Haque
Janet Hardy
John Hermos
Sonia Hernández-Diaz, FISPE
Robin Hertz
Mikael Hoffmann
William Holden
Amalia Issa
Cynthia Jackevicius
Jessica Jalbert
Michele Jara
Catherine Johannes
Saga Johansson
Pamela Johnson
Judith K. Jones, FISPE
Juhaeri Juhaeri
Rachna Kasliwal
Judith Kelly
Mirjam-Colette Kempf
Alena Khromava
Victor Kiri
Olaf Klungel
Carol Koro
Edeltraut Kroger
Ludmila Kryzhanovskaya
Kiyoshi Kubota
Tobias Kurth
Stephan Lanes
Kate Lapane, FISPE
Deborah Layton

Charles Leonard
James Lewis
Michael Lewis, FISPE
Geoffrey Liu
Jeanne Loughlin
Mark Lunt
Thomas MacDonald, FISPE
Andrew Maguire
Hilal Maradit-Kremers
Ramona Mateos-Campos
Giampiero Mazzaglia
Andrew McAfee
Hans-Ulrich Melchert
Donald R. Miller
Daniel Mines
Eileen Ming
Montserrat Miret
Allen A. Mitchell, FISPE
Xiaoyao Mo
Yola Moride, FISPE
Elaine Morrato
Stephen Motsko
C. Ineke Neutel, FISPE
Mette Noergaard
Jude Nwokike
Susan Oliveria
Antoine Pariente
Byung-Joo Park, FISPE
Sallie-Anne Pearson
Susana Perez-Gutthann, FISPE
Ingemar Persson
Joseph D. Piorkowski
Jennifer Polinski
Vitali Pool
Brian Quilliam
Marsha Raebel
June Raine
Jeremy Rassen
Annie Marie Reglat
Robert Reynolds
Roelof Risselada
Elena Rivero, FISPE
Susan Sinclair Roberts
Evelyn Rodriguez, FISPE
Kenneth J. Rothman, FISPE
Annalisa Rubino
Leo Russo
Sabine Ruths
Susan Sacks, FISPE
Patricia Saddier
Maribel Salas
Nancy Santanello
Emilio Sanz
Delphine Saragoussi
Hedi Schelleman

Sebastian Schneeweiss, FISPE
Wilma Marieke Schoonen
John Seeger
Harry A. Seifert
Soko Setoguchi
Theresa Shireman
Cathy Sigler
Susan Sinclair-Roberts
Jay Sirois
Svetlana Skurtveit
Meredith Smith
Daniel Solomon
Henrik Toft Sorensen
Patrick Souverein
Paul Stang, FISPE
Margaret Stedman
Michael Steinbuch
Monika Stender
Miriam Sturkenboom
Til Sturmer, FISPE
Stephanie Tcherny-Lessenot
Lina Titievsky
Sengwee Toh
Thierry Trenque
Ilse Truter
Aage Tverdal
Marianne Ulcickas Yood
John Urquhart, FISPE
Jan Willem Van der Velden,
FISPE
Liset Van Dijk
J.W.F. van Mil
Robert Vander Stichele
Cristina Varas-Lorenzo
Zdravko Vassilev
Priscilla Velentgas
Katia Verhamme
Piet Vervae
Steven Vlad
Vera Vlahovic-Palcevski
Alexander M. Walker, FISPE
Baoguang Wang
Alex Ward
Johathan Weiner
Michael Wess
Jean-Frederic Westphal
James Wilson
Robert Wise, FISPE
Jasmanda Wu
Huiying Yang
Zhong Yuan
Xiaozheng Zhang
Rong-yuan Zheng
Wei Zhou
Gergana Zlateva

MEETING AT-A-GLANCE

Saturday, August 16, 2008

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	8:00pm	9:00pm	10:00pm	
	8:00am-5:00pm ISPE Strategic Planning Session <i>(By Invitation)</i> Dansk Design Center				Lunch		ISPE Board of Directors Meeting Dansk Design Center (Open to ISPE Members)									
					Noon-5:00pm Registration/Auditorium Foyer (Bella Center)					5:00-7:00pm Student Meet & Greet/TBA						
						1:00-5:00pm Intro to Pharmacoepi Room 18/19 (Bella Center)				5:30-7:00pm Journal Club Room 18/19 (Bella Center)						

Sunday, August 17, 2008

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	8:00pm	9:00pm	10:00pm
	8:00am-6:00pm Registration/Auditorium Foyer														
	8:00am-5:00pm Speaker Ready Room Room 7									6:00-7:30pm Welcome Reception Auditorium Foyer					
					Noon-5:00pm Exhibitor Move-In Hall A1										
	8:30-Noon Regulatory Epidemiology/PH Decision Making Auditorium 10					1:30-5:30pm Advanced Topics in Pharmacoepidemiology Auditorium 10									
	Introduction to Drug Utilization Research Auditorium 11				LUNCH ON YOUR OWN		Introduction to Risk Management Auditorium 11								
	Student Skills Workshop Room 18/19				Luncheon for New Members/Student Prize Winners/Scholarship Recipients <i>(By Invitation)</i> Bella Vista Restaurant 4/5										
					12:00-1:15pm Education Committee Mtg. Bella Vista Restaurant 3										

Monday, August 18, 2008

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	8:00pm	9:00pm	10:00pm
	7:30am-6:00pm Registration/Auditorium Foyer														
	7:30am-5:00pm Speaker Ready Room Room 7									5:00-6:00pm ISPE COUNCIL MEETINGS					
	7:30-8:15am Poster Session A Set-Up Hall A1										Govt/Regulator/ Room 16 Academic/ Room 17	5:00-6:00pm EuroDURG General Assembly Room 20			
	8:00am-6:00pm Exhibitors/Poster Session A Hall A1							3:00-3:30pm Break/Posters/ Exhibits Hall A1		3:30-5:00pm SYMPOSIUM ENCePP Aud 10 SYMPOSIUM Evaluating Benefit-Risk for Decisions Aud 11 SYMPOSIUM Observational Cohort Studies Aud 12 SYMPOSIUM Measuring Cessation Room 18/19 SYMPOSIUM Biological Medicinal Products Room 20		Industry/ Room BV 2			
	8:15-9:45am OPENING SESSION Chair: Jesper Hallas Local Welcome: Jens Peter Balling Pres. Address: Yola Moride Keynote: Mads Melbye Aud 10-12	9:45-10:30am Break/ Posters/ Exhibit Hall A1	10:30-Noon APPLIED METHODS Aud 10 CARDIOVASCULAR Aud 11 TO ERR IS HUMAN Aud 12 ANALGESICS Room 18/19 ADHERENCE Room 20		12:15-1:30pm Lunch Poster Session A Poster Walks Exhibits Hall A1 ISPE COMMITTEE/ COUNCIL MEETINGS Public Policy/ Room 16 Student Council/ Room 17 Fellowship & Awards/ Room 18A Development/ Room 18B Finance/ Room 23		1:30-3:00pm PREGNANCY EXPOSURE Aud 10 PHARMACOVIGILANCE Aud 11 PSYCHOTROPICS Aud 12 CNS DRUGS Room 18/19 RESPIRATORY MEDS Room 20						7:00-8:30pm PDS Editorial Board <i>(By Invitation)</i> Radisson SAS Scandinavian Hotel		
												7:00-10:00pm Student Social Event <i>(Check Registration Desk for details)</i>			

MEETING AT-A-GLANCE


Tuesday, August 19, 2008

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	8:00pm	9:00pm	10:00pm	
7:30am-6:00pm Registration/Auditorium Foyer																
7:30am-5:00pm Speaker Ready Room Room 7																
7:30-8:15am Poster Session B Set-Up Hall AI																
8:00am-6:00pm Exhibitors/Poster Session B Hall AI																
8:00-9:30am HOT TOPICS SESSION: Adverse Effects of Antidiabetic Therapy Aud 10-12	9:30-10:15am ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY Aud 10-12		11:00-12:30am Determinants Outcomes of Therapy Aud 10 Theoretical Methods Aud 11 Cancer Aud 12 Pharmacovigilance Room 18/19 Potpourri I Room 20 DUR SIG Special Poster Session Hall AI	12:30-2:00pm Lunch Sponsored by IB Poster Session A Poster Walk Exhibits Hall AI ISPE COMMITTEE MEETINGS Global Development/ Room 16 Membership/ Room 18A Publications/ Room 18B Bylaws & Policies/ Room 23	2:00-3:30pm Diabetes Aud 10 Therapeutic Use Aud 11 Cardiovascular Drugs Aud 12 Databases Room 18/19 Potpourri II & Late Breakers Room 20	3:30-4:00pm Break/ Posters/ Exhibits Hall AI	4:00-5:30pm SYMPOSIUM Nordic Cohort Aud 10 SYMPOSIUM Selective Prescribing Aud 11 WORKSHOP Publishing in PE Aud 12 SYMPOSIUM Concerns in Databases Room 18/19 SYMPOSIUM Linking PE & Pharmacoecon Room 20	5:30-6:30pm SIG Meds in Pregnancy Room 16 Database Room 17 Drug Use/HSR Room 20 Biologics Room 21 Molecular Epi/ Pharmacogenetics Room 23	7:30pm-Midnight Evening at Langelinie Pavillionen							

Wednesday, August 20, 2008

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	8:00pm	9:00pm	10:00pm	
7:30am-4:30pm Registration/Auditorium Foyer																
7:30am-3:30pm Speaker Ready Room Room 7											4:30-5:30pm ICPE 2009 Scientific Program Committee/ Room 16					
7:00-8:00am Poster Session C Set-Up Hall AI																
8:00am-1:45pm Exhibits/Poster Session C/Hall AI																
8:30-10:00am Psychotropic Meds in Children Aud 10 Potpourri III Aud 11 Anti-Psychotic Treatment Aud 12 Drug Safety & Insurance Policy Room 18/19 Anti-Infectives Room 20	10:00-10:30am Break/ Posters/ Exhibit Hall AI	10:30-Noon SYMPOSIUM Fetal Risks Aud 10 WORKSHOP Instrumental Variable Methods in PE Aud 11 WORKSHOP Risk Mgt Plans Aud 12 SYMPOSIUM Pharmacovigilance Room 18/19 SYMPOSIUM Safety, Costs & Use Room 20	Noon-1:30pm Lunch Poster Session C Poster Walks Exhibits Hall AI ISPE Board of Directors Luncheon Bella Vista Restaurant 4/5	1:30-2:30pm INVITED PLENARY PE: A Regulator's Perspective Aud 10-12	2:30-4:00pm PLENARY SESSION Self-Controlled Designs Aud 10-12	4:00-4:30pm THE FINAL WORD ICPE 2008 Poster Awards ICPE 2009 Providence, Rhode Island ADJOURN- MENT OF ICPE 2008 Aud 10-12										

ICPE EXHIBITORS & SPONSORS



The International Society for Pharmacoepidemiology (ISPE) gratefully acknowledges the generous support of the following organizations and institutions. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2008. Thank you.



24th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

ISPE SPONSORS

Corporate Benefactor

- Astra Zeneca R & D
- Pfizer

ANNUAL MEETING SPONSORS (as of July 24, 2008)

Platinum: \$12,500

- John Wiley & Sons
- Novartis Clinical Epidemiology
- Pfizer

Gold: \$6,500

- Amgen
- The Degge Group
- Eli Lilly & Company
- Genentech
- GlaxoSmithKline
- HealthCore
- i3 Drug Safety
- Merck Research Laboratories
- Procter & Gamble
- ProSanos/Phimap
- Roche
- RTI Health Solutions
- The MattsonJack Group
- United BioSource Corporation
- Wyeth

Silver: \$3,500

- Amylin Pharmaceuticals
- Celegne Corporation
- Johnson & Johnson Pharmaceutical R&D
- RISKMR
- Sanofi Pasteur

Bronze: \$1,500

- Allergan
 - Analysis Group
 - EpiSource
 - REGISTRAT
- ### Academic Programs
- University of Texas at Austin, College of Pharmacy
 - University of North Carolina at Chapel Hill

EXHIBITORS (as of July 24, 2008)

- | | |
|---|--|
| ■ Centre for Risk Research | ■ ProSanos/Phimap |
| ■ DrugLogic, Inc. | ■ RTI Health Solutions |
| ■ i3 Drug Safety | ■ Thomson Reuters |
| ■ GPRD | ■ The Degge Group |
| ■ HealthCore | ■ The MattsonJack Group |
| ■ IMS Health | ■ The Uppsala Monitoring Centre |
| ■ IPCI: Erasmus University Medical Center | ■ United BioSource Corporation |
| ■ John Wiley & Sons | ■ WHO Collaborating Centre for Drug Statistics Methodology |
| ■ Outcome | ■ Wolters Kluwer Health |
| ■ PharmIdeas | |
| ■ PHARMO Institute | |
| ■ Phase Forward | |
| ■ PPD | |

IN THIS PROGRAM

24th ICPE Agenda

■ Saturday	7
■ Sunday	8
■ Monday	10
■ Tuesday	19
■ Wednesday	30

24th ICPE Posters

■ Poster Presentation Guidelines	34
■ Poster Session A	36
■ Poster Session B	45
■ Poster Session C	52

24th Abstract Index

■ Abstract Index	62
■ Advertiser's Index	68

AGENDA - SATURDAY, AUGUST 16

8:00am-5:00pm

ISPE Board of Directors Meeting (Dansk Design Center)
(Open to ISPE members; notify staff if you plan to attend)

Noon-5:00pm

Registration (Auditorium Foyer/Bella Center)

PRE-CONFERENCE EDUCATIONAL SESSION

1:00-5:00pm

Introduction to Pharmacoepidemiology (Room 18/19)

[*Registration required; included as part of the full meeting registration]

Chair: Andrew McAfee

Ralph Edwards, *Spontaneous Reporting*

Andrew McAfee, *Cohort Studies*

Lolkje de Jong-van den Berg, *Case-Control Studies*

Daniel Fife, *FISPE, Confounding*

5:30-7:00pm

Journal Club (Room 18/19)

5:00-7:00pm

Student Meet and Greet (TBA)

Organized by the ISPE Student Council

BELLA CENTER


All pre-ICPE courses, ICPE, committee, council and SIG meetings will be held at the Bella Center, Center Boulevard 5, Copenhagen, Denmark.

BADGES

All attendees at ICPE 2008 must wear their name badges to all events.

A badge will be needed for admission to meeting related functions, such as the scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets for admission will be required.

Badge Legend



-  Student - YELLOW
-  New Member - BLUE
-  One Day Attendees - RED

2008

ISPE'S Third Asian Meeting



(Asian Conference on Pharmacoepidemiology/ACPE-Korea 2008)

Convened in conjunction with the Korean Society for Pharmacoepidemiology and Risk Management (KoPERM)




-  November 3-5, 2008
-  Convention Center, Grand Hilton Seoul, Korea

2009

ISPE Mid-Year Meeting 2009

-  April 25-27, 2009
-  Karolinska University Hospital
-  Stockholm, Sweden

25th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management

-  August 16-19, 2009
-  Rhode Island Convention Center
-  Providence, Rhode Island, USA

Visit the ISPE website, www.pharmacoepi.org, for meeting updates and information.

FUTURE MEETINGS

AGENDA - SUNDAY, AUGUST 17

8:00am-6:00pm

Registration
(Auditorium Foyer)

8:00am-5:00pm

Speakers' Ready
Room (Room 7)

*Admission by ticket only.
Tickets will be included in
registration materials for
those who registered for
these sessions.

PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30am-Noon

Regulatory Epidemiology/Public Health Decision Making* (Auditorium 10)

Educational Objectives

- Understand the intent and structure of regulation to protect the Public Health
- Appreciate the challenges of decision making with weak data
- Know about practical approaches typically chosen by regulators
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- Have an overview of world wide challenges for drug regulatory agencies and variation in approaches
- Know about current strategies to strengthen regulation in the face of these challenges

Chair: Gerald Dal Pan

Gerald Dal Pan, US FDA, *Regulation & Challenges of Decision Making with Weak Data*

June Raine, EMEA, *Regulatory Decision Making Approaches in Europe*

Stephen Evans, London School of Tropical Medicine, *An Epidemiologist's View of Public Health Decision Making*

Ralph Edwards, WHO Collaborating Centre for International Drug Monitoring, *Global Perspective on Regulatory Utilization of Pharmacovigilance Data*

8:30am-Noon

Introduction to Drug Utilization/Health Services Research* (Auditorium 11)

Educational Objectives

- To explain the definition and scope of the eclectic discipline of Drug Utilization Research within the context of Pharmaco-epidemiology.
- To motivate researchers providing international cross-national comparisons of national drug utilization data to cooperate on the collection of a minimal dataset of reliable and comparable drug utilization data in their country, in terms of volume, expenditures and quality of drug use.
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for drug policy research (time series analysis)

Co-Chairs: Robert Vander Stichele
& Julie Zito

Robert Vander Stichele, *Methodological Framework and Tools for Cross-National Comparisons of Drug Utilization*

Marit Rønning, *Classifying and Quantifying Drug Use for Cross National Comparison. The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose Methodology*

Monique Elseviers, *Strengths and Limitations of Drug Utilization Research Methods*

Morten Andersen, *Assessing Validity of Prescribing Quality Indicators*

Colin Dormuth, *Time Trend Analyses for Program Evaluation*

8:30am-12:00pm

Students Only - Special Skills Workshop: How Do I Get There? (Room 18/19)

[* Included as part of full meeting registration; sign-up required]
· Organized by ISPE Student Council

Co-Chairs: Imran Syed Haider &
Sengwee Darren Toh

Speakers:

Susana Perez-Gutthann, FISPE, RTI Health Solutions

Brian L. Strom, FISPE, University of Pennsylvania

Miriam CJM Sturkenboom, Erasmus University Medical Center

Claudia S. Cabrera, AstraZeneca

Frank de Vries, Universiteit Utrecht

Mara McAdams, US Food & Drug Administration

Topics include (but not limited to)

- Potential career paths upon graduation
- Factors that drive your decision
- What are recruiters looking for in a candidate
- Advice to current students

Noon-1:30pm

Lunch on your own.

AGENDA - SUNDAY, AUGUST 17

Noon-1:30pm

Luncheon for New Members/Student Prize Winners/Scholarship Recipients

(Bella Vista Restaurant-BV 4/5)

- By Invitation

Noon-1:15pm

ISPE Education Committee Meeting

(Bella Vista Restaurant-BV3)

Noon-5:00pm

Exhibitor Move-In (Hall A1)

6:00-7:30pm

Welcome Reception

(Auditorium Foyer)

· Admission by badge or ticket · Cash Bar

Welcome

Jesper Hallas, Chair, 2008 Scientific Program Committee

Yola Moride, FIPSE, ISPE President

PRE-CONFERENCE EDUCATIONAL SESSIONS

1:30-5:30pm

Advanced Topics in Pharmacoepidemiology* (Auditorium 10)

Chair: Sebastian Schneeweiss, FISPE

Doug Altman, *Indirect Comparison of Randomized Clinical Trial Results*

Ken Rothman, FISPE, *Effect Measure Modification*

Lawrence McCandless, *Bayesian Adjustments for Unmeasured Confounders in Epidemiologic Studies*

John Seeger, *Transparency in the*

Use of Propensity Scores

*Admission by ticket only. Tickets will be included in registration materials for those who registered for these sessions.

1:30-5:30pm

Introduction to Risk Management*

(Auditorium 11)

Co-Chairs: Elizabeth Andrews, FISPE, & Carla van Bennekom

Elizabeth Andrews, FISPE, *Introduction to Therapeutic Risk Management*

Stella Blackburn, *Implementation and Experiences in the EU*

Carla van Bennekom, *Examples of Risk Management Programs and Evaluations*

Judith Jones, FISPE, *Developing Risk Management Plans*

Health.

It's what we care about.

Wyeth is a global leader in pharmaceutical, biotechnology and vaccine products. We are united in a common mission with shared values and unique talents that allow us to achieve our ambitious vision: to lead the way to a healthier world.

Wyeth is proud to be a Gold Sponsor of the
24th International Conference on Pharmacoepidemiology
and Therapeutic Risk Management.

The growing epidemiology group at Wyeth addresses questions of natural history of disease, drug safety, and drug utilization. We provide consultation to colleagues in research and development, pharmacovigilance, risk management, and medical affairs.

To learn more about opportunities at Wyeth, visit us online at:

www.wyeth.com/careers

Equal Opportunity Employer M/F/D/V

Wyeth

Leading the way to a healthier world

August 17-20, 2008

Bella Center

Copenhagen, Denmark

ICPE 2008



AGENDA - MONDAY, AUGUST 18

7:30-8:15am

Poster Session A Set-up (Hall A1)

7:30am-6:00pm

Registration (Auditorium Foyer)

7:30am-5:00pm

Speakers' Ready Room (Room 7)

8:00am-6:00pm

Exhibits/Posters (Hall A1)

8:15-9:45am

OPENING SESSION (Auditorium 10-12)

▮ Welcome

Jesper Hallas, Chair, Scientific Program Committee

Jens Peter Balling, Chair, Local Host Committee

▮ Presidential Address

Yola Moride, FISPE, ISPE President

▮ Keynote Address

Mads Melbye, Statens Serum Institut, Copenhagen, *When An Entire Country is a Cohort*

9:45-10:30am

Break/Posters/ Exhibits (Hall A1)

10:30am-12:00pm

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Applied Methods (Auditorium 10)

Moderators: Til Stürmer, FISPE, & Morten Andersen

10:30am

▮ An Algorithm To Identify Antidepressant Users with a Diagnosis of Depression from Prescription Data [1]

Helga Gardarsdottir, Toine CG Egberts, Liset van Dijk, Miriam Sturkenboom, Eibert R Heerdink. (Netherlands)

Student Award Recipient – Best Methods Abstract

10:45am

▮ Active Safety Surveillance of Influenza Vaccines: Potential for Using Large Insurers' Claims [2]

Kristen Moore, M Miles Braun, Grace Lee, Martin Kulldorff, Najat Ziyadeh, Dale Burwen, Robert Ball, Sukhminder Sandhu, Richard Platt, Jeffrey Brown. (United States)

11:00am

▮ Alternative Statistical Methods for Rare Event Count Data [3]

Liping Huang, Karen Wilcock, Susan Sacks, Jamie Robinson. (United States)

11:15am

▮ Impact of Patient Visit Frequency and Physician Activity on the Weighted Analysis of a Cross Sectional Survey [4]

Patrick Blin, Nathalie Schmidely, Bruno Bregman, Florence Mercier, Coralie Poncet, Françoise Roudot-Thoraval. (France)

11:30am

▮ Re-Evaluation of SCORTEN, a Predictive Score of Mortality for Patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [5]

P Sekula, A Dunant, M Mockenhaupt, M Schumacher, A Sidoroff, S Halevy, JP Fagot, for the RegiSCAR-Study Group. (Germany)

11:45am

▮ A Validation Study of Self Reported Antiretroviral Use within a Clinical Cohort of HIV Positive Patients [6]

Emily S Brouwer, Sonia Napravnik, Amanda H Corbett, Joseph J Eron. (United States)



Working together for a healthier world™



Pfizer Epidemiology: Committed to Patient Safety

Pfizer, Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals.

With 2007 actual spending of \$8.1 billion in research & development (R&D), Pfizer has the industry's largest pharmaceutical R&D organization.

Our search for new treatments spans hundreds of research projects across forty-eight major disease groups in 10 therapeutic areas.

We build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues.

Every day we help 38 million patients, utilize the skills of more than 12,000 medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses – adding both years to life, and life to years.

The Epidemiology Group at Pfizer partners with development teams to bring new medicines to patients by providing epidemiologic research strategies throughout the development continuum.

We are committed to the conduct of research meeting the highest scientific and ethical standards to assess the benefits and risks of our medicines.

Pfizer Epidemiology is proud to support the 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management and welcomes the opportunity for the open exchange of scientific ideas and research findings in order to advance the science of pharmacoepidemiology and risk management.

AGENDA - MONDAY, AUGUST 18

Cardiovascular: Effect Modification, Genetics and Beyond

(Auditorium 11)

Moderators: Anke-Ilse Maitland & Jeanne Dieleman

10:30am

Association of Cardiovascular Drugs and NOSIAP with QTc Prolongation and Sudden Cardiac Death [7]

Charlotte van Noord, Albert-Jan LHJ Aarnoudse, Miriam CJM Sturkenboom, Sabine MJM Straus, Jacqueline CM Witteman, Bruno HCh Stricker. (Netherlands)

10:45am

Renin-Angiotensin System Polymorphisms, Use of ACE Inhibitors and the Risk of Myocardial Infarction [8]

Olaf H Klungel, Diane van Wieren-de Wijer, Anthonius de Boer, Abraham A Kroon, Paul Schiffers, Peter W de Leeuw, Bruce M Psaty, Cornelia van Duijn, Bruno HCh Stricker, Anke Hilse Maitland-van der Zee. (Netherlands)

11:00am

The Influence of Reduced Activity of Cytochrome P450 CYP2C9 and Vitamin K Epoxide Reductase Complex Subunit 1 on Anticoagulation with Acenocoumarol or Phenprocoumon [9]

Martina Teichert, Bruno Stricker, Loes Visser. (Netherlands)

11:15am

The Effect of Seven Genetic Variants on the Response to Clopidogrel [10]

Ankie M Harmsze, Jochem W van Werkum, Vera H Deneer, Henk J Ruven, Olaf H Klungel, Chris M Hackeng, Jurrien M ten Berg, Anthonius de Boer. (Netherlands)

11:30am

Risk of Hospitalization for Angioedema with Combination Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers [11]

Jennifer B Christian, Anne L Hume, Charles B Eaton, Lan Jiang, Peter D Friedmann, Kate L Lapane. (United States)

11:45am

Duration of Clopidogrel Treatment after Acute Myocardial Infarction with or without Percutaneous Coronary Intervention [12]

Rikke Sorensen, Gunnar H Gislason, Steen Z Abildstrom, Mette Madsen, Tina K Schramm, Fredrik Folke, Morten L Hansen, Lars Kober, Christian Torp-Pedersen. (Denmark)

To Err is Human, To Improve is Divine (21)

(Auditorium 12)

Moderators: Judith Jones, FISPE, & Michael Lewis, FISPE

10:30am

Effect of a Computerized Physician Order Entry (CPOE) System on Prescribing Errors and Preventable Adverse Drug Events (pADEs) [13]

J van Doormaal, R Zaal, P Mol, J Kosterink, F Haaijer-Ruskamp, A Egberts, A Lenderink, P van den Bemt. (Netherlands)

10:45am

Increasing Exposure to Drug-Drug Interactions between 1992 and 2005 in People Aged \geq 55 Years [14]

Matthijs L Becker, Loes E Visser, Teun van Gelder, Albert Hofman, Bruno HCh Stricker. (Netherlands)

11:00am

Systematic Review Examining the Prevalence and Nature of Prescribing Errors in Hospital Inpatients [15]

Penny Lewis, Kathryn Bell, Tim Dornan, David Taylor, Mary P Tully, Darren Ashcroft. (United Kingdom)

11:15am

Identifying, Understanding, and Overcoming Barriers to Medication Error Reporting in Hospitals in Nova Scotia, Canada [16]

Nicole R Hartnell, Neil J MacKinnon, Ingrid Sketris, Steven M Smith, Mark Fleming. (Canada)

11:45am

Compliance with Clinical Monitoring Guidelines for Novantrone® (Mitoxantrone) in Multiple Sclerosis [17]

Donnie Funch, Heather Norman, Judy Wong, Randy Bennett, Jill Hillier, Ahmad Al-Sabbagh, John Seeger. (United States)

AGENDA - MONDAY, AUGUST 18

Analgesics / Anti-inflammatory Drugs (2) (Room 18/19)

Moderators: James Lewis & Gunnar Gislason

10:30am

COX-2 Inhibitors Associated with Lower Risk of Hospitalization for Gastrointestinal Events Compared to Traditional NSAIDs Plus Proton Pump Inhibitors [18]

Michiel W van der Linden, Ernst J Kuipers, Myrthe P Sukel, Ron M Herings, Sabine Gaugris. (Netherlands)

10:45am

Interactions between Warfarin and Fluoroquinolones, Sulfonamides, and Azole Antifungals and the Risk of Serious Gastrointestinal Bleeding [19]

Hedi Schelleman, Warren B Bilker, Colleen M Brensinger, Xiaoyan Han, Stephen E Kimmel, Sean Hennessy. (United States)

11:15am

Use of Oral Glucocorticoids and Risk of Atrial Fibrillation/Flutter – A Population Based Case-Control Study [20]

Christian Christiansen, Steffen Christensen, Frank Mehnert, Henrik Toft Sørensen. (Denmark)

11:30am

Does the Varied Use of NSAIDs Explain the Differences in the Risk of Myocardial Infarction? [21]

Tjeerd P van Staa, Stephan Rietbrock, Efrosini Setakis, Hubert GM Leufkens. (United Kingdom)

11:45am

Increased Mortality and Cardiovascular Morbidity Associated with Use of Non-Steroidal Anti-Inflammatory Drugs in Chronic Heart Failure [22]

Gunnar H Gislason, Jeppe N Rasmussen, Emil L Fosboll, Tina K Schramm, Morten L Hansen, Fredrik Folke, Rikke Sorensen, Soren Rasmussen, Steen Z Abildstrom, Christian Torp-Pedersen. (Denmark)



What does Lilly provide to patients?

Answers.

We impact lives by delivering answers to some of the world's toughest health care questions. And, with over a century of experience behind our name, there is no one better prepared than Eli Lilly and Company to tackle these questions and the challenges of our changing industry.

We have laid the foundation for continued success with a rich pipeline of best-in-class, first-in-class pharmaceutical products and a collaborative culture that supports people in reaching their greatest potential. It is through the diverse perspectives and accomplishments of our people that we are able to touch the lives of patients by providing the medicines that will enable them to lead longer, healthier lives.

Today and in the future, Lilly will provide "Answers That Matter."

www.lilly.com

Lilly
Answers That Matter.

AGENDA - MONDAY, AUGUST 18

Adherence (Room 20)

Moderators: Brian Quilliam & Bernard Vryens

10:30am

▀ Trends in Adherence to Secondary Prevention Medications in Post-Myocardial Infarction Medicare Beneficiaries [23]

Niteesh K Choudhry, Soko Setoguchi, Raisa Levin, Wolfgang C Winkelmayr, William H Shrank. (United States)

10:45am

▀ Does Guideline Adherence Yield Better Outcomes? A Study on the Treatment of Acute Myocardial Infarction Based on Routine Data [24]

Jutta Küpper-Nybelen, Lothar Heymans, Martin Hellmich, Reinhard Griebenow, Ingrid Schubert. (Germany)

11:00am

▀ Initiation and Persistence of Warfarin or Aspirin Treatments in Chronic Atrial Fibrillation: Do the Appropriate Patients Receive Stroke Prophylaxis? [25]

Arlene M Gallagher, Stephan Rietbrock, Jonathan Plumb, Tjeerd P van Staa. (United Kingdom)

11:15am

▀ Is Adherence to Prescription Guidelines a General Trait or Dependent of Drug Type? A Multilevel Logistic Regression Analysis in Scania, Sweden [26]

Henrik Ohlsson, Juan Merlo. (Sweden)

11:30am

▀ Persistence among Osteoporotic Patients Having Started Weekly Oral Bisphosphonate Therapy [27]

Odile Sheehy, Christian Kindundu, Martin Barbeau, Jacques LeLorier. (Canada)

11:45am

▀ Primary Medication Adherence in Patients Receiving Electronic Prescriptions [28]

Michael A Fischer, Margaret Stedman, Joyce Lii, Christine Vogeli, Joel S Weissman. (United States)

12:15-1:30pm

Lunch/Poster Session A/Exhibits (Hall A1)

Poster Walks: ▀ Drug Utilization ▀ Biologics

ISPE Committee/Council Meetings

· Open to all participants. · Lunches will be available in meeting rooms

▀ Public Policy Committee (Room 16)

▀ Student Council (Room 17)

▀ Fellowship & Awards Committee (Room 18A)

▀ Development Committee (Room 18B)

▀ Finance Committee (Room 23)

Genentech
IN BUSINESS FOR LIFE

Genentech is a leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns to our stockholders, based on the continual pursuit of scientific and operational excellence.

A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States: Avastin™ (bevacizumab), Tarceva™ (erlotinib), Rituxan® (Rituximab), Herceptin® (Trastuzumab), Lucentis® (Ranibizumab), Xolair® (Omalizumab), RAPTIVA® (efalizumab), TNKase™ (Tenecteplase), Activase® (Alteplase, recombinant), Cathflo™ Activase® (Alteplase, Nutropin® [somatropin (rDNA origin) for injection], Nutropin AQ® [somatropin (rDNA origin) injection], Pulmozyme® (dornase alfa, recombinant).



EPIDEMIOLOGY

The Genentech Epidemiology group provides evidence-based epidemiology strategy, expertise and data to optimize Genentech's therapeutic molecule selection, development, and commercialization. Our activities range from estimating disease incidence and prevalence, describing clinical course of disease and real world treatment practices and providing epidemiological context for adverse events, to collaborating in the design, analysis, and reporting of observational studies and patient registries.

CONTACT INFORMATION

Genentech, Inc. - 1 DNA Way, South San Francisco, CA 94080-4990
Phone: (650) 225-1000 - www.gene.com

AGENDA - MONDAY, AUGUST 18

1:30-3:00pm

CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Pregnancy Exposures and Adverse

Outcomes: From Erection to Resurrection (Auditorium 10)

Moderators: Susan Roberts & Elizabeth Andrews, FISPE

1:30pm

▮ **Impact of Prior Prenatal Testing on Birth Defect Prevalence in Pregnancy Exposure Registries [29]**

Deborah Covington, Susan S Roberts, Laura McKain. (United States)

1:45pm

▮ **Maternal Use of Fluconazole and Risk of Congenital Malformations: A Danish Population-Based Cohort Study [30]**

Mette Nørgaard, Lars Pedersen, Mette Gislum, Rune Erichsen, Kirstine K Sogaard, Henrik C Schønheyder, Henrik T Sørensen. (Denmark)

2:00pm

▮ **Antifungal Medications and the Risk of Hypoplastic Left Heart Syndrome [31]**

Carol Louik, Martha M Werler, Allen A Mitchell. (United States)

2:15pm

▮ **Lamotrigine and Orofacial Clefts [32]**

Janneke Jentink, Helen Dolk, Maria Loane, Joan Morris, Lolkje TW De Jong-van den Berg. (Netherlands)

2:30pm

▮ **Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension [33]**

Sengwee Toh, Allen A Mitchell, Christina D Chambers, Carol Louik, Martha M Werler, Sonia Hernandez-Diaz. (United States)

2:45pm

▮ **Stillbirth and Early Neonatal Death Risk Is Reduced in Those Using Analogue Compared with Those Using Human Insulin [34]**

Corinne de Vries, Julia Snowball, David Russell-Jones, Annie Hutchison. (United Kingdom)

Methods for Pharmacovigilance

(Auditorium 11)

Moderators: Andrzej Czarnecki, FISPE, & Juergen Dinger

1:30pm

▮ **Patterns of Adverse Event Reporting for Four Members of the Angiotensin II Receptor Blockers Class of Drugs: Revisiting the Weber Effect [35]**

Mara A McAdams, Kate Gelperin, Laura A Governale, Lynette Swartz, Tarek A Hammad, Gerald J Dal Pan. (United States)

1:45pm

▮ **Exploring the Relationship of a Statistical Alerts and Clinical Relevance [36]**

Sheila R Weiss Smith, Stephanie Chung, Deborah A Sturpe, Guarav Desphande, Bryan Hayes, Victor Gogolak. (United States)

2:00pm

▮ **The Index of Blame: Agreement between Subjective vs. Objective Designation of "Suspect" Drugs in Pharmacovigilance [37]**

Alan M Hochberg, Ronald K Pearson. (United States)

2:15pm

▮ **Drug-Drug-ADR Screening in Spontaneous Reports as a Tool for Detecting Clustered Reporting and Brand Name Confusion [38]**

Johanna Strandell, Niklas G Norén, Andrew Bate, Ralph I Edwards. (Sweden)

2:30pm

▮ **Signal Detection of Rosuvastatin by a Novel Data Mining Approach in Health Insurance Claims Database [39]**

Nam-Kyong Choi, Yoosoo Chang, Seokyoung Hahn, Byung-Joo Park. (Republic of Korea)

2:45pm

▮ **Web-Based Intensive Monitoring, a Promising Method for Active Surveillance of New Drugs [40]**

Kees van Grootheest, Linda Härmark, Ingrid Oosterhuis, Eugène P van Puijenbroek. (Netherlands)

AGENDA - MONDAY, AUGUST 18

Psychotropics: Utilization and Risks (Auditorium 12)

Moderators: Dan Mines & Julie Zito

1:30pm

D Factors Associated to the Initiation of Psychoactive Drug Use in a Sample of Healthy Workers in France: Results of the VISAT Study [41]

Olivia Boeuf-Cazou, Jean-Claude Marquie, Maryse Lapeyre-Mestre. (France)

1:45pm

D Selective Prescribing and Channeling of Antipsychotics: Baseline Data from the French Prospective Cohort Study on Schizophrenia [42]

L Abenham, F Rouillon, H Verdoux, B Falissard, J Benichou, M Rossignol, P Blin, F Depont, B Astruc. (France)

2:00pm

D Better Persistence on Treatment with Escitalopram Compared with Citalopram [43]

Larry Ereshefsky, Nicolas Despiégl, Khaled Maman, Clément François, Delphine Saragoussi. (France)

2:15pm

D No Increase in Risk of Road Traffic Accidents after Prescriptions of Mood Stabilizers [44]

Jørgen G Bramness, Svetlana Skurtveit, Ineke Neutel, Jørg Mørland, Anders Engeland. (Norway)

2:30pm

D Patterns of Patient Monitoring after Initiation of Antidepressant Medications [45]

Joshua J Gagne, Philip S Wang, Sebastian Schneeweiss. (United States)

2:45pm

D Fatal and Non-Fatal Pneumonia Associated with Atypical and Typical Antipsychotic Use in Elderly Patients [46]

Gianluca Trifiro, Elif F Sen, Achille P Caputi, Miriam CJM Sturkenboom. (Netherlands)

CNS Drugs and Health Outcomes

(Room 18/19)

Moderators: Paul Stang, FISPE, & Edward Bortnichak

1:30pm

D Atypical Antipsychotic Use and Risk of Fracture in Persons with Parkinson's Disease [47]

David D Dore, Amal N Trivedi, Vincent Mor, Joseph H Friedman, Kate L Lapane. (United States)

1:45pm

D Risk of Ischemic Events among Patients with Parkinson's Disease Using Dopamine Agonists [48]

Maurits EL Arbouw, Kris LL Movig, Henk-Jan Guchelaar, Kees Neef, Toine CG Egberts. (Netherlands)

2:00pm

D Taking Low Dose Aspirin Is Associated with More Stable Drug Treatment for Lithium Users [49]

Pieter Stolk, Patrick C Souverein, Ingeborg Wilting, Hubert GM Leufkens, Donald F Klein, Stanley I Rapoport, Eibert R Heerdink. (Netherlands)

2:15pm

D ACE Inhibitors Are Associated with Complex Regional Pain Syndrome (CRPS) [50]

Marissa de Mos, Bruno HCh Stricker, Frank JPM Huygen, Jeanne P Dieleman, Miriam CJM Sturkenboom. (Netherlands)

2:30pm

D Seizures in a Pediatric Population Treated with Atomoxetine or Stimulant Medications [51]

Andrew T McAfee, Joan Landon, Meghan E Jones, Mark E Bangs, Nayan Acharya, Kenneth Hornbuckle, Judy Wong. (United States)

2:45pm

D Exploring Channelling Bias of Anti-Epileptic Drugs in Epilepsy Patients in a US Claims Database and a UK General Practice Database [52]

Lianna Ishihara-Paul, David J Webb, Maneesh Juneja, Ponmani Kanakaraj, John Weil. (United Kingdom)

AGENDA - MONDAY, AUGUST 18

Respiratory Medications and Health Outcomes (Room 20)

Moderators: Colin Dormouth & Jordi Castellsague

1:30pm

▀ Long-Acting Beta Agonists and Risk of Death and Asthma Exacerbation [53]

Tobias Kurth, Heather Norman, Carlos Fernandez Vidaurre, John Seeger. (United States)

1:45pm

▀ Inhaled Anticholinergic Drugs and Risk of Acute Urinary Retention [54]

Ana SM Afonso, Katia MC Verhamme, Bruno Ch Stricker, Guy GO Brusselle, Miriam CJM Sturkenboom. (Netherlands)

2:00pm

▀ Does Asthma Medication Increase the Risk of Dental Caries among Children? [55]

Régis Blais, Jean-Marc Brodeur, Claudine Laurier, Christophe Bedos. (Canada)

2:15pm

▀ Palivizumab Utilization and Compliance with Recommendations in Florida [56]

Christian Hampp, Almut G Winterstein, Arwa Saidi, Huazhi Liu. (United States)

Student Award Recipient - Best Drug Utilization Abstract

2:30pm

▀ Treatment and Survival in Patients with Pulmonary Arterial Hypertension (PAH) [57]

Hilal Maradit Kremers, Joshua P Slusser, Christopher G Scott, Paola Primatesta, Michael D McGoan. (United States)

3:00-3:30pm

Break/Posters/Exhibits (Hall A1)



Celebrating 20 years of Consulting and Research in Drug Safety and Pharmacoepidemiology!

Proud sponsor of this year's International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Please visit our website at <http://www.deggegroup.com> to learn more about us.

AGENDA - MONDAY, AUGUST 18

3:30-5:00pm

CONCURRENT SESSIONS: SYMPOSIA

SYMPOSIUM: A European Network of Centres for Pharmacovigilance and Pharmacoepidemiology (ENCePP) [58] (Auditorium 10)

▮ **Noel A Wathion, Stella Blackburn, Xavier Kurz, Ingemar R Persson, Yola Moride, Miriam CJM Sturkenboom** (Sweden)

SYMPOSIUM: Evaluating Quantitative Benefit-Risk Analysis for Drug-Approval Decision Making in Europe and the United States [59] (Auditorium 11)

▮ **Bruno Flamion, Michael Arrighi, Reed Johnson, Susana Perez** (United States)

SYMPOSIUM: Recent Advances in Statistical Methods for Analyzing Observational Cohort Studies: New Opportunities for Pharmaco-Epidemiology [60] (Auditorium 12)

▮ **M Abrahamowicz, R Cook, P Gustafson, P Royston, W Sauerbrei** (Canada)

SYMPOSIUM: Practical Issues in Measuring Cessation and Re-Initiation of Drug Use in Databases [61] (Room 18/19)

▮ **Morten Andersen, M Alan Brookhart, Robert J Glynn, Henrik Stovring, Til Stürmer** (United States)

SYMPOSIUM: Biological Medicinal Products: Special Considerations for Pharmacoepidemiology and Risk Management [62] (Room 20)

▮ **Wei Dong, Judith K Jones, HGM Leufkens, Joanna F Haas** (United States)

5:00-6:00pm

ISPE Council Meetings

Open to all interested participants.

- ▮ **Government/Regulatory Council** (Room 16)
- ▮ **Academic Council** (Room 17)
- ▮ **Industry Council** (Room BV2)
- ▮ **EuroDURG General Assembly** (Room 20)


7:00-8:30pm

PDS Editorial Board (Helsinki Room, Radisson SAS Scandinavia Hotel)
- **By Invitation**

7:00-10:00pm

**Student Social Event -
A Night Out in Copenhagen**

Open to all students.
Organized by the ISPE Student Council



AGENDA - TUESDAY, AUGUST 19

7:30-8:15am

Poster Session B Set-up (Hall A1)

7:30am-6:00pm

Registration (Auditorium Foyer)

7:30am-5:00pm

Speakers' Ready Room (Room 7)

8:00am-6:00pm

Exhibits/Posters (Hall A1)

8:00-9:30am

PLENARY SESSION (Auditorium 10-12)

Hot Topics Session: Adverse Effects of Antidiabetic Therapy

Chair:


Stephen Evans

Speakers:

Jerry Avorn, FISPE

Stephen Evans

John Ioannidis



Copenhagen, Denmark

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that bring population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases
- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug uses and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development

Please visit our website at <http://epidemiology.gsk.com/organization.html> to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Developing talent through equality of opportunity



AGENDA - TUESDAY, AUGUST 19

9:30-10:15am

ANNUAL MEETING OF ISPE

MEMBERS & AWARDS CEREMONY (Auditorium 10-12)

·Open to all participants.

Annual Meeting of ISPE Members

- ▀ **Yola Moride**, FISPE, ISPE President
- ▀ **Corinne de Vries**, ISPE Vice President Finance



Awards Ceremony

ICPE 2008

- ▀ **Jens Peter Balling**, Chair, Local Host Committee
- ▀ **Jesper Hallas**, Chair, 2008 Scientific Program Committee

Student Awards

- ▀ **Presented by Jesper Hallas**, Chair, 2008 Scientific Program Committee

Best Drug Utilization Abstract: **Christian Hampp**, University of Florida, *Palivizumab Utilization and Compliance with Recommendations in Florida* [56]

Best Methods Abstracts: **Helga Gardarsdottir**, Utrecht University, *An Algorithm To Identify Antidepressant Users with a Diagnosis of Depression from Prescription Data* [1]

Third Best Abstract: **Annette Østergaard Jensen**, Aarhus University Hospital, *Use of Photosensitizing Diuretics and Risk of Skin Cancer: A Population Based Case Control Study* [247]

Second Best Abstract: **Adela Corina Boila**, University of Medicine and Pharmacy Targu-Mures, *Diuretics and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study* [540]

Edlavitch Award (Best Abstract): **Jochem G. Gregoor**, Utrecht University, *Polymorphisms of the LEP- and LEPR Gene and Obesity in Psychiatric Patients Using Antipsychotic Medication* [463]

Induction of ISPE Fellow (FISPE)

- ▀ **Allen A. Mitchell**, FISPE, Chair, Fellowship & Awards Committee

Inductees:

Andrzej Czarnecki, FISPE **Joanna F. Haas**, FISPE
Jean-Pierre Grégoire, FISPE **Sonia Hernández-Díaz**, FISPE

ISPE-PDS Prizes for Best Papers Published in PDS Volume 16 (2007)

- ▀ **Presented by Ronald D. Mann**, FISPE, Editor-in-Chief, **Brian Strom**, FISPE, Regional Editor for the Americas, **Joerg Hasford**, Regional Editor for Europe, and **Richard Hughes**, Managing Editor, *Pharmacoepidemiology & Drug Safety* (PDS)

10:15-11:00am

Break/Posters/Exhibits (Hall A1)



ICPE 2008



24th Annual International Conference on
Pharmacoepidemiology & Therapeutic
Risk Management

AGENDA - TUESDAY, AUGUST 19

11:00am-12:30pm

CONCURRENT SESSIONS - CONTRIBUTED PAPERS

Surprising Determinants and Outcomes of Therapy (Auditorium 10)

Moderators: Alec Walker, FIPSE, & Walter Straus

11:00am

▮ **Stopping Hormone Replacement Therapy (HRT), What's Next?** [235]

Stefan Vegter, Pieterneel Kolling, Marjolein Toben, Paul B van den Berg, Lolkje TW de Jong-van den Berg. (Netherlands)

11:15am

▮ **Contraceptive Efficacy of Oral Contraceptives under Real Life Conditions: The Impact of a 24-Day Regimen on Contraceptive Effectiveness** [236]

Juergen Dinger, Anita Assmann, Mathias Altmann. (Germany)

11:30am

▮ **Setting Prices for Generic Medications: A Survey of Patients Perceptions** [237]

Niteesh K Choudhry, Emily Cox, Michael A Fischer, Jyotsna Mehta, William H Shrank. (United States)

11:45am

▮ **Prescribing Quality Indicators for Cardiovascular Treatment in Type 2 Diabetes: Should We Assess Treatment Decisions over Time?** [238]

Jaco Voorham, Flora M Haaijer-Ruskamp, Bruce H Wolffenbuttel, Ronald P Stolk, Petra Denig, GIANTT Group. (Netherlands)

12:00pm

▮ **Pharmacologically Inappropriate Prescriptions for Elderly Patients in General Practice - How Common? Baseline Data from the Prescription Peer Academic Detailing (Rx-PAD) Study** [239]

Mette Brekke, Rognstad Sture, Joerund Straand, Kari Furu, Svein Gjelstad, Trine Bjoerner, Ingvild Dalen. (Norway)

12:15pm

▮ **The Effect of Altitude on Erythropoietin Dosing and Achieved Hematocrit Levels in End-Stage Renal Disease** [240]

M Alan Brookhart, Sebastian Schneeweiss, Jerry Avorn, Brian D Bradbury, Kenneth J Rothman, Jyotsna Mehta, Michael Fischer, Wolfgang Winkelmayr. (United States)

11:00am-12:30pm

DUR SIG SPECIAL POSTER SESSION

Resources for Cross-National Comparison of Drug Utilization Data: Results of a SIGDUR/EuroDURG Survey (Hall A1)

(Special poster session. Note: these posters will be up Monday-Wednesday)

Co-Chairs: Monique Elseviers, Vera Vlahovic-Palcevski & Katrin Janhsen

Theoretical Methods (Auditorium 11)

Moderators: Gergana Zlateva & Henrik Sørensen

11:00am

▮ **Doubly Robust Estimation under Realistic Conditions of Model Misspecification** [241]

Michele L Jonsson Funk, Daniel Westreich. (United States)

11:15am

▮ **Performance of Disease Risk Scores in Case-Control Studies** [242]

Patrick G Arbogast, Lisa Kaltenbach, Wayne A Ray. (United States)

11:30am

▮ **Propensity Score Calibration in the Absence of Surrogacy** [243]

Mark Lunt, Robert J Glynn, Kenneth J Rothman, Jerry Avorn, Til Stürmer. (United States)

11:45am

▮ **Using Tree-Based Survival Analysis To Identify Risk Factors Associated with the Onset of Cardiovascular Events among SLE Patients** [244]

Liping Huang, Karen Wilcock. (United States)

12:00pm

▮ **A Method for Estimating the Completeness of a Literature Search** [245]

Charlie H Goldsmith, Gary Foster. (Canada)

12:15pm

▮ **A Consideration on Sample Size Determination for Stratified Case-Cohort Studies** [246]

Akira Wakana, Kiyoshi Kubota. (Japan)

AGENDA - TUESDAY, AUGUST 19

Cancer (Auditorium 12)

Moderators: Laurel Habel and Soren Friis

11:00am

Use of Photosensitizing Diuretics and Risk of Skin Cancer: A Population Based Case Control Study [247]

Annette O Jensen, Henrik F Thomsen, Anne B Olesen, Henrik T Sorensen, Margaret R Karagas. (Denmark)

Student Award Recipient - Third Best Abstract

11:15am

Occurrence of Lymphoma among Patients with Atopic Dermatitis and/or Treated with Topical Immunosuppressants in the United Kingdom [248]

Felix M Arellano, Alejandro Arana, Charles E Wentworth III, Eulogio Conde, Carlos Fernandez-Vidaurre, Raymond Schlienger. (Spain)

11:30am

Topical Treatments for Atopic Dermatitis and Comparative Risk of Lymphoma [249]

Sebastian Schneeweiss, Mike Doherty, Shao Zhu, Donnie Funch, Raymond G Schlienger, Carlos Fernandez Vidaurre, John D Seeger. (United States)

1:45am

Short-Term Exposure to Pioglitazone Is Not Associated with an Increased Risk of Cancer at the 10 Most Common Sites [250]

Assiamira Ferrara, Laurel A Habel, James D Lewis, Stephen K Van Den Eeden, Brian L Strom, Charles P Quesenberry. (United States)

12:00pm

Recombinant Human Bone Morphogenetic Protein-2 and Pancreatic Cancer: A Retrospective Cohort Study [251]

Gregory S Cooper, Daniel Mines, Yun Gu. (United States)

12:15pm

Use of Thiazolidinediones for Elderly Diabetic Patients with Cardiac Disease [252]

Jong-Mi Seong, Nam-Kyong Choi, Sun-Young Jung, Yoosoo Chang, Ye-Jee Kim, Byung-Joo Park. (Korea)

Clinical • Medical • Post-Market



QSCAN[®]

Safety for the Real World

Advanced Analytics
Workflow Control/SOPs
RiskMAPs and REMS

Pharmacovigilance

SafeStart HostingSM
Multi-Database Access
Regulatory Reporting

 **DrugLogic[®]**
Your Partner in Risk Management

www.druglogic.com

See you at ISPE • Copenhagen • August 17-20, 2008

AGENDA - TUESDAY, AUGUST 19

Investigations in Pharmacovigilance (Room 18/19)

Moderators: M. Miles Braun, FISPE, & Paul Beninger

11:00am

D Tramadol Dependence: A Survey of Spontaneously Reported Cases in Sweden [253]

Micaela Tjäderborn, Anna K Jönsson, Johan Ahlner, Staffan Hägg, (Sweden)

11:15am

D Kawasaki Disease after Vaccination: Reports to the Vaccine Adverse Event Reporting System (VAERS) 1990-2007 [254]

Wei Hua, Hector S Izurieta, Barbara Slade, Ermias Belay, Penina Haber, Rosemary Tiernan, Emily Jane Woo, John Iskander, M Miles Braun, Robert Ball. (United States)

11:30am

D Combined Pioglitazone-Insulin Use: Analysis from the Pioglitazone Prescription-Event Monitoring Study [255]

Rachna Kasliwal, Victoria Cornelius, Lynda V Wilton, Saad AW Shakir. (United Kingdom)

11:45am

D Photochemical and Other Molecular Characteristics and the Risk of Drug-Related Photosensitivity [256]

BM Verdel, PC Souverein, RHB Meyboom, HGM Leufkens, ACG Egberts. (Netherlands)

12:00pm

D GPRD for Proactive Safety Surveillance of a Rare Outcome: The Example of Bone Marrow Fibrosis among Patients with ITP [257]

Diego Wyszynski, Chuck Wentworth, Steven Cha, Victor Gastanaga, George

12:15pm

D Anaphylaxis after Measles, Mumps and Rubella (MMR) Vaccine during 2006-7 in the U.S. [258]

Hector S Izurieta, Steven K Tobler, Patrick M Garman, Wei Hua, Penina Haber, John Iskander, M Miles Braun, Robert Ball. (United States)

Potpourri I (Room 20)

Moderators: Ron Herings, FISPE, & Hedi Schelleman

11:00am

D Comparative Effectiveness of Osteoporosis Drugs for Nonvertebral Fracture Prevention [259]

Suzanne M Cadarette, Jeffrey N Katz, M Alan Brookhart, Til Stürmer, Margaret R Stedman, Daniel H Solomon. (United States)

11:15am

D Definition of Chronic Kidney Disease by Creatinine Based Methods May Be Strongly Misleading in Patients with Diabetes [260]

Dietrich Rothenbacher, Qiu-Li Zhang, Nuria Riera-Guardia, Wolfgang Koenig, Hermann Brenner. (Germany)

11:30am

D Cohort Effect or Selective Prescribing by Indication in the Prescription of New Atypical Antipsychotic in Schizophrenia? [261]

L Abenham, B Astruc, H Verdoux, B Falissard, J Benichou, M Rossignol, P Blin, F Depont, F Rouillon. (France)

11:45am

D Mortality and Long-Lasting Sequelae in Patients with Severe Cutaneous Adverse Reactions [262]

M Mockenhaupt, P Sekula, JC Roujeau, A Sidoroff, S Kardaun, Y Liss, M Bounoua, for the RegiSCAR-Study Group. (Germany)

12:00pm

D Impact of Severe Premenstrual Disorders on Work, Daily Life, Social Relations, and Quality of Life: Preliminary Results of a Multinational Follow-Up Study [263]

Anita Assmann, Juergen Dinger, Anna Filonenko, Do Minh Thai, Lothar Heinemann. (Germany)

12:15pm

D Safety Assessment after Recall of Haemophilus influenzae Type B (Hib) Vaccine — United States, 2007-2008 [264]

WT Huang, S Chang, ER Miller, EJ Woo, AR Hoffmaster, JE Gee, T Clark, J Iskander, R Ball, K Broder. (United States)

AGENDA - TUESDAY, AUGUST 19

12:30-2:00pm

Lunch/Poster Session B/Exhibits (Hall A1)

-Sponsored by i3 Drug Safety

Poster Walk: **D Medicines in Pregnancy**

ISPE Committee Meetings

- Open to all participants.
- *Lunches will be available in meeting rooms*

D Global Development Committee (Room 16)

D Membership Committee (Room 18A)

D Publications Committee (Room 18B)

D Bylaws and Policies Committee (Room 23)

2:00-3:30pm

CONCURRENT SESSIONS - CONTRIBUTED PAPERS

Diabetes: Treatment Related Risks and Benefits (Auditorium 10)

Moderators: Donald Miller & Hubert GM Leufkens, FISPE

2:00pm

D Cardiovascular Disease Risks with Rosiglitazone and Pioglitazone Use in U.S. Veterans [266]

Donald R Miller, Cindy Christiansen, Madhuri Palnatti, Jean-Philippe LaFrance, Leonard Pogach, Francesca Cunningham. (United States)

2:15pm

D Determinants of Stopping Treatment with Oral Antidiabetic Drugs in Daily Practice [267]

Fernie JA Penning-van Beest, Sjoukje van der Bij, Joelle A Erkens, Heather Falvey, Ron MC Herings. (Netherlands)

2:30pm

D Risk Factors for Thiazolidine-Related Peripheral Edema [268]

Patricia Tennis, Neil Roskell, Elizabeth Andrews, Kenneth J Rothman. (United States)

2:45pm

D Assessing Returns from Recommended Medication Use by US Medicare Beneficiaries with Diabetes [269]

Bruce Stuart, Linda Simoni-Wastila, Lirong Zhao, Jalpa Doshi. (United States)

3:00pm

D ACE-Inhibitors and Angiotensinogen M235T Variant Interact in Type 2 Diabetes Mellitus Risk [270]

Mark Eijgelsheim, Olaf H Klungel, Bruno H Stricker. (Netherlands)

3:15pm

D Reduced Risk of Hypoglycaemia in Analogue Compared with Human Insulin: An Observational Study in the UK [271]

Annie Hutchison, David Russell-Jones, Victoria Hordern, Corinne S de Vries. (United Kingdom)

AGENDA - TUESDAY, AUGUST 19

Quality and Appropriateness of Therapeutic Use (Auditorium 11)

Moderators: Lynn Bosco & Steven Bailey

2:00pm

■ The Validity of Treatment Gaps in the Evaluation of Pharmacotherapy Adherence Following Acute Myocardial Infarction [622]

Jeppe N Rasmussen, Gunnar H Gislasen, Soren Rasmussen, Mette Madsen, David A Alter. (Denmark)

2:15pm

■ Effect of Regulatory Warnings on Antipsychotic Prescribing for Nursing Home Residents with Dementia [273]

Tobias Gerhard, Judith Lucas, Mark Olfson, Donald Hoover, Ece Kalay, Stephen Crystal. (United States)

2:30pm

■ Trends in Treatment for Pediatric Depression – Before and after FDA Advisory on Risk of Suicidality with Antidepressants [274]

Shih-Yin Chen, Sengwee Toh. (United States)

2:45pm

■ What Impact Has Restrictions on Use of COX-2 Inhibitors Had in Ireland? [275]

Kathleen Bennett, Mary Teeling, John Feely. (Ireland)

3:00pm

■ Savings from a State-Funded Program of Academic Detailing [276]

Michelle K Spetman, Sebastian Schneeweiss, Frank W May, Jerry Avorn. (United States)

3:15pm

■ Pattern and Prevalence of Herbal and Dietary Supplements in an Elderly Cohort: AGES-Reykjavik Study [277]

Vilborg Halldorsdottir, Anna Birna Almarsdottir, Adalsteinn Gudmundsson, Hjalmarfridur Nikulasdottir, Tamara B Harris, Lenore Launer, Gudny Eiriksdottir, Vilmundur Gudnason. (Iceland)

Cardiovascular Drugs and Outcomes (Auditorium 12)

Moderators: Nicholas Moore, FISPE, & Christina Varas-Lorenzo

2:00pm

■ A Cohort Study of Venous Thromboembolism, Anticoagulant Use, and Subsequent Cardiovascular Disease [278]

Robert J Glynn, Til Stürmer, Helen Mogun, Sebastian Schneeweiss. (United States)

2:15pm

■ Association Between Calcium Channel Blockers and Gingival Hyperplasia [283]

Gaganpreet Kaur, Katia MC Verhamme, Jeanne P Dieleman, Ann Vanrolleghem, Eva M van Soest, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)

2:30pm

■ Preadmission Statin Use and One-Year Mortality Among Intensive Care Patients [280]

Steffen Christensen, Reimar W Thomsen, Martin B Johansen, Lars Pedersen, Henrik T Sørensen. (Denmark)

2:45pm

■ Withdrawal of Endothelium Affecting Drugs and Risk of Subarachnoid Hemorrhage (SAH) [281]

R Risselada, H Straatman, R Herings, M Sturkenboom. (Netherlands)

3:00pm

■ Short-Acting Dihydropyridine Calcium Channel Blockers and Risk of Stroke Occurrence in Elderly Hypertensive Patients [282]

Sun-Young Jung, Nam-Kyong Choi, Hwa-Jung Kim, Ye-Jee Kim, Jong-Mi Seong, Jung-Yub Lee, Byung-Joo Park. (Republic of Korea)

3:15pm

■ Different Incidence Rates of Hospitalisations for Cardiovascular Events among Users of Statins in Real Life [279]

Edith M Heintjes, Fernie JA Penning-van Beest, Saga Johansson, Anton F Stalenhoef, Ron MC Herings. (Netherlands)

AGENDA - TUESDAY, AUGUST 19

Databases: Truth or Consequences? (Room 18/19)

Moderators: Susan Oliveria & Nancy Santanello

2:00pm

D Determining the Predictive Value of Read Codes To Identify Incident Acute Myocardial Infarction in the General Practice Research Database [284]

Tarek A Hammad, Mara A McAdams, Andrea Feight, Solomon Iyasu, Gerald J Dal Pan. (United States)

2:15pm

D Positive Predictive Value of Computerized Medical Records for Uncomplicated Upper Gastrointestinal Ulcer [285]

Andrea Margulis, Luis A García Rodríguez, Sonia Hernández-Díaz. (United States)

2:30pm

D One Question, Several Countries: Understanding Health Systems and Standardising Recording Habits in Primary Care Databases in France, Germany, Italy and the UK [637]

Andrew Maguire, Marie-Sophie Schwalm. (United Kingdom)

2:45pm

D Identification of Mother-Infant Pairs in the German Pharmacoepidemiological Database [287]

Elke Scharnetzky, Frank Andersohn, Ingo Langner, Edeltraut Garbe. (Germany)

3:00pm

D A Systematic Approach for Unassigned ICD-9 Codes in a Health Insurance Claims Database [288]

Hoa V Le, Kathleen J Beach. (United States)

3:15pm

D Developing a Model Predicting Poor Outcome in Chronic Obstructive Pulmonary Disease [289]

Stuart Schembri, Anderson William, Winter John, Winter Janet, MacDonald Thomas. (United Kingdom)

Advancing science. Serving patients.



Amgen, a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

To learn more about Amgen, our vital medicines, our pioneering science, and our career opportunities, visit www.amgen.com/careers.

AMGEN

Pioneering science delivers vital medicines™

www.amgen.com/careers

As an EEO/AA employer, Amgen values a diverse combination of perspectives and cultures. M/F/D/V.

AGENDA - TUESDAY, AUGUST 19

Potpourri II & Late Breakers (Room 20)

Moderators: Sean Hennessy, FISPE, & Eibert Heerdink

2:00pm

Use of Phthalate-Containing Medications and Urine Phthalate Concentrations [291]

Sonia Hernández-Díaz, Allen A Mitchell, Russ Hauser. (United States)

2:15pm

Peginterferon alfa-2a Treatment in 2101 HCV Infected Patients: Quality Criteria and Results from the French HEPATYS Cohort [290]

Cecile Hayem, Marc Bourliere, Marie-Odile Barbaza, Alexandrina Pinta, François Montestruc, Muriel Vray. (France)

2:30pm

Anti-Epileptic Medication Drug Formulation Changes and Their Relationship to Outcomes (Ambulance, Emergency Department, and Inpatient Events) [292]

KL Rascati, MJ Johnsrud, KM Richards, TA Mann. (United States)

2:45pm

Death and Renal Dysfunction with Aprotinin Use in Cardiac Surgery: A Meta-Analysis of Observational Studies [293]

Joshua J Gagne, Donald EG Griesdale, Sebastian Schneeweiss. (United States)

3:00pm

A New Approach to Pharmacovigilance in Pregnancy in Australia [294]

Lyn Colvin, Carol Bower, Linda Slack-Smith. (Australia)

3:15pm

Comparative Effects of Anti-Fibrinolytic Drugs in Cardiac Surgery: Updated Cochrane Review of Mortality [295]

D Henry, P Carless, A Laupacis, D Fergusson. (Canada)

Specialization and scientific depth that effectively manage risk and change.

i3 Drug Safety provides the data and services to meet regulatory requirements and support risk management programs for drugs, devices, and biologics throughout the product development and commercialization lifecycle. Our proven expertise cultivates a safer health care experience for all.

www.i3drugsafety.com

epidemiology
risk management
pharmacovigilance
signal detection

Come visit us in the exhibit hall to learn more about how we can support your product.

i3 drug safety
The company of specialists.

AGENDA - TUESDAY, AUGUST 19

3:30-4:00pm

Break/Posters/Exhibits (Hall A1)

4:00-5:30pm

CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

SYMPOSIUM: The Nordic Countries as a Cohort [296]
(Auditorium 10)

▮ **Henrik T Sørensen, Kari Furu, Morten Andersen, Jaana Martikainen, Ulf Bergman** (Norway)

SYMPOSIUM: Selective Prescribing, Frailty, and Healthy-User Effects in Pharmacoepidemiology [297] (Auditorium 11)

▮ **M Alan Brookhart, Colin Dormuth, Sascha Dublin, Robert J Glynn, Amanda R Patrick, Kenneth J Rothman** (United States)

WORKSHOP: Publishing in Pharmacoepidemiology [298]
(Auditorium 12)

▮ **Brian L Strom, Ronald Mann, Joerg Hasford** (United States)

SYMPOSIUM: Identifying Potential Safety Concerns in Claims and Electronic Health Record (EHR) Databases [299] (Room 18/19)

▮ **Nancy Santanello, Susan Sacks, Andrew Bates, A Lawrence Gould, Patrick Ryan, Paul Stang, Alexander Walker** (United States)

SYMPOSIUM: Linking Pharmacoepidemiology with Pharmacogenomics: Opportunities To Incorporate Genomics into Pharmacoepidemiology Studies [300] (Room 20)

▮ **Andrew N Freedman, Leah B Sansbury, Geoffrey Liu** (United States)

5:30-6:30pm

Special Interest Group (SIG) Meetings

Open to all participants.

▮ **Medications in Pregnancy SIG** (Room 16)

▮ **Database SIG** (Room 17)

▮ **Drug Utilization Research SIG** (Room 20)

▮ **Biologics** (Room 21)

▮ **Molecular Epidemiology/Pharmacogenetics SIG** (Room 23)

7:30pm-Midnight

Evening at the Langelinie Pavillon

- Admission is by badge or ticket.
- Cash bar (no credit cards)

Join us for a relaxing evening of camaraderie, food, and music at Langelinie Pavillon. The British life-style magazine, *Wallpaper*, acclaimed Langelinie Pavillon as being "one of the most spectacular spots in the city.

It's a popular venue for fashion and media parties." Music will be provided by Copyright, one of Denmark's best dance bands, and feature Christina Boelskifte.



Transportation. Tour boats will shuttle between the ICPE pick-up/drop-off point at **Nyhavn/Havnegade** and the restaurant beginning at 7:00pm. The first departure from the restaurant to **Nyhavn/Havnegade** will be at 9:30pm; the last at 12:30am. [NOTE: A one-way ride takes about a 25-minutes. Bring a sweater or jacket; it can be cool on the water at night.]



Pharmacoepidemiology AND DRUG SAFETY

Official Journal of the International Society for Pharmacoepidemiology

Editor-in-Chief: **Professor Ronald D. Mann**

Pharmacoepidemiology and Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

- * Free online access for ISPE members via the society website
- * Latest Impact Factor: 2.475 (JCR 2007)

A selection of the top-downloaded papers from the 2007 Volume (16)

- Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present
David L. McClure, Robert J Valuck, Morton Glanz et al. Volume 16, Issue 2, Pages 132 – 143
- Asthma drug use and the development of Churg-Strauss syndrome (CSS)
Leslie R. Harrold, M. Kay Patterson, Susan E. Andrade et al. Volume 16, Issue 6, Pages 620 – 626
- Coronary heart disease outcomes in patients receiving antidiabetic agent
Andrew T. McAfee, Carol Koro, Joan Landon et al. Volume 16, Issue 7, Pages 711 - 725
- Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials
Li-Chia Chen, Darren M Ashcroft. Volume 16, Issue 7, Pages 762 - 772
- A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
Charles M. Gerrits, Mondira Bhattacharya, Shivaji Manthena et al. Volume 16, Issue 10, Pages 1065 – 1071



For more information on these top papers and other journal features, please visit

www.interscience.wiley.com/journal/pds

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2008 Volume: 17 • Frequency: Monthly

 **WILEY-BLACKWELL**

AGENDA - WEDNESDAY, AUGUST 20

7:00-8:00am

Poster Session C Set-up (Hall A1)

7:30am-4:30pm

Registration (Auditorium Foyer)

7:30am-3:30pm

Speakers' Ready Room (Room 7)

8:00am-1:45pm

Exhibits/Posters (Hall A1)

8:30-10:00am

CONCURRENT SESSIONS - CONTRIBUTED PAPERS

Psychotropic Medication in Children (Auditorium 10)

Moderators: Ulf Bergman, FISPE, & Elizabeth Andrews, FISPE

8:30am

Medicine Use for Pain and Psychological Complaints among Children and Adolescents: Trends 1988-2006 [449]

Anette Andersen, Bjorn E Holstein, Pernille Due, Ebba H Hansen. (Denmark)

8:45am

Psychotherapy Use among Adolescents Prescribed Antidepressants and Antipsychotics [450]

Tami Mark, Stacey R Long. (United States)

9:00am

Use of Antidepressants in Children and Adolescents [451]

Dominique Milea, Nicolas Despiégl, Patrice Verpillat, Gérard Duru. (France)

9:15am

Impact of Comorbid Disruptive Disorders on Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder in Publicly-Insured U.S. Youth [452]

Julie M Zito, Satish Valluri, Sarah D Hundley, Daniel J Safer, James F Gardner, Mark Maneval, James J Korelitz, Diane L McNally, Perdita Taylor-Zapata, Donald R Mattison. (United States)

9:30pm

Treatment Persistence among Youths Newly Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) [453]

CY Chen, AG Winterstein. (United States)

9:45pm

Mortality Following Antiepileptic Drugs in Paediatrics with Epilepsy - Preliminary Results Using the General Practice Research Database (GPRD) [454]

Ruth Ackers, Frank MC Besag, Ian CK Wong. (United Kingdom)

Potpourri III (Auditorium 11)

Moderators: Morten Andersen & Walter Straus

8:30am

Role of Dose-Potency in the Prediction of Risk of Myocardial Infarction Associated with Nonsteroidal Anti-Inflammatory Drugs in the General Population [455]

Luis A García Rodríguez, Stefania Tacconelli, Paola Patrignani. (Spain)

8:45am

National Register Study on Atrial Fibrillation, Ischemic Stroke, and Myocardial Infarction in Fracture Patients Treated with Oral Bisphosphonates [456]

Bo Abrahamsen, Pia A Eiken, Kim Brixen. (Denmark)

9:00am

Drug-Treated Diabetes and Poor Long-Term Glycemic Control Increase the Risk of Hospitalization with Pneumonia: Population-Based Case-Control Study [457]

Jette B Kornum, Reimar W Thomsen, Anders Riis, Hans-Henrik Lervang, Henrik C Schönheyder, Henrik T Sørensen. (Denmark)

9:15am

Postmenopausal Hormone Therapy and Coronary Heart Disease: Adjusting for Imperfect Adherence [458]

Sengwee Toh, Sonia Hernandez-Diaz, Miguel A Hernan. (United States)

9:30pm

Instrumental Variable Analysis for Estimation of Absolute and Relative Treatment Effects with Binary Outcomes [459]

Jeremy A Rassen, Sebastian Schneeweiss, Robert J Glynn, Murray A Mittleman, M Alan Brookhart. (United States)

9:45pm

Assessment of Brookhart's Instrumental Variable Approach in Pharmacoepidemiology: The Impact of Using a Weak Instrument [460]

Raluca Ionescu-Ittu, Michal Abrahamowicz, Joseph A Delaney. (Canada)

AGENDA - WEDNESDAY, AUGUST 20

Anti-Psychotic Treatment: Metabolic Outcomes and Death

(Auditorium 12)

Moderators: Eibert Heerdink & Jessica Jalbert

8:30am

D The Prevalence and Costs of Metabolic Conditions among Patients with Bipolar Disorders as Compared to Matched Controls [461]

Tami L Mark, Franca Centorrino, Alessandra Talamo, Kelly Oh, Jane Chang. (United States)

8:45am

D Risk of Developing Diabetes among Adolescents with Bipolar Disorder or Schizophrenia [462]

Cheryl Enger, Meghan E Jones, Ludmila Kryzhanovskaya, Michael Doherty, Andrew T McAfee. (United States)

9:00am

D Polymorphisms of the LEP- and LEPR Gene and Obesity in Psychiatric Patients Using Antipsychotic Medication [463]

Jochem G Gregoor, Jan van der Weide, Hans Mulder, Harold JGM van Megen, Antoine CG Egberts, Eibert R Heerdink. (Netherlands)

Student Award Recipient - Edlavitch Award (Best Abstract)

9:15am

D Metabolic Testing after the FDA Warning on Atypical Antipsychotic Drugs and Diabetes Risk [464]

Elaine H Morrato, John W Newcomer, Siddhesh Kamat, Onur Baser, James Harnett, Brian Cuffel. (United States)

9:30pm

D Use of Antipsychotic Polypharmacy among Patients with Schizophrenia and Risk of Death [465]

Christiane Gasse, Lone Baandrup, Merete Nordentoft, Birte Y Glenthoj, Henrik Lublin, Vibeke Dahl Jensen, Lars Krogsgaard Thomsen, Jan Poulsen, Preben B Mortensen. (Denmark)

9:45pm

D Comparative Mortality Associated with Ziprasidone vs. Olanzapine in Real-World Use: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) [466]

Brian L Strom, Gerald Faich, Sybil Eng, Robert Reynolds, Ralph D'Agostino, Jeremy Ruskin, John Kane. (United States)

The World's A' Changing: International Comparisons of Drug Safety and National Insurance Policy (Room 18/19)

Moderators: Judith Jones, FISPE, & Patrick Waller

8:30am

D Timing of Safety-Related Labeling Changes and Marketing Withdrawals for New Molecular Entities (1991-2007) [467]

Mara A McAdams, Judy A Staffa, Solomon Iyasu, Gerald J Dal Pan. (United States)

8:45am

D A Drug's Life Cycle and Communication of Safety Issues [468]

Peter Mol, Jonie de Vries, Sabine Straus, Pieter de Graeff, Flora Haaijer-Ruskamp. (Netherlands)

9:00am

D Cardiovascular Risk Factors and Medical History of Cardiovascular (CV) and Gastrointestinal (GI) Event among Etoricoxib Users in the United Kingdom (UK) before and after the COX-2 Urgent Safety Restriction [469]

Bing Cai, Douglas Watson. (United States)

9:15am

D Predictors of Medicare Part D Enrollment: The Experience of Medicare Drug Demonstration Participants with Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) [470]

Jennifer M Polinski, Penny E Mohr, Lorraine Johnson. (United States)

9:30pm

D The Effect of Transitioning to Medicare Part D Drug Coverage in Seniors Dually Eligible for Medicare and Medicaid [471]

William H Shrank, Amanda R Patrick, Alex Pedan, Jennifer M Polinski, Laleh Varesteh, Raisa Levin, Nan Liu, Sebastian Schneeweiss. (United States)

9:45pm

D The Effect of Prescription Drug Policy Changes on Mental Health Service Use in British Columbia [472]

Sebastian Schneeweiss, Amanda R Patrick, Colin R Dormuth, Malcolm Maclure, Claire F Canning, Philip S Wang. (United States)

AGENDA - WEDNESDAY, AUGUST 20

The Spectrum of Anti-Infectives (Room 20)

Moderators: Jan Willem van der Velden, FISPE, & Zdravko Vassilev

8:30am

Antibiotic Prescribing for Otitis Media in Children in UK Primary Care: Have the National Guidelines Affected GP Prescribing Practice? [624]

Paula L Thompson, Ruth Gilbert, Paul F Long, Sonia Saxena, Mike Sharland, Ian CK Wong. (United Kingdom)

8:45am

Use of Fluoroquinolones and the Risk of Methicillin Resistant Staphylococcus Aureus (MRSA) [474]

Katia MC Verhamme, Marie-Christine De Smet, Paul Jordens. (Belgium)

9:00am

Effect of Antibiotics for Otitis Media on Mastoiditis in Children: Retrospective Cohort Study Using the UK General Practice Research Database [475]

Paula L Thompson, Ruth Gilbert, Paul Long, Sonia Saxena, Mike Sharland, Ian Wong. (United Kingdom)

9:15am

Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes [476]

V Lo Re III, V Amorosa, R Localio, R O'Flynn, V Teal, Z Dorey-Stein, J Kostman, R Gross. (United States)

9:30pm

Antibiotics for Upper Respiratory Infections [477]

Sharon B Meropol, Zhen Chen, Joshua P Metlay. (United States)

9:45pm

Pre- and Post-HAART Prevalence, Incidence, and Type-Specific HPV Persistence among HIV-Positive Adolescents [478]

Sadeep Shrestha, Laura H Bachmann, Craig M Wilson, Mirjam C Kempf. (United States)

10:00-10:30am

Break/Posters/Exhibits (Hall A1)

10:30am-Noon

CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

SYMPOSIUM: Understanding Fetal Risks of Antihypertensive Medication Use During Pregnancy [479] (Auditorium 10)

William O Cooper, Alissa R Caton, Lolkje TW de Jong-van den Berg, Allen A Mitchell (United States)

WORKSHOP: Instrumental Variable Methods in Pharmacoepidemiology [480] (Auditorium 11)

M Alan Brookhart, Jeremy Rassen, Sebastian Schneeweiss (United States)

WORKSHOP: New Epidemiology Requirements for Risk Management Plans - Experiences and Challenges [481] (Auditorium 12)

Patricia Saddier, Susana Perez-Gutthann, Annette Stenhagen, Joanna Haas (United States)

SYMPOSIUM: Benefit-Harm Modelling: What Is This and What Can It Contribute to Pharmacovigilance? [482] (Room 18/19)

Tjeerd P van Staa, Larry D Lynd, Hubert GM Leufkens, June Raine, Hans Petri (United Kingdom)

SYMPOSIUM: Monitoring the Introduction of New Drugs: Methods Focusing on Safety, Costs, and Appropriate Use [483] (Room 20)

Petra Denig, Lars L Gustafsson, Ken Paterson, Björn Wettermark (Sweden)

Noon-1:30pm

Lunch/Poster Session C/Exhibits (Hall A1)

Poster Walks:

- Databases**
- Molecular Epidemiology/Pharmacogenetics**
- Medicines in Pregnancy/Birth Defects**

ISPE Board of Directors Luncheon (Bella Vista Restaurant-BV 4/5)
(Open to ISPE members; notify staff if you plan to attend)

1:30-2:30pm

INVITED PLENARY (Auditorium 10-12)

Pharmacoepidemiology: A Regulator's Perspective

Hubert GM Leufkens, FISPE, Chair of Dutch Medicines Evaluation Board

AGENDA - WEDNESDAY, AUGUST 20

2:30-4:00pm

PLENARY SYMPOSIUM: SELF-CONTROLLED DESIGNS [484]

(Auditorium 10-12)

Co-Chairs:

Kenneth J Rothman, FISPE
Sonia Hernandez-Diaz, FISPE

Speakers:

C. Paddy Farrington
Samy Suissa
Jesper Hallas

4:00-4:30pm

THE FINAL WORD (Auditorium 10-12)

Poster Awards

Lolkje T. de Jong-van den Berg, Chair, Poster Awards Committee
ICPE 2009- Providence, Rhode Island
Kate Lapane, FISPE, Chair, 2009 ISPE Scientific Program Committee

4:30-5:30pm

2009 Scientific Program Committee Meeting (Room 16)
Kate Lapane, FISPE, Chair, 2009 ISPE Scientific Program Committee
Open to all participants
Adjournment of ICPE 2008

ICPE 2008



24th Annual International Conference On
Pharmacoepidemiology & Therapeutic
Risk Management

ICPE
International Conference
on Pharmacoepidemiology &
Therapeutic Risk Management
2009
25th Anniversary Meeting

Rhode Island
Convention Center
AUGUST 16-19, 2009

Abstract
Submission Deadline:
FEBRUARY 16, 2009

The online abstract site will be
operational by mid-December 2008.
Meeting information will be posted
at www.pharmacoepi.org

POSTER SESSION GUIDELINES

OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

POSTER SESSION

Posters will be displayed in room Hall A1 of the Bella Center from August 18-20. Each day will have a separate poster session. Poster for a day's session must be removed that day.

- **Monday, August 18**, Poster Session A
- **Tuesday, August 19**, Poster Session B
- **Wednesday, August 20**, Poster Session C

1. Set Up

- 7:30am–8:15 amMonday and Tuesday
- 7:00am–8:00 amWednesday

2. Hours

- **Hall A1 will be open for the attendees from:**
8:00am–6:00pmMonday and Tuesday
8:00am – 1:45pmWednesday

3. Discussion Time

- **General:** Presenters should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45pm on Tuesday.

- **Poster Walks** – organized by the ISPE Special Interest Groups (SIG)

Monday*Drug Utilization & Biologics*
Tuesday*Medicines in Pregnancy*
Wednesday*Databases; Molecular Epidemiology/Pharmacogenetics;
& Medicines in Pregnancy/Birth Defects*

The poster walks will offer presenters the opportunity to present their work and to discuss their results with an audience. Participants in these categories should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45 (Tuesday). When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

4. Poster Prizes

A group of judges will select the best posters of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE.

5. Take Down

All posters must be taken down by 6:30 pm on Monday and Tuesday; posters must be taken down by 5:00pm on Wednesday.

NOTE: ISPE and the Bella Center are not responsible for any poster that is left up overnight or is lost or damaged.

NUMBERING SYSTEM

- Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program, which will be available at the ISPE Registration Desk (Bella Center/Auditorium Foyer). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the Final Program and the special issue of Pharmacoeconomics and Drug Safety, is in brackets [] after the title of the abstract.

POSTER SPECIFICATIONS

1. Posters must be designed to fit a space 3 feet WIDE x 5 feet HIGH (90 cm WIDE x 150 cm HIGH). POSTER ORIENTATION: PORTRAIT Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board
2. Posters may be attached to the boards using Velcro tape. All poster presenters are encouraged to bring their own supplies.
3. A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the 1-year period before the ICPE. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed.



At the
convergence of
science, technology
and innovation

UBC has engineered a new kind of company to move you faster along the steps of drug development and commercialization.



Evidence Matters.®

US 866 458 1096 EU +44 207 299 4550
unitedbiosource.com

See us at Booth #11 at ICPE

UBC has an epidemiologic approach to:

Risk Management

- Risk Assessment
- Intervention Design & Implementation
- Program Evaluation
- Risk-Benefit Modeling
- Risk Evaluation & Mitigation Strategies

Registries & Large Streamlined Studies

Individual Patient Database Analyses

Pharmacovigilance & Safety Signaling

Systematic Literature Reviews & Meta-Analysis

Customized Literature Reviews

BIOLOGICS (SIG)

- 1 Diagnostic Testing, Treatment, and Outcomes of Adverse Events after Use of Intravesical Bacillus Calmette-Guérin [63]**
Karen C Lee, Meghan T Ferris, Rosemary Tiernan, Robert P Wise. (United States)
- 2 Infections in Systemic Inflammatory Diseases [64]**
Eva M van Soest, Jeanne P Dieleman, Jennifer Hollowell, Miriam CJM Sturkenboom. (Netherlands)
- 3 Observational Post-Marketing Safety Studies of Biologic Drugs in Patients with Rheumatoid Arthritis (RA) – Can Structured Analysis and Reporting Improve Comparability? [65]**
William G Dixon, Johan Asklung. (United Kingdom)
- 4 Off-Label Trastuzumab Use in Australia: Evidence from the National Herceptin Program for HER-2 Positive Metastatic Breast Cancer [66]**
Sallie Pearson, Clare L Ringland, Robyn L Ward. (Australia)
- 5 Safety Related Regulatory Actions for Biologics Approved in the US and Europe Since 1995 [67]**
Thijs J Giezen, Aukje K Mantel-Teeuwisse, Sabine M Straus, Huub Schellekens, Hubert G Leufkens, Antoine C Egberts. (Netherlands)
- 6 Specialty Biologic Drug Coverage under Medicare Part D: The Experience of Beneficiaries with Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) [68]**
Jennifer M Polinski, Penny E Mohr, Lorraine Johnson. (United States)

CNS/NEUROLOGICAL

- 7 Highly Selected Subset of Clinical Patients with Epilepsy Qualifies for Antiepileptic Drug Trials [69]**
Eva Thusta, Kim B Handoko, Marian Majoie, Toine CG Egberts, Jiri Vlcek, Eibert R Heerdink. (Netherlands)
- 8 Non-Adherence to Antiepileptic Drugs and Increased Mortality [70]**
Edward Faught, Mei Sheng Duh, Jennifer R Weiner, Annie Guerin, Marianne C Cunningham. (United States)
- 9 Chronic Atrial Fibrillation: Incidence, Prevalence and Prediction of Stroke Using the CHADS2 Risk Stratification Scheme [71]**
Arlene M Gallagher, Stephan Rietbrock, Emma Heeley, Jonathan Plumb, Tjeerd P van Staa. (United Kingdom)
- 10 The Italian Natalizumab Registry: A 1-Year Follow-Up [72]**
Carlo Piccinni, Laura Periotto, Antonio Addis, Maria Pia Amato, Giovanni Luigi Mancardi, Elisabetta Poluzzi, Nicola Montanaro, Neurological Panel. (Italy)
- 11 Off-Label Prescribing of Anticonvulsant Drugs – National Pattern between 1992-2005 [73]**
Ahunna J Onyenwenyi, Almut G Winterstein. (United States)
- 12 Factors Associated with Rapid Cognitive Decline in Patients Suffering from Mild to Moderate Alzheimer's Disease [74]**
Antoine Pariente, Thibaut Sanglier, Jean-Francois Dartigues, Nicholas Moore, Annie Fourier-Reglat. (France)
- 13 Antihypertensives and White Matter Lesion Progression, a Population-Based Cohort Study [75]**
Mendel Haag, Albert Hofman, Monique Breteler, Bruno Stricker. (Netherlands)
- 14 Monitoring the Use of Disease-Modifying Drugs in Multiple Sclerosis [76]**
Elisabetta Poluzzi, Carlo Piccinni, Chiara Sacripanti, Maria Rosaria Tola, Roberto DAlessandro, Nicola Montanaro, ER-SM Study Group. (Italy)
- 15 Suicidal Behavior in a Cohort of Swedish Patients with Severe Acne Treated with Isotretinoin [77]**
Anders Sundström, Gunilla Sjölin-Forsberg, Barbro Gerdén, Jussi Jokinen. (Sweden)

- 16 Factors Associated with Persistence to Anti-Alzheimer Drugs in France [78]**
Marion Pinet, Antoine Pariente, Yvon Merliere, Yola Moride, Nicholas Moore, Annie Fourier-Reglat. (France)
- 17 Depression and Comorbid Panic Symptoms in Primary Care Patients [79]**
Angela M DeVeugh-Geiss, Suzanne L West, William C Miller, Betsy Sleath, Kurt Kroenke, Bradley N Gaynes. (United States)

CANCER

- 18 Accuracy of ICD-10 Discharge Diagnoses of Skeletal Related Events and Bone Metastases Secondary to Prostate Cancer and Breast Cancer in a Danish Population-Based Hospital Registry [80]**
Annette O Jensen, Mette Norgaard, Deidre Cronin-Fenton, Annalisa Rubino, Jon P Fryzek, Henrik T Sorensen. (Denmark)
- 19 Use of Oral Glucocorticoids and Risk of Skin Cancer and Non-Hodgkin's Lymphoma: A Population Based Case Control Study [81]**
Annette O Jensen, Henrik F Thomsen, Anne B Olesen, Soren Friis, Margarat R Karagas, Henrik T Sorensen. (Denmark)
- 20 Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention: VATTC Trial [82]**
Jennifer B Christian, Kate L Lapane, Anne L Hume, Charles B Eaton, Martin A Weinstock. (United States)
- 21 Evaluation of Chemotherapy Practices in Patients Treated for Colorectal Cancer in the Bordeaux Teaching Hospital: Methods and Preliminary Results of the COLCHIC Study [83]**
M Rouyer, D Smith, E Terrebbonne, D Breilh, JP Pometan, A LeMonies, D Jayles, N Moore, A Fourier-Réglat. (France)
- 22 Pravastatin Use and Cancer Risk: A Meta-Analysis of Patient Data from Long-Term Prospective Controlled Trials in Japan [84]**
Yasuyuki Matsushita, Masahiro Sugihara, Junpei Kaburagi, Masumi Ozawa, Mikio Iwashita, Sanae Yoshida, Hanako Saito, Yoko Hattori. (Japan)

POSTER SESSION A: MONDAY, AUGUST 18

- 23 **Antidepressant Use and Risk of Colorectal Cancer [85]**
DP Cronin-Fenton, A Riis, TL Lash, SO Dalton, S Friis, D Robertson, HT Sorensen. (Denmark)
- 24 **Recording of Pancreatic, Colorectal, and Lung Cancer Incidence in the Health Improvement Network (THIN) [86]**
Kevin Haynes, Rita Schinnar, Patricia Wong, Brian Strom, James Lewis. (United States)
- 25 **Occurrence of Cardiovascular Comorbidity in Head and Neck Cancer Patients by Treatment Modality [87]**
Umesh Doobaree, Sarah Landis, Annette Beiderbeck, Iman El-Hariry, Amit Shukla, Maurille Feudjo-Tepie, Alexandra Frost, Jerzy Tyczynski. (United Kingdom)
- 26 **Real-Life Post-Marketing Study in France of Bevacizumab Use, a Targeted Therapy for Metastatic Colorectal Cancer [88]**
M Rouyer, A Ravaud, D Jayles, A Balestra, N Moore, A Fourrier-Réglat. (France)
- 27 **Risk Factors Related to the Incidence of Phlebitis with Vinorelbine Infusion [89]**
Mayumi Mochizuki, Hiroki Miyata, Yuka Miyao, Yuya Ise, Masayuki Hashiguchi, Shiro Katayama. (Japan)
- 28 **registHER: An Observational Cohort Study of Patients with HER2+ Metastatic Breast Cancer [90]**
Marianne Ulcickas Yood, Peter A Kaufman, Musa Mayer, Hope Rugo, Adam Brufsky, Elizabeth Tan-Chiu, Denise Yardley, Soonmyung Paik, Lisa Wang, Merrill Birkner, Melissa Brammer, Debu Tripathy. (United States)
- 29 **The Use of Oral Cytostatic Drugs in the Netherlands in the Period 1998-2006: Increased Consumption Is Caused by a Raise of the Use of Capecitabine [91]**
Lonneke Timmers, Myrthe PP Sukel, Jacqueline G Hugtenburg. (Netherlands)
- 30 **Non Steroidal Anti-Inflammatory Drug Use and Risk of Pancreatic Cancer: A Nested Case-Control Study [92]**
Marie C Bradley, Liam Murray, Carmel Hughes, Marie Cantwell. (Ireland)

- 31 **Review: The Use of Common Pharmaceuticals and Nutraceuticals and the Prevention of Cancer [93]**
Leah B Sansbury, Arnie L Potosky, Sheila R Weiss-Smith, Andrew N Freedman. (United States)
- 32 **Incidence of Cardiovascular and Cerebrovascular Events among Men with Prostate Cancer [94]**
Alicia W Gilsenan, Amy Ladner, Cristina Varas, Tine Kold Olesen, Cathrina Karup, Elizabeth Andrews. (United States)

DRUG UTILIZATION STUDIES (SIG)

- 33 **The Nordic Countries as a Cohort in Pharmacoepidemiology – Comparison of Nationwide Prescription Databases [95]**
Karolina Andersson, Mikael Hoffmann, Björn Wettermark, Kari Furu, Matthias Halldórsson, Jaana Maartikainen, Jan Poulsen, Marit Ronning, on Behalf of the Nordic Working Group on Drug Registries. (Sweden)
- 34 **Comparison of Drug Utilisation in Hospital Out-Patients and Primary Care Patients [96]**
Soren Ilsoe-Kristensen, Steffen Thirstrup, Mette Rasmussen. (Denmark)
- 35 **Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Alzheimer's Disease [97]**
V Gardette, M Lapeyre-Mestre, C Cantet, S Gillette-Guyonnet, F Nourhashemi, PJ Ousset, S Andrieu, JL Montastruc, B Vellas. (France)
- 36 **Impact of Government Regulatory Actions on Prescription of Anti-Influenza Drugs in Korea [98]**
Yoonsook Lee, Hyun Joo Park, Tae Sun Kang, Sun Wook Woo. (Republic of Korea)
- 37 **Refill Adherence to Methotrexate among Patients with Rheumatoid Arthritis in the County of Aarhus, Denmark [99]**
Annette de Thurah, Mette Noergaard, Martin B Johnsen, Kristian Stengaard-Petersen. (Denmark)

- 38 **Pattern of Drug Use in Children – Prevalence and Associated Factors in Northeast Brazil [100]**
Djanilson B Santos, Mauricio L Barreto, Helena LL Coelho. (Brazil)
- 39 **Exposure to Cardioprotective Drugs in Elderly with Diabetes Is Dependent on Age [101]**
Caroline Sirois, Jocelyne Moisan, Julie Couture, Paul Poirier, Jean-Pierre Grégoire. (Canada)
- 40 **Characterization of Polypharmacy in the Elderly [102]**
Sandra Guedes, Zilda Mendes, Ana C Miranda, Francisco B Marques. (Portugal)
- 41 **The Use of GP-Databases in Comparative Research: The Case of Diabetes Care in Sweden and the Netherlands [103]**
Liset Van Dijk, Ulf Lindblad, Arne Melander, Robert A Verheij. (Netherlands)
- 42 **Patients' Declared Adherence to Respiratory Drugs in COPD. Preliminary Data from the PRE-SPIRO Study [104]**
L Laforest, F Denis, E Van Ganse, C Ritleng, C Saussier, N Passante, G Devouassoux, G Chatté, Y Pacheco. (France)
- 43 **Potential Drug Interactions and Associated Factors in a Brazilian Hospital [105]**
Cristiano S Moura, Francisco A Acurcio, Najara O Belo. (Brazil)
- 44 **Impact of Rofecoxib Withdrawal and Lumiracoxib Introduction on COX-2 Inhibitor Utilization in Concession Beneficiaries in Australia [106]**
Nadia Barozzi, Susan Tett. (Australia)
- 45 **Potentiated Penicillins Utilization and Susceptibility of Bacterial Pathogens: A Ten-Year Hospital Survey [107]**
Karel Urbanek, Vladimira Vojtova, Dominika Hajdu, Milan Kolar. (Czech Republic)
- 46 **Exposure to Antibacterials with QT Liability in 15 European Countries: Trends over a 7-Year Period [108]**
Elisabetta Poluzzi, Emanuel Raschi, Chiara Zuliani, Arno Muller, Herman Goossens, Fabrizio De Ponti. (Italy)

POSTER SESSION A: MONDAY, AUGUST 18

- 47 Evaluation of a Method for Influencing Costs and Quality in Drug Prescribing [109]**
Kristian Aranas, Kerstin Bjorkman-Lundberg. (Sweden)
- 48 Use of Antibacterials and Urinary Tract Prophylactic Agents in Norwegian Nursing Homes [110]**
Jenny Bergman, Hege S Blix, Jan Schjott. (Norway)
- 49 The Impact of Pharmacists on Drug-Related Problems in Nursing Home [111]**
Kjell H Halvorsen, Sabine Ruths, Anne Gerd Granas, Kirsten K Viktil. (Norway)
- 50 A Comparison of Two Methods for the Assessment of Handwriting Legibility in a Developing Country [112]**
Obehi A Akoria, Ambrose O Isah. (Nigeria)
- 51 Impact of Prescribing Analgesic of Tramadol/Acetaminophen on Risk of COX-2 Inhibitors [113]**
Ching-lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)
- 52 New Methods To Study Complexity of Drug Information Queries [114]**
Linda Amundstuen, Olav Spigset, Jan Schjoett. (Norway)
- 53 Antidepressants Prescription Patterns for the Korean Elderly Ambulatory Care Patients [115]**
Ye-Jee Kim, Sun-Young Jung, Nam-Kyong Choi, Hwa-Jung Kim, Jong-Mi Seong, Joong-Yub Lee, Byung-Joo Park. (Korea)
- 54 Respiratory Drug Use in Children in the Netherlands, Italy and United Kingdom [116]**
EF Sen, K Verhamme, A Neubert, C Giaquinto, M Sturkenboom. (Netherlands)
- 55 Effectiveness of a Clinical Informatics Tool To Promote Patient Safety during the Medication Monitoring Stage in Nursing Homes [117]**
Kate L Lapane, Carmel M Hughes, Rebecca B Toppa, Kathleen A Cameron, Janice L Feinberg. (United States)
- 56 Recommendations from ESAC-2 Hospital Care Subproject [118]**
Faranak Ansari, Mats Erntell, Herman Goossens, Hassan Molana, Peter Davey, on Behalf of the ESAC-2, HC Study Group. (United Kingdom)
- 57 Antidiabetic Drug Use in Italy [119]**
Marina Maggini, Roberto Da Cas, Stefania Spila-Alegiani, Roberto Raschetti, OsMed Study Group. (Italy)
- 58 Quality of Perioperative Chemoprophylaxis in Neurosurgery: Preliminary Results of ASPPOC in 4 European Countries [120]**
Paraskevi Papaioannidou, Vera Vlahovic-Palcevski, Ljubica Pejakov, Kimon Nanas-sis, Milos Stojiljkovic, Philip Tsitsopoulos. (Greece)
- 59 Use of Lipid Modifying Drugs and Monitoring of Serum Lipids in a Cohort of Older Finns in 2000-2005 [121]**
Maarit J Korhonen, Sanna Savolainen, Hannes Enlund, Paivi Hiitola, Sirpa Hartikainen. (Finland)
- 60 Quality of Perioperative Chemoprophylaxis in Obstetrics and Gynecology in Greece, Serbia and Croatia [122]**
Paraskevi Papaioannidou, Vera Vlahovic-Palcevski, Ana Sabo, Olga Horvat, Demetrios Vavilis, Basil Tarlatzis, John Bontis. (Greece)
- 61 The Use of Acamprosate in the Ambulatory Setting [123]**
Johan De Haes, André De Swaef. (Belgium)
- 62 The Impact on Prevalence of Various Definitions for Co-Medication Use of Cholinesterase Inhibitors (ChEIs) and Potentially Contraindicated Medications in Alzheimer's Disease [124]**
Alison L Supina, David B Hogan, Scott B Patten, Braden J Manns, Winanne Downey, Patricia Beck, Colleen J Maxwell. (Canada)
- 63 Are Parents a Reliable Source of Information on Adolescent Medication Use? [125]**
Judith P Kelly, David W Kaufman, Louis Vernacchio, Katherine Kelley, Allen A Mitchell. (United States)
- 64 Appropriateness of Gastroprotection during Treatment with NSAIDs or ASA in Northern Italy [126]**
Marco Villa, Salvatore Mannino, Alfredo Cocci, Stefano Zenoni, Walter Locatelli. (Italy)
- 65 Prescription and Nonprescription Drug Use in Children in Northeast Brazil [127]**
Djanilson B Santos, Mauricio L Barreto, Helena LL Coelho. (Brazil)
- 66 Patterns of Use of Medicines in University Students [128]**
Diana Gonzalez-Bermejo, Nuria Gonzalez-Bermejo, Ramona Mateos-Campos. (Spain)
- 67 First Line Use of Pain Medication in Neuropathic Facial Pain [129]**
Seppie Koopman, Marissa de Mos, Frank Huygen, Jeanne Dieleman, Miriam Sturkenboom. (Netherlands)
- 68 Prescription of Medicines for 0 to 19-Year-Old Danes in 2006: National Register-Based Study [130]**
Ebba H Hansen, Tina H Duedahl, Bjorn E Holstein. (Denmark)
- 69 Pain Control in a Cohort of Cancer Patients in Italy [131]**
Salvatore Mannino, Marco Villa, Giovanni Apolone, Erminio Ebbli, Stefano Zenoni, Walter Locatelli. (Italy)
- 70 Achieving Optimal Use of Paracetamol: Not so Simple for This Analgesic [132]**
Judith M Mackson, Angela Wai, Maxine Robinson, Louise E Bartlett, Jeff Elliott, Holly K Parsons. (Australia)
- 71 Trends of Antimicrobial Consumption in Hospital Care in Russia in 2001-2006 [133]**
Alexander Fokin, Svetlana Ratchina, Sergey Kozlov, Aidar Ishmukhametov, Maria Denisova. (Russian Federation)
- 72 Use of Cough and Cold Medications in Children in the Netherlands and Italy [134]**
EF Sen, K Verhamme, G Picelli, C Giaquinto, L Cantarutti, M Sturkenboom. (Netherlands)

POSTER SESSION A: MONDAY, AUGUST 18

- 73 Osteoporosis Therapy Following Bone Densitometry – Patient Expectations as Determinants of Drug Initiation and Persistence [135]**
Dorthe Brask-Rasmussen, Suzanne M Cadarette, Peter C Eskildsen, Bo Abrahamson. (Denmark)
- 74 Changes in the Utilization of Antimicrobials in Clinical Centre University of Sarajevo (CCUS) for Three Years (2003-2005) and Impact of List of Reserve Antimicrobials [136]**
Begler Begovic, Amra Cabaravdic, Lejla Begovic. (Bosnia and Herzegovina)
- 75 Contribution of Online Antibiotic Guidelines to the Appropriateness of Antibiotic Prescribing in a Teaching Hospital: A 5-Year Time-Series Study in Pneumonia [137]**
Frederic Westphal, Herve Javelot, Francois Jehl. (France)
- 76 Persistence of Oral Anticoagulation Therapy in Atrial Fibrillation: A Retrospective Cohort Study in Primary Care in Italy [138]**
M Alacqua, G Mazzaglia, A Filippi, C Bianchi, A Shakespeare, W Cowell, C Cricelli. (Italy)
- 77 Prescription of Statins in Northern Italy: Can We Do Any Better? [139]**
Salvatore Mannino, Marco Villa, Silvia Lucchi, Stefano Zenoni, Walter Locatelli. (Italy)
- 78 Comparison of Schizophrenic Patients According to Conventional and Atypical Antipsychotic Therapy: The EPIONE Survey [140]**
E Van Ganse, L Laforest, R Arnaud, L Depret-Bixio, JY Loze, A Dillenschneider, F Rouillon. (France)
- 79 Cost Evolution of Antidiabetic Drugs in Castilla-León (Spain). 1988-2005 [141]**
María I Jiménez-Serranía, Ramona Mateos-Campos, Javier Garcia del Pozo. (Spain)
- 80 Quality of Perioperative Chemoprophylaxis in General Surgery: Preliminary Results of ASPPOC in 8 European Countries [142]**
P Papaioannidou, V Vlahovic-Palcevski, A Sabo, D Loncar-Stojiljkovic, R Benko, M Stojiljkovic, A Kamparoudis, L Pejakov, T Gerasimidis, B Beovic, R Velickovic-Radovanovic, M Jakovljevic, S Jankovic, G Benoni, G Velo. (Greece)
- 81 Patient Focused Drug Surveillance on Elderly Patients in Nursing Homes [143]**
Inger Nordin Olsson, Peter Engfeldt. (Sweden)
- 82 In Fine Pharma: A Community-Pharmacy Network Dedicated to Pharmacoepidemiological Surveys: A Feasibility Study [144]**
E Van Ganse, J Longin, G Chamba, MJ Augé-Caumon, G Desamericq, L Laforest, C Ritleng. (France)

Our work is someone's hope.
Join us.



Merck & Co., Inc., established in 1891, is a global research-driven pharmaceutical company dedicated to putting patients first. Join us and experience our culture first-hand – one of strong ethics & integrity, diversified experiences and a resounding passion for improving human health. As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.

MRL Epidemiology – Improving research to assess patient outcomes. Our mission is the scientific study of disease, endpoints and patient outcomes to evaluate benefits and the risks of our products. At Merck, we pride ourselves on meeting patient expectations – leveraging the most complete data and a strong cohesive effort to make the products that make life better.

We provide epidemiologic and outcomes research for all Merck drugs and vaccines. Using existing information, database analyses and conducting epidemiology studies across the globe, we characterize disease natural history for new therapeutic areas, assist in clinical trial design based on the epidemiology of the disease, link biomarkers to outcomes and help understand the safety of our products pre- and post-launch. Our team is an active member of clinical development and outcomes research teams. A new addition to MRL Epidemiology is the creation of the Pharmacoepidemiology and Database Research Unit (PEDRU) which concentrates Merck's efforts to lead in the application and development of pharmacoepidemiologic methods, and to further the appropriate use of large automated databases to address drug safety and risk/benefit issues across the full spectrum of Merck's portfolio.

Merck is a global research-driven pharmaceutical company dedicated to putting patients first in all we do. That philosophy was first articulated by George Merck and it still guides us today. Join our Epidemiology Department and participate in our investigative design and interpretation that enable us to bring life-enhancing products to market. Visit <http://merckcareers.jobs/1592> to find out how.

<http://merckcareers.jobs/1592>

Where patients come first



Merck is an equal opportunity employer, M/F/D/V – proudly embracing diversity in all of its manifestations.

POSTER SESSION A: MONDAY, AUGUST 18

- 83 Use of Preventive Medication in Elderly Persons in Kuopio, Finland [145]**
Maria Rikala, Johanna Jyrkka, Hannes Enlund, Maarit Korhonen, Sirpa Hartikainen. (Finland)
- 84 Utilization Patterns of Extended Release Niacin and Other Lipid Modifying Drugs in Regular Clinical Practice [146]**
Marc Dorais, Vasilisa Sazono, Glenn M Davies, Susan Grant, Jacques LeLorier. (Canada)
- 85 Obesity Therapeutic Management in a Population at Risk for Cardiovascular Disease [147]**
José Guerreiro, Sandra Guedes, Zilda Mendes, Ana Miranda. (Portugal)
- 86 Drug Utilisation and Safety of Atrovent® (Ipratropium) Inhaler CFC-Free MDI in Children in a Cohort of First Users in England [148]**
C Fogg, R Waller, L Wilton, S Shakir. (United Kingdom)
- 87 Failure from Initial Drug Therapy with Antihypertensive Drugs: A Population-Based Study Comparing Italy, Netherlands and Sweden [149]**
Federica Nicotra, Giovanni Corrao, Miriam Sturkenboom, Michael Fored, Björn Wettermark, Rino Bellocco, Andrea Parodi. (Italy)
- 88 Pharmacotherapeutic Profile of Patients under Surveillance in the Geriatric Ambulatory of the Brasilia University Hospital, Brazil [150]**
Janeth OS Naves, Emilia V Silva, Carlos CF Vidotti, Anelise M Correia, Alexandre V Machado, Eduardo DG Souza, Juliana P Oliveira. (Brazil)
- 89 Evaluating Prescriber Characteristics Associated with NSAID Prescribing Practices in the Netherlands [151]**
Deborah Layton, Patrick C Souverein, Eibert R Heerdink, Toine CG Egberts, Saad AW Shakir. (United Kingdom)
- 90 Clinical Significance of GST pi, P-Glycoprotein and HBx in Lamivudine Resistant Chronic Hepatitis B: A Multi Center, Case Control Study [152]**
Sepideh Arbabi Bidgoli, Maryam Motamedi, Atoosa Miri, Nasser Ebrahimi Daryani, Parisa Poor Samimi. (Islamic Republic of Iran)
- 91 Simvastatin and Atorvastatin Initiations by Patient Morbidity in Finland 1998-2004 [153]**
Heli Halava, Arja Helin-Salmivaara, Risto Huupponen. (Finland)
- 92 Indications Associated with Antidepressant Use in a Large US Claims Database [154]**
Dominique Milea, Nicolas Despiègel, Patrice Verpillat, Michel Lamure. (France)
- 93 Profile of Medicines Dispensed by the Ambulatory Pharmacy Service, in a Brazil's Countryside City [155]**
Emilia V Silva, Gizelli Lourenco, Lilia Ferreira, Luiza Faria, Carlos Vidotti, Janeth Naves, Juliana Silveira, Aline Silva. (Brazil)
- 94 Polypharmacy Prescription Pattern among Korean Elderly Ambulatory Patients [156]**
Hwa Jung Kim, Nam-kyung Choi, Sun-young Jung, Ju-young Kim, Ye-jee Kim, Joongyub Lee, Byung-joo Park. (Republic of Korea)
- 95 A Pharmacoepidemiology Study of the Use of Bisphosphonates in a Cohort of Elderly Persons [157]**
Ana Blagojevic, Linda E Levesque, James M Brophy. (Canada)
- 96 Medicine Use among Non-Western Ethnic Minority Groups Compared to Ethnic Danes [158]**
Birthe Sondergaard, Ebba H Hansen. (Denmark)
- 97 Socioeconomic Variations in Medicine Use among Children and Adolescents: Parent-Reported Data from the Five Nordic Countries [159]**
Bjorn E Holstein, Anette Andersen, Ebba Holme Hansen, Mette Madsen, Lennart Köhler. (Denmark)
- 98 Association between Nursing Home Staffing Levels and Off-Label Use of Antipsychotics [160]**
Tobias Gerhard, Judith Lucas, Stephen Crystal. (United States)
- 99 Adherence to Secondary Prevention One Year after Stroke. A Nation-Wide Follow-Up Study [161]**
Eva-Lotta Glader, Michael Lundberg. (Sweden)
- 100 Does Use of Prescribed Analgesics in Norway Differ between Young Adults with Norwegian and Immigrant Background? [162]**
Tomas Log, Svetlana Skurtveit, Ingeborg Hartz, Aage Tverdal, Kari Furu. (Norway)
- 101 Evaluation of the Fleetwood Model of Long Term Care Pharmacy [163]**
Kate L Lapane, Carmel M Hughes, Jennifer B Christian, Lori A Daiello, Kathleen A Cameron, Janice L Feinberg. (United States)
- 102 Quality of Perioperative Chemoprophylaxis in Orthopedics Surgery in Greece and Croatia [164]**
Paraskevi Papaioannidou, Vera Vlahovic-Palcevski, Fares Saieh, Branko Sestan, George Kapetanios. (Greece)
- 103 Drug Utilisation in First Users of Solifenacin (Vesicare) in General Practice in England [165]**
C Fogg, L Wilton, S Shakir. (United Kingdom)
- 104 Under-Prescribing of Prophylactic Oral Bisphosphonate Therapy for Osteoporotic Type Fractures [166]**
Kathleen Bennett, Bernadette McGowan, John Feely. (Ireland)
- 105 Drug Switching Patterns among Patients Using Ezetimibe: Claims Data Study [167]**
Sigal Kaplan, Tarek A Hammad. (United States)
- 106 Tumor Types and Chemotherapies Associated with rHuEPO Prescription [168]**
Sumitra Shantakumar, Monica G Kobayashi, Page E Abrahamson, Ashlee W Duncan. (United States)

POSTER SESSION A: MONDAY, AUGUST 18

107 Adverse Drug Reaction Reporting in Children: The Role of Community Pharmacies in Nigeria [169]

Kazeem A Oshikoya, Oduunayo I Sebanjo, Olisamedua FNjokanma. (Nigeria)

108 Pharmacoepidemiology (PE) and Adverse Drug Events (ADE): From Identification to Prevention [170]

A Gilbert, E Roughton, R Peck, G Killer. (Australia)

109 Use of Intravitreal (IVT) Injection Therapies in the General Population of the United States of America [171]

Charles W Wentworth, Felix M Arellano, Elena Rivero, Marco Pavesi, Debashish Dey, Alejandro Arana. (Spain)

110 Medication Use during Pregnancy: A Danish Population-Based Study [172]

Anne-Mette Bay Bjoern, Vera Ehrenstein, Heidi Hundborg, Mette Noergaard, Henrik Toft Sorensen. (Denmark)

DRUG DEVELOPMENT

111 Priority Diseases To Push for New Drugs and Licenses in Brazil in 2007 [173]

Carlos CF Vidotti, Lia LC Castro, Paulo F Almeida, Juliana P Oliveira, Vinicius Morita. (Brazil)

112 Development of a Tool for Blinded Safety Data Review [174]

Laura E Burlison, Claudia R Turner. (United States)

ECONOMICS

113 A GPRD Study of Healthcare Cost Associated with Different First-Line Antidepressant Treatments in Severe Depression [175]

Alan G Wade, Delphine Saragoussi, Nicolas Despiègel, Florent Guelfucci, Clément François. (France)

114 Incidence and Economic Burden of Renal Disease in HIV [176]

Beth L Nordstrom, Kathy H Fraeman, Matthew W Reynolds, Maria E Watson, M Keith Rawlings. (United States)

115 The Contribution of Persistence and Compliance with Bisphosphonates on Fracture Outcomes [177]

Stephan Rietbrock, Melvin Olson, Tjeerd P van Staa. (United Kingdom)

116 Persistence of Weekly Oral Bisphosphonate Therapy: Wasted Drug and Fracture Costs Due to Early Discontinuation [178]

Odile Sheehy, Christian Kindundu, Martin Barbeau, Jacques LeLorier. (Canada)

117 Economic Model for Newly Diagnosed Patient with Schizophrenia [179]

Sylvie Perreault, Alice Dragomir, Carey Levinton, Pierre Drapeau, Guy Rouleau. (Canada)

118 Management and Cost of Parkinson's Disease in the United States [180]

Judith A O'Brien, Alex Ward, Piedad Alvarez, Clare Pitoniak-Morse, Shannon Michels, Spyridon Tzivelekis. (United States)

119 Decision Model for the Evaluation of New Therapeutic Target in Patients with Schizophrenia [181]

Sylvie Perreault, Alice Dragomir, Carey Levinton, Pierre Drapeau, Guy Rouleau. (Canada)

EFFECTIVENESS RESEARCH

120 Use of Electronic Medical Records for Assessing Type 2 Diabetes Care [182]

Suzanne L West, Catherine Blake, Zhiwen Liu, Maryann Oertel, Nikki McKoy, Timothy S Carey. (United States)

121 Evaluation of Pharmacoepidemiology Trials: Rigour Methodologica Versus Rigor Mortis [183]

Anne Holbrook, Ivan Shcherbatykh, Janine Arkinson, Kathy Li, Kevin Wong, Daria O'Reilly, Ron Goeree, Hani Abushomar, Lehana Thabane, Lisa Dolovich, Janusz Kaczorowski. (Canada)

122 Choosing an Intervention To Reduce the Use of Benzodiazepine and Related Compounds in Australia [184]

Alesha J Smith, Susan E Tett. (Australia)

123 Real Time Post Marketing Evaluation of Therapeutic Risk Management Plans (RMPs) – A Novel Pharmacoepidemiological Tool? [185]

Anjan K Banerjee, Simon Ingate, Malgorzata Zienowicz, Freddie MacMahon, Andrew Hobbs. (United Kingdom)

124 What Is the Effectiveness of Computerised Alerts and Prompts on Clinicians' Prescribing Behaviour? [186]

Angela Schedlbauer, Tony Avery, Vibhore Prasad, Caroline Mulvaney, Wendy Stanton. (United Kingdom)

GASTROINTESTINAL

125 Concurrent Use of SSRIs and NSAIDs: Estimating the Number of Potential Gastrointestinal Events in Belgium Using an Ambulatory Prescription Database (Farmanet) [187]

Johan De Haes, André De Swaef. (Belgium)

126 Risk of Upper Gastrointestinal Complications with COX-2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs [188]

J Castellsague, CN Holick, CC Hoffman, MR Stang, L Lueck-Conteh, S Perez-Gutthann. (United States)

127 Abdominal Pain Is Commonly Associated with Other Pains in the General Population: Olmsted County Health Study [189]

Bahman Farahmand, Gunnar Brobert, Barbara Yawn, Mari-Ann Wallander. (Sweden)

128 Preadmission Use of Selective Serotonin Reuptake Inhibitors (SSRIs) Alone or in Combination with NSAIDs and Outcome of Peptic Ulcer Bleeding [190]

Christiane Gasse, Steffen Christensen, Anders Riis, Preben B Mortensen, Sven Adamsen, Reimar W Thomsen. (Denmark)

129 Association of New Onset Diabetes with Pancreatic Cancer [191]

Raja Tamaz, Marc Dorais, Agnes Rakel, Benoit Panzini, Jacques LeLorier. (Canada)

POSTER SESSION A: MONDAY, AUGUST 18

MEASUREMENT METHODS

- 130 Prescription Data Improve the Medication History in Primary Care [192]**
Bente Glintborg, Sara K Andersen, Henrik E Poulsen. (Denmark)
- 131 Is It Appropriate To Use Cardiovascular Risk Scores in Patients with Psychotic Disorders? [193]**
Katja Taxis, Susanne G Schorr, Manon Fouchier, Cees J Slooff, Richard Bruggeman. (Netherlands)
- 132 Measurement of 9 Pharmacoepidemiology Studies Database Quality [194]**
David Pau, Marie-Odile Barbaza, Nolwenn Hamon, Noemie Duffau, Francois Montestruc, Monique Malchiodi, Celine Rembliez, Estelle Schabelman. (France)
- 133 Diagnostic Codes for Sudden Cardiac Death and Ventricular Arrhythmia Functioned Poorly To Identify Outpatient Events in the General Practice Research Database [195]**
Sean Hennessy, Charles E Leonard, Cristin M Palumbo, Warren B Bilker, Craig Newcomb, Stephen Kimmel. (United States)
- 134 Utility of Multiple Databases in a Surveillance Program for Prescription Narcotic Analgesics [196]**
Kirk Midkiff, Catherine Johannes, Aparna Mohan. (United States)
- 135 Assessing Measures of Medication Adherence in Patients with Diabetes [197]**
Pamela J Johnson, Stephen Kogut. (United States)
- 136 Sensitivity Analyses of Methods Used To Estimate Concurrent Drug Use in a Register on Dispensed Drugs [198]**
Eva Lesen, Karolina Andersson, Anders Carlsten, Max Petzold. (Sweden)
- 137 Validation of Cases of Lymphoma in THIN [199]**
Felix M Arellano, Eulogio Conde, Charles E Wentworth III, Raymond Schlienger, Carlos Fernandez-Vidaurre, Alejandro Arana. (Spain)

- 138 Validity of Medication-Based Comorbidity Indices in the Australian Elderly Population [200]**
Agnes I Vitry, Soo Ann Wong, Elizabeth E Roughead, Emmae Ramsay. (Australia)

PSYCHOTROPICS

- 139 Comparing the Use of Drug Products Often Considered To Be Sleep Medication with Those Known To Be Taken for Express Purpose of Enhancing Sleep [201]**
C Ineke Neutel. (Canada)
- 140 Changes in Antidepressant Prescribing Patterns in Germany and the Netherlands in the Context of SSRI Warnings [202]**
Katrin Janhsen, Lolkje TW de Jong-van den Berg, Gerd Glaeske, Michael G Koelch. (Germany)
- 141 Risk of Ventricular Arrhythmia in Association with Atomoxetine Use in Adults [203]**
David D Dore, Jeanne Loughlin, Meghan E Jones, Mark E Bangs, Shao Zhu, Saadia B Chaudhry, John D Seeger. (United States)
- 142 Impact of Dosage and Duration of Therapy on the Risk of Hip Fracture Associated with the Use of Benzodiazepines and Related Drugs in the Elderly [204]**
Kristina Zint, Walter E Haefeli, Robert J Glynn, Helen Mogun, Jerry Avorn, Til Stürmer. (Germany)
- 143 Introduction of Low Dose Transdermal Buprenorphine – Did It Influence Use of Potentially Addictive Drugs in Chronic Non-Malignant Pain Patients? [205]**
Svetlana Skurtveit, Kari Furu, Stein Kaasa, Peter Borchgrevink. (Norway)
- 144 The Use of Lithium, Valproate or Lamotrigine as Mood Stabilizers in Children and Adolescents in Norway 2004-2007 [206]**
Jorgen G Bramness, Berit Groholt, Anders Engeland, Kari Furu. (Norway)

- 145 Factors Associated with Severe Adverse Reactions in Cholinesterase Inhibitor Users [207]**
Antoine Pariente, Dina Joseph-Reinette, Françoise Haramburu, Ghada Miremont-Salame, Nicholas Moore, Annie Fourrier-Reglat. (France)

- 146 Antidepressant Use among the Australian Elderly: A Longitudinal Study [208]**
Ying Zhang, Agnes Vitry, Veronica Chow, Gillian E Caughey. (Australia)

- 147 The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): How Design Impacted Operations [209]**
Sybil M Eng, Francesca Kolitsopoulos, Brian L Strom, Gerald Faich, Robert F Reynolds. (United States)

- 148 The Use of Lithium in the Adult Population (18 – 69 Years) in Denmark, Norway and Sweden [210]**
Jorgen G Bramness, Gunilla Ringbäck Weitoft, Jesper Hallas. (Norway)

- 149 Pharmaco-Economical Comparison across Antidepressant Treatments: Impact of Non-Persistence [211]**
Antoine Pariente, Mathieu Lebeau, Marie Tournier, Guillaume Galbaud du Fort, Ralph Crott, Thierry Ducruet, Yola Moride. (France)

- 150 Disability Pension Predict Use of Anxiolytics and/or Hypnotics 20 Years Later – A Prospective Study [212]**
Eldar Lundesgaard, Svetlana Skurtveit, Aage Tverdal, Ingeborg Hartz. (Norway)

- 151 Risk Assessment & Drug Utilization of Anti-Depressants in Korea [213]**
JaYoung Kim, HongSerck Choi, MyungSil Hwang, EunKyung Yoon, BoKyung Son, DongDeuk Jang, Tae Moo Yoo. (Korea)



- 152 Psychotropic Drug Prescribing Patterns in the Norwegian General Population [214]**
Svein R Kjosavik, Sabine Ruths, Steinar Hunskaar. (Norway)

POSTER SESSION A: MONDAY, AUGUST 18

- 153 Drug Use Pattern of Centrally Acting Sympathomimetic Agents and Combinations with SSRIs and Melatonin [215]**
Jonny Olsson, Nils Feltelius, Michael Lundberg, Jane Ahlqvist-Rastad, Hans Melander, Lars von Knorring, Gunilla Sjölin-Forsberg. (Sweden)
- 154 Risk of Developing Dyslipidemia among Adolescents with Bipolar Disorder or Schizophrenia [216]**
Cheryl Enger, Meghan E Jones, Ludmila Kryzhanovskaya, Michael Doherty, Andrew T McAfee. (United States)
- 155 Changes in US Antidepressant and Antipsychotic Prescription Patterns in the Time Period Following FDA Actions [217]**
Carol Pamer, Sigal Kaplan, Yu-Te Wu, Tarek A Hammad, Andrew D Mosholder, George Rochester. (United States)

- 156 Risk of Suicide Attempts in Elderly Patients Receiving Antidepressants in Korean National Database Cohort [218]**
Ju-young Kim, Sun-young Jung, Ye-je Kim, Hwa-jung Kim, Byung-joo Park. (Republic of Korea)
- 157 Risk Drinking Behaviour among Psychotropic Drug Users in an Ageing Finnish Population: The FinDrink Study [219]**
Jenni Ilomaki, Maarit J Korhonen, Hannes Enlund, Abraham G Hartzema, Jussi Kauhanen. (Finland)
- 158 Comparison of Postmarketing Spontaneously Reported Adverse Events in Olanzapine-Treated Adolescent and Adult Patients [220]**
Ludmila Kryzhanovskaya, Deborah Falk, Leslie M Schuh, Joachim Wernicke. (United States)

- 159 The Prospective Association of Insomnia with Non-Medical Sedative Use Disorder [221]**
Boji Huang, Bridget F Grant, Deborah A Dawson, S Patricia Chou, Frederick F Stinson, Roger P Pickering. (United States)
- 160 Utilization and Switching of Antidepressants among Young and Old Adults [222]**
Karolina Andersson, Max G Petzold, Susanna M Wallerstedt. (Sweden)
- 161 Antipsychotic Use in the Nursing Home: The Role of the Special Care Unit [223]**
Jessica J Jalbert, Andrea Gruneir, Brian R Ott, Kate L Lapane. (United States)
- 162 Characteristics and Outcomes in Hospitalized Patients Treated with Intramuscular Antipsychotics: Analysis of a US Hospital Database [224]**
Karen C Holdridge, William B Saunders, Kenneth Hornbuckle, John Polzer, Meghan E Jones, John Houston, Sebastian Sorsaburu. (United States)



From **variables** to **value**.
 From **research** to **relevance**.
 From **data** to **discovery**.
 From **clarity of insight** to **real-world impact**.

At HealthCore, this is our purpose.
 To make health care better.



Safety & Epidemiology Research
 Prospective Effectiveness Research
 Health Economics & Outcomes Research

800 Delaware Ave., Fifth Floor / Wilmington, DE 19801
 P 302.230.2156 / F 302.230.2046 / info@healthcore.com
 www.healthcore.com

Visit us in the Exhibit Hall

POSTER SESSION A: MONDAY, AUGUST 18

USE OF INDICATORS

(Quality of Life, Patient's Perceptions, Quality of Care)

- 163 Blood Pressure Values Versus Diagnosis of Hypertension in Prescribing Quality Assessment [225]**

Liana Martirosyan, Flora M Haaijer-Ruskamp, Petra Denig. (Netherlands)

- 164 Quality and Efficiency in Swedish Health Care – Presentation of National Health Care Quality Indicators from the Prescribed Drug Register [226]**

Rickard Ljung, Max Köster, Gunilla Ringbäck Weitoft, Örjan Ericsson, Johan Fastbom. (Sweden)

- 165 Using Spatial Analysis To Show Heterogeneity of Drug Prescription Behavior [227]**

Tzu-Ming Liu. (Taiwan)

- 166 Quality Assessment Indicators at Diagnosis and at Follow-Up of Patients with Asthma and COPD: The Skaraborg Primary Care Research Database [228]**

Paolina Weidinger, J Lars G Nilsson, Ulf Lindblad. (Sweden)

- 167 Measuring Utilization of Potentially Inappropriate Psychotropics [229]**

Eva Lesen, Karolina Andersson, Anders Carlsten, Max Petzold. (Sweden)

- 168 Defining Explicit Criteria for Assessing Inappropriate Prescriptions to Elderly Patients in General Practice – A Modified Delphi Study [230]**

Sture Rognstad, Mette Brekke, Arne Fetveit, Joerund Straand. (Norway)

- 169 Quality of Life One Year after Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [231]**

A Dunant, P Sekula, JC Roujeau, L Naldi, S Halevy, B Davidovici, for the RegiSCAR-Study Group. (Germany)

- 170 Acceptance of General Practitioner Guidelines: Feedback from Questionnaire and Prescribing Data [232]**

Ingrid Schubert, Ingrid Koester, Veronika Lappe, Peter Ihle, Joachim Fessler. (Germany)

- 171 Assessment of Cardiovascular Risk Factors Revealing by Family Doctors and Its Lifestyle Modifications in Patients with Arterial Hypertension [233]**

Zulfia T Radjapova, Aynagul S Djumagulova, Andrew G Polupanov. (Kyrgyzstan)

- 172 Indicators for Preventable Adverse Drug Events in Type 2 Diabetic Patients: Development, Validity and Feasibility [234]**

Linda AA Thomsen, Birthe Sondergaard, Arne Melander. (Denmark)

End Session A

PROSANOS[®]
CORPORATION

Safety Signal Investigation

AERS & Spontaneous Reports

Pharmacovigilance Plan Tracking

Safety Epidemiology

Phase IV Studies

Leaders in
Real World
Safety and
Effectiveness

phimap

Patients in Real Practice

Pharmacoepidemiology

Outcomes Epidemiology

Observational Research

Product & Disease Registries

PASS

Pleased to announce the commercial release of
SAEfyWorks for active surveillance using medical
records and claims data.

SAEFYWORKS[™]
for observational pharmacovigilance

www.prosanos.com

www.adelphigroup.com

ANALYSIS METHODS

- 1 **Exenatide and Acute Pancreatitis: Time to Event Analysis [301]**
Syed Rizwanuddin Ahmad, David J Graham. (United States)
- 2 **Fixed Effects Models May Bias Meta-Analytic Summary Estimates [302]**
Almut G Winterstein, Jonathan Shuster. (United States)
- 3 **Deconstruction of Confounding by Indication in Non-Randomized, Observational Studies: Putting the Cart before the Horse [303]**
L Paige Chavers, L Scott Chavers. (United States)
- 4 **An Exploration of Methodologies To Individualize and Integrate Warfarin's Benefit and Harm [304]**
Jennifer A Pereira, Anne M Holbrook, Lehana Thabane, Carl van Walraven, Daniel M Witt, Thomas Delate. (Canada)
- 5 **Toward Automated Covariate Selection for Propensity Score Estimation [305]**
Ronald K Pearson. (United States)
- 6 **High-Dimensional Proxy Adjustment in Claims Data Studies of Drug Effects [306]**
Sebastian Schneeweiss, Jeremy Rassen, Robert J Glynn, Helen Mogun, Alan Brookhart. (United States)
- 7 **A Survey of the Conduct and Reporting of Systematic Reviews Assessing Adverse Effects of Drug Interventions [307]**
V Cornelius, M Perrio, L Smith, S Shakir. (United Kingdom)
- 8 **Neglected and Immortal Time Bias in Observational Studies: Anti-depressant Drug Use and Risk of Relapse/Recurrence [308]**
Helga Gardarsdottir, Toine CG Egberts, Eibert R Heerdink. (Netherlands)
- 9 **Variable Selection for Propensity Score Models Based on Risk Factors for the Outcome [309]**
Amanda R Patrick, Sebastian Schneeweiss, M Alan Brookhart, Robert J Glynn, Kenneth J Rothman, Jerry Avorn, Til Stürmer. (United States)

- 10 **A Dynamic Regression Model To Predict Impact of Fluoroquinolone Use on Ciprofloxacin-Resistant Escherichia Coli [310]**
A Gallini, E Degris, M Desplas, R Bourrel, M Archambaud, M Lapeyre-Mestre, JL Montastruc, A Sommet. (France)
- 11 **Estimation of the Distribution of Inter-Renewal Times of Prescriptions during Continuous Drug Use – An Approach Using Cross-Sectional Validation Data [311]**
Lars H Nielsen, Ellen C Loekkegaard, Yrsa A Hundrup, Niels Keiding. (Denmark)
- 12 **A Semi-Automated Process for the Evaluation of Safety Signals in Administrative Databases [312]**
Robertino M Mera, Gregory E Powell, Kathleen J Beach, Patrick B Ryan, Ed N Pattishall. (United States)
- 13 **Analysis of Hypoglycemic Events in Patients Treated with Anti-Diabetic Agents in a Claims Database [313]**
Rolin Wade, Ralph Quimbo. (United States)
- 14 **The Utilisation of Sample Selection Models To Account for Unobserved Confounding in Epidemiology [314]**
George Quartey, Mathieu Joyau, Maurille Feudjo-Tepie. (United Kingdom)
- 15 **Abstract Withdrawn by Author [315]**
- 16 **Identifying Cases of Persistent Pulmonary Hypertension in the Newborn within the General Practice Research Database Using the Clinical Free-Text Entries [316]**
Scott Devine, Tarek Hammad, Sigal Kaplan, Susan McCune, Hany Aly. (United States)

- 17 **Absence of Evidence and Evidence of Absence in Population-Based Studies [317]**
Marco Pavesi, Zuleika Aponte. (Spain)

ENDOCRINE/DIABETES

- 18 **Dramatic Rise in Anti-Obesity Drug Prescribing in Children and Adolescents: A Population-Based Study in the UK [318]**
Yingfen Hsia, Antje C Neubert, Russell M Viner, Ian CK Wong. (United Kingdom)

- 19 **An Increase in the Prevalence of Type 1 and 2 Diabetes in Children and Adolescents: A Population-Based Study in the UK [319]**
Yingfen Hsia, Antje C Neubert, Fariz Rani, Russell M Viner, Peter C Hindmarsh, Ian CK Wong. (United Kingdom)
- 20 **Change from Oral Antidiabetic Therapy to Insulin and Risk of Urinary Tract Infections in Type 2 Diabetic Patients: A Population-Based Prescription Study [320]**
Anne Katrine Sanden, Martin Berg Johansen, Lars Pedersen, Hans-Henrik Lervang, Henrik Carl Schonheyder, Henrik Toft Sorensen, Reimar Wernich Thomsen. (Denmark)
- 21 **INSTIGATE Study (Insulin Titration: Gaining an Understanding of the Burden of Type 2 Diabetes in Europe): French Results after a 6 Month Follow up [321]**
Marie-Aline Charles, Carole Salaun-Martin, Jonathan Pentel, Florence Chartier, Stephaie Tchery, Francis Fagnani. (France)
- 22 **Use of Bisphosphonates and Risk of Atrial Fibrillation and Flutter [322]**
Steffen Christenen, Frank Mehnert, Lars Pedersen, Roland D Chapurlat, Steven R Cummings, John A Baron, Henrik T Sorensen. (Denmark)
- 23 **Non-Persistent Use of Oral Antidiabetic Drugs Leads to 20% Decreased Probability of HbA1c Goal Attainment in Daily Practice [323]**
Fernie JA Penning-van Beest, Sjoukje van der Bij, Joelle A Erkens, Heather Falvey, Ron MC Herings. (Netherlands)
- 24 **Utilization & Patient Experience with Obesity Prescriptions in the US [324]**
S Pokras, D Klingman, K Annunziata, J Chapnick, J Tierce. (United States)
- 25 **Femoral Bone Mineral Density and Warfarin Therapy; an Analysis of NHANES III [325]**
Mitsuyo Kinjo, Daniel H Solomon, Soko Setoguchi. (Japan)

POSTER SESSION B: TUESDAY, AUGUST 19

26 Factors Associated with Prescription of Obesity Medications in the US [326]

Shibani Pokras, David Klingman, Jonothan Tierce. (United States)

27 Cardiovascular Morbidity and Mortality in Patients with Diabetes Receiving Glucose-Lowering Treatment: A Population Based Study of 3.3 Million [327]

Tina K Schramm, Gunnar H Gislason, Soren Rasmussen, Jeppe N Rasmussen, Mette Madsen, Allan Vaag, Christian Torp-Pedersen. (Denmark)

28 Primary Preventative Cardiovascular Therapies for Diabetes Patients in Ireland [328]

Nur Zaharan, Kathleen Bennett, John Feely. (Ireland)

29 Relation between Diabetes Related Lifestyle Factors and Medication Use in Diabetes Management [329]

C Ineke Neutel. (Canada)

30 Psoriasis and Incident Diabetes Mellitus [330]

Yolanda B Brauchli, Susan S Jick, Christoph R Meier. (Switzerland)

31 HbA1c Goal Attainment in Relation To Dose among Compliant Diabetes Patients Using Metformin [331]

Fernie JA Penning-van Beest, Bruce HR Wolffenbuttel, Ron MC Herings. (Netherlands)

32 Exubera Large Simple Trial To Evaluate Pulmonary and Cardiovascular Safety (VOLUME Study): Design and Rationale [332]

Nicolle M Gatto, Richard Riese, Neville Jackson, Robert F Reynolds. (United States)

33 Timing of Thiazolidinedione Initiation and Risk of Acute Myocardial Infarction [333]

David D Dore, Amal N Trivedi, Vincent Mor, Kate L Lapane. (United States)

34 Corticosteroids Prescribing and Diabetes in Primary Care [334]

Nur Zaharan, Kathleen Bennett, John Feely. (Ireland)

ERROR PREVENTION/ PATIENT SAFETY

35 Potentially Inappropriate Prescribing for the Elderly [335]

Kira I Megyesi, Maria Matuz, Ria Benko, Peter Doro, Gyongyver Soos. (Hungary)

36 Consumer Perceptions on Drug Safety: Results from a Population-Based Survey [336]

Kristen B Levine, Suzanne L West, Mary Mease, Axel K Olsen. (United States)

37 The Influence of Educational Level on Polypharmacy and Inappropriate Drug Use in the Elderly: A Register-Based Study of over 600,000 Older People [337]

Syed Imran Haider, Kristina Johnell, Mats Thorslund, Gunilla Ringbäck Weitoft, Johan Fastbom. (Sweden)

38 Prescriptions to Patients Discharged from Hospitals Requiring Pharmacists Interventions [338]

Svein Haavik, Silje Soeviknes, Inge Kjoeniksen, Margrete Einen, Anne G Granas. (Norway)

39 Drug-Related Problems Associated with Various Antibiotics: Risk Grading by Use of a Novel Method [339]

Hege S Blix, Kirsten K Viktil, Tron A Moger, Aasmund Reikvam. (Norway)

40 Pharmacists' Actions To Tackle Medication-Related Safety Problems in General Practices [340]

Sarah Rodgers, Sadaf Qureshi, Anthony J Avery. (United Kingdom)

GASTROINTESTINAL DRUGS

41 Patterns of Crohn's Disease Medications among U.S. Veteran Patients: Associations with Fistulas and Cancers [341]

John A Hermos, Elizabeth V Lawler, Melissa M Young, Erika F Holmberg, David R Gagnon, Richard E Scranton. (United States)

42 In Patients with Preexisting Renal Dysfunction Oral Sodium Phosphate Is Associated with Creatinine Increase Compared to Polyethylene glycol [342]

Stefan Russmann, Lois Lamerato, Stephen P Motsko, John Pezzullo, Mark Faber, Judith K Jones. (Switzerland)

43 Fracture Risk in Patients Receiving Concomitant Bisphosphonate and Proton Pump Inhibitors or Bisphosphonates Alone: The UK General Practice Research Database [343]

Frank de Vries, Alun Cooper, Richard Logan, Sarah Cockle, Cyrus Cooper, Tjeerd-Pieter van Staa. (United Kingdom)

44 Influence of New Reimbursement Regulations in Norway on the Use of Proton Pump Inhibitors [344]

Christian Berg, Solveig Sakshaug. (Norway)

45 Patterns of PPI Prescription during Outpatient Medical Visits from 1995-2004 in the US [345]

Brian J Quilliam, James Higginbottom, E Paul Larrat. (United States)

HEMATOLOGICAL

46 How Effective Are Dose-Adjusted Warfarin and Aspirin for the Prevention of Stroke in Patients with Chronic Atrial Fibrillation? An Analysis of the UK General Practice Research Database [346]

Arlene M Gallagher, Stephan Rietbrock, Jonathan Plumb, Tjeerd P van Staa. (United Kingdom)

47 Systematic Review of Case Reports: Nonchemotherapy Drug-Induced Agranulocytosis in Children [347]

Frank Andersohn, Christine Konzen, Edeltraut Garbe. (Germany)

48 Risk of Cataracts among Persons with Idiopathic Thrombocytopenia Purpura [348]

Cheryl Enger, Dimitri Bennett, Ulla Forssen, Claire Chiang, Andrew T McAfee. (United States)

POSTER SESSION B: TUESDAY, AUGUST 19

- 49 Glucocorticoid Use Is Not Associated with Neutrophilia among Hospitalised Patients [349]**
Karin J Velthove, Madelon Bracke, Patrick C Souverein, René C Schweizer, Hubert MG Leufkens, Wouter W van Solinge. (Netherlands)
- 50 Real-Life Post-Marketing Use of Bortezomib, a Targeted Therapy, in France [350]**
Angela Grelaud, Magali Rouyer, Alise LeMonies, Jérémy Jové, Patrick Thomare, Nicholas Moore, Annie Fourrier-Réglat. (France)
- 51 Chemotherapeutic Agents Used in Patients with Malignant Mesothelioma and Their Myelotoxicity: A Retrospective Survey in the West Part of Japan [351]**
Shuko Nojiri, Tsugumichi Sato, Takuhiro Yamaguchi, Kennichi Gemba, Keisuke Aoe, Katsuya Kato, Takumi Kishimoto, Kiyoshi Kubota. (Japan)
- 52 Evaluation of Safety Outcomes with Hepatitis C Therapy in the United States Department of Veterans Affairs [371]**
Lewis E Kazis, Sheikh U Iqbal, Francesca Cunningham, Austin Lee, Donald Miller. (United States)
- 56 Opioid Analgesic Treatment during Pregnancy and Adverse Fetal Outcomes [355]**
CS Broussard, J Reefhuis, JM Friedman, S Rasmussen, M Jann, M Honein, the National Birth Defects Prevention Study (NBDPS). (United States)
- 57 Determinants of Early Medical Management of Nausea and Vomiting of Pregnancy [356]**
Anais Lacasse, Evelyne Rey, Ema Ferreira, Caroline Morin, Anick Berard. (Canada)
- 58 Use of Meta-Analysis To Interpret a Signal in Pregnancy Registries [357]**
George Quartey, Camille Maringe, Marianne Cunnington, John Weil. (United Kingdom)
- 59 Drug Use in Pregnancy – Service and Clinical Impact of Drug Information Centres [358]**
Sofia Frost Widnes, Jan Schjott. (Norway)
- 60 Use of Antirheumatic Drugs in Mothers and Fathers before and during Pregnancy – 2004-2006 [359]**
Kari Furu, Anders Engeland, Kirsten KViktil. (Norway)
- 61 First Trimester Paroxetine Use and the Prevalence of Congenital, Specifically Cardiac, Defects: A Meta-Analysis [360]**
Keele E Wurst, Charles Poole, Sara A Ephross, Andrew F Olshan. (United States)
- 62 Discontinuation of Antihypertensive Drug Use during the 1st Trimester of Pregnancy and the Risk of Pre-Eclampsia and Eclampsia [361]**
Hamid Reza Nakhai-Pour, Driss Orachi, Evelyne Rey, Anick Berard. (Canada)
- 63 The General Practice Research Database as a Pregnancy Registry System: Anticonvulsants as an Example [362]**
Rachel Charlton, John Weil, Marianne Cunnington, Corinne de Vries. (United Kingdom)
- 64 Changes in Antibiotic Prescription in Pregnancy Are Not Explained by Present Guidelines [363]**
Jon Andersen, Jeppe Rasmussen, Bente Glintborg, Susan Pedersen, Christian Torp-Pedersen, Anne-Marie Andersen, Mette Madsen, Jesper Hallas, Henrik Poulsen. (Denmark)
- 65 The Role of Chance in the Generation of Signals for Specific Defect Types among Multiple Anti-Epileptic Drug Pregnancy Registries [364]**
Marianne Cunnington, Camille Maringe, George Quartey, John Weil. (United Kingdom)
- 66 Exposure to Herbal Products during Pregnancy and the Risk of Preterm Birth [365]**
Krystal Moussally, Driss Oraichi, Anick Berard. (Canada)
- 67 Therapeutic Opioid Analgesic Use before and during Pregnancy, National Birth Defects Prevention Study (NBDPS), 1997-2003 [366]**
CS Broussard, JM Friedman, SA Rasmussen, J Reefhuis, MW Jann, MA Honein, the NBDPS. (United States)
- 68 EFEMERIS: Evaluation Chez la Femme Enceinte des Medicaments et de Leur RISque. A French Database Allowing Evaluation of Risks Related to Drugs in Pregnancy [367]**
Isabelle Lacroix, Caroline Hurault, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 69 Prevalence and Predictors of Antibiotics Use during Pregnancy [368]**
Fabiano Santos, Driss Oraichi, Anick Berard. (Canada)
- 70 Antiepileptic Drug Use during Pregnancy and Pregnancy Outcomes [369]**
M Artama, H Malm, A Ritvanen, M Gissler, M Paldán, T Sévon, K Tyrkkö, J Meriläinen, T Klaukka, E Palva, O Nylander. (Finland)
- 71 Buprenorphine High Dosage in Pregnancy: A Prospective Survey [370]**
Isabelle Lacroix, Alain Berrebi, Daniel Garipuy, Laurent Schmitt, Christine Damase-Michel. (France)

MEDICATIONS IN PREGNANCY (SIG)

- 53 Oral Contraception Use before Pregnancy and the Risk of Gestational Hypertension, Pre-Eclampsia and Eclampsia [352]**
Anick Berard, Driss Oraichi. (Canada)
- 54 Do Drug Warnings and Withdrawals Have an Impact on the Number of Calls to Teratogen Information Services (TIS)? [353]**
Marie-Pierre Gendron, Driss Oraichi, Anick Berard. (Canada)
- 55 Herbal Product Use during Pregnancy: Prevalence and Predictors [354]**
Krystal Moussally, Driss Oraichi, Anick Berard. (Canada)

PHARMACOVIGILANCE

- 72 Causality and Definitions: How General Practitioners Decide What To Report to Spontaneous Reporting Schemes [372]**
Anthony R Cox, John F Marriott, Kay MG Wood, Robin E Ferner. (United Kingdom)

POSTER SESSION B: TUESDAY, AUGUST 19

- 73 **RevAssist®: Initial and Follow-Up Knowledge Surveys [373]**
Edgar H Adams, Paige Chavers, Carmen Castaneda, Maria Luisa Salomon, Nancy A Brandenburg. (United States)
- 74 **Sudden Death and Treatment with New Generation Antipsychotics: Data from the WHO Database of Adverse Drug Reactions (Vigibase) [374]**
John Karlsson, Staffan Hägg, Kristina Star, Susanna M Wallerstedt. (Sweden)
- 75 **Association between Alendronate Usage and Vitreous Detachment: A Cohort Study [375]**
Anna CE Shafe, Lesley Wise. (United Kingdom)
- 76 **Assessment of a Potential Signal for Severe Gastrointestinal Complications with Antipsychotics [376]**
Helen Huang, Zhiping Huang. (United States)
- 77 **Comparisons of Data Mining Algorithms for ADRs: An Empirical Study Based on the AERS of the FDA [377]**
Yan Chen, Jeff J Guo, Nick C Patel, Michael Steinbuch, Xiaodong Lin, Charles R Buncher. (United States)
- 78 **Knowledge and Attitude to the Spontaneous ADR Reporting System; Doctors and Pharmacists in Korea [378]**
Joongyub Lee, Hwa Jung Kim, Byung-Joo Park. (Republic of Korea)
- 79 **Safety Profile of Modafinil Used in General Practice in England: A Modified Prescription Event Monitoring Study [379]**
M Davies, L Wilton, S Shakir. (United Kingdom)
- 80 **Risk of Hepatotoxicity Associated with the Use of Telithromycin (Ketek®): A Safety Signal from the AERS [380]**
Yan Chen, Jeff J Guo, Nick C Patel, Michael Steinbuch, Xiaodong Lin, Charles R Buncher. (United States)
- 81 **Detection of Drug Induced Blood Dyscrasias, Hepatitis and Pancreatitis – Outcomes of the Case-Control Surveillance Study from the National Pharmacovigilance-Center Berlin (PVZ-FAKOS) [381]**
Michael Thomae, Elisabeth Bronder, Frank Andersohn, Andreas Klimpel, Edeltraud Garbe. (Germany)
- 82 **Clinical Features of Adverse Drug Reactions in Korea [382]**
Yoo Seob Shin, Yong Won Lee, Young Hwa Choi, Byung Joo Park, Young Koo Jee, Sung Kyu Choi, Eng Kyu Kim, Chein-Soo Hong, Jung-Won Park. (Republic of Korea)
- 83 **Abstract Withdrawn by Author [383]**
- 84 **Fixed Dose Combinations and Call for Effective Pharmacovigilance System in Action in India [384]**
Deepa Alimchandani, Pipasha Biswas. (United Kingdom)
- 85 **Comparison of Sensitivity and Specificity of Two Nonlinear Models To Detect Opioid Analgesic Abuse [385]**
Meredith Smith, David Banks, Jarad Niemi. (United States)
- 86 **Pregabalin – Interim Results of the Intensive Monitoring Study [386]**
Linda Härmark, Eugène P van Puijenbroek, Ingrid Oosterhuis, Kees van Grootheest. (Netherlands)
- 87 **Selfreported Adverse Effects in Heart Failure Patients: Proportion, Coping Strategies, and Patients at Risk [387]**
Ruth HE De Smedt, Tiny Jaarsma, Flora M Haaijer-Ruskamp. (Netherlands)
- 88 **The Effect of Bolus Reports from Published Literature on Signal Detection: The Thioguanine (Tabloid) Experience [388]**
Isaac W Hammond, Lina R Bharné, Gregory E Powell, Trevor G Gibbs. (United States)
- 89 **Design & Evaluation of a Specific Algorithm for Drug Causality Assessment in Stevens-Johnson and Toxic Epidermal Necrolysis [389]**
B Sassolas, C Haddad, A Dunant, M Mockhenhaupt, D Vieluf, K Bork, UF Hausteiner, H Le Louet. (France)
- 90 **Respiratory Adverse Events and Outcomes with Salmeterol-Fluticasone: Post-Marketing Experience [390]**
June Almenoff, Dawn Clines, Steve Yancey, Nancy Yuen. (United States)
- 91 **Clinical Pattern of Adverse Drug Reactions Associated with Antibiotics in a Korean University Hospital Inpatient Population [391]**
Hye-Ryun Kang, Yoo-Rim Kim, So-Young Uhm, Eun-Kyung Lee. (Korea)
- 92 **Syncope, Convulsive Syncope and Traumatic Injury after Human Papillomavirus and Other Adolescent Immunizations [392]**
Andrea Sutherland, Hector S Izurieta, Robert Ball, Claudia Vellozzi, Laura Leidel, Wan-Tin Huang, Jane Woo, Wei Hua, John Iskander, Nancy Miller, Douglas Pratt, M Miles Braun. (United States)
- 93 **Adverse Drug Reaction Hospitalization Index: A Comparison of the Most Frequently Implicated Therapeutic Groups [393]**
Zdravko P Vassilev, Alvin F Chu, Edgar H Adams, Steven M Marcus. (United States)
- 94 **Montelukast and Psychiatric Disorders in Children [394]**
Susanna M Wallerstedt, Gertrud Brunlöf, Anders Sundström, Anna L Eriksson. (Sweden)
- 95 **Do Standardized MedDRA Queries Add Value to Safety Data Mining? [395]**
Nancy Yuen, David Fram, Dana Vanderwall, June Almenoff. (United States)
- 96 **Empirical Bayesian Data Mining for Discovering Safety Signals in Military Electronic Health Records [396]**
Trinka S Coster, David Fram, William DuMouchel, Ana Szarfman, Azra Dobardzic, Suji Xie. (United States)
- 97 **An Analysis of Glitazone Use and Small Bone Fractures Using the GPRD Database [397]**
David Irvine, Lesley Wise. (United Kingdom)

POSTER SESSION B: TUESDAY, AUGUST 19

- 98 **Abstract Withdrawn by Author [398]**
- 99 **Datamining Using a Company's Proprietary Safety Database: Preliminary Results [399]**
SR Bailey, A Singh, R Azadian, P Huber, M Blum. (United States)
- 100 **Resources Required To Investigate Prospective Datamining on 6 Marketed Drugs [400]**
SR Bailey, P Huber, R Azadian, A Singh, M Blum. (United States)
- 101 **Safety Profile of Pimecrolimus Used in General Practice in England: A Prescription Event Monitoring Study [401]**
Yvonne Buggy, Lynda Wilton, Vanessa Marshall, Saad Shakir. (United Kingdom)
- 102 **Time from Factory Release To Use of Medication: A Neglected Issue When Adjusting Adverse Event Report Counts for Exposure [402]**
Wenjun Jiang, Daniel Fife, Aparna K Mohan, Nicole Cossrow. (United States)
- 103 **Who Reports Suspected Adverse Drug Reactions to the Spontaneous Reporting System in Sweden? [403]**
Ingela Jacobsson, Marit Danell Boman, Anna K Jönsson, Staffan Hägg. (Sweden)
- 104 **A 24-Month Modified Prescription Event Monitoring (PEM) Study for Travoprost [404]**
M Davies, L Wilton, S Shakir. (United Kingdom)
- 105 **Seminars on Adverse Drug Reactions to Primary Health Care Centres - Effects on Frequency and Quality of Adverse Drug Reaction Reports [405]**
Gertrud Brunlöf, Marie-Louise Johansson, Anna L Eriksson, Susanna M Wallerstedt (Sweden)
- 106 **Patients Starting Anti-Obesity Drugs Carry Higher Psychiatric and Cardiovascular Risk [406]**
Marjolein JC Willemsen, Aukje K Mantel-Teeuwisse, Sabine MJM Straus, Antoine CG Egberts, Hubert GM Leufkens, Miriam CJM Sturkenboom. (Netherlands)
- 107 **A Review of Post-Marketing Safety Studies Submitted to the UK Regulator from 1993-2005 [407]**
Anna CE Shafe, Lesley Wise, Patrick Waller. (United Kingdom)
- 108 **Observational Screening: A Novel Approach to Analyzing Observational Data To Supplement Post-Approval Signal Detection [408]**
Patrick B Ryan, Gregory E Powell, Ed N Pattishall. (United States)
- 109 **Health Care Professionals' Attitudes and Awareness of US Spontaneous AE Reporting System: Survey Results [409]**
Paul Stang, Gretchen Dieck, Linda Hostetler, Jean-Louis Saillot, Glen Gormley, Bruce Burlington. (United States)
- 110 **Results of a Subsequent Datamining Run on AERS after Completion of Initial Signal Detection Analysis [410]**
SR Bailey, P Huber, R Azadian, A Singh, M Blum. (United States)



Now Available
for Brazil,
Russia, India,
and China

The Most Trusted Industry Resource

Epi Database® is the premier online database that provides reliable, documented, and well-researched epidemiological estimates.

Unsurpassed Breadth of Coverage

Epi Database® includes over 190 indications¹ and covers the following geographies: France, Germany, Italy, Spain, the United Kingdom, Japan, the United States, **Brazil, Russia, India, and China**

In-Depth Analysis with Projections to 2025

All epidemiologies are thoroughly researched in scientific literature, including public and private data sources.

Breakouts are provided by country, indication, and year, as well as gender, race, and age if applicable.²

Fully documented sources provide complete transparency.

Epis are reviewed on an annual basis and updated periodically.

Trusted for Major Product Decisions

The first place to start for key management decisions:

- Market Definitions / Potential
- Go / No-Go Decisions
- Additional Indications for In-Line Products
- Licensing Opportunities
- Drug Discovery Prioritization

¹ Indications may vary by country. ² Gender, age, and race breakouts may vary by indication and country.

MATTSONJACK

11960 Westline Drive, Suite 180 • St. Louis, Missouri 63146 USA
Tel: 314.469.7600 Fax: 314.469.6794
products@mattsonjack.com • www.mattsonjack.com

POSTER SESSION B: TUESDAY, AUGUST 19

111 Prescription of Topical Immunomodulators – How Recommendations Are Followed in Denmark [411]
Mary Rosenzweig. (Denmark)

112 Repeated E-Mails with ADR Information and a Current Case Report May Affect the ADR Reporting Rate and the Quality of the Reports [412]
Marie-Louise Johansson, Gertrud Brunlof, Christina Edward, Susanna M Wallerstedt. (Sweden)

113 RevAssist® – A Comprehensive Risk Minimization Program for Preventing Fetal Exposure to Lenalidomide [413]
Carmen Castaneda, Nancy A Brandenburg, Maria Luisa F Salomon, John Freeman. (United States)

114 Adverse Drug Reactions Induced by Cardiovascular Drugs in Hospitalized Patients [414]
Kheirollah Gholami, Niayesh Mohebbi, Gloria Shalviri, Jamshid Salamzadeh, Mojtaba Salarifar. (Islamic Republic of Iran)

115 Choice of Comparison and Impact of Stratification in Vaccine Pharmacovigilance [415]
Malin Jakobsson, Niklas G Norén, Johan Hopstadius, Andrew Bate. (Sweden)

116 Fluoroquinolones and the Risk of Achilles Tendon Disorders: A Self-Controlled Case Series Study [416]
Yan Chen, Vitali Pool, Kenneth Hornbuckle, Indiana M Strombom. (United States)

PULMONARY/RESPIRATORY

117 The Association between Use of Asthma Drugs and Prevalence of Demarcated Opacities in Permanent Teeth in 6-to-8-Year-Old Danish Children [417]
Pia Wogelius, Dorte Haubek, Alin Nechifor, Mette Noergaard, Torben Tvedebrink, Sven Poulsen. (Denmark)

118 Outcomes Evaluation Following 12-Month Treatment with Once Daily Tiotropium Compared with Four Times Daily Ipratropium/Salbutamol: A GPRD Study on Patients with COPD [418]
Jane Griffin, Sally Lee, Maria Caiado, David Price, Steven Kesten. (United Kingdom)

119 An Analysis of the Utilisation of Medicines Dispensed for the Management of Severe Asthma in Ireland [419]
Bernie McGowan, Kath Bennett, Michael Barry. (Ireland)

120 Management of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: Results of a French Cohort Study [420]
P Blin, S Lignot, S Lamarque, R Lassalle, M-A Bernard, D Guillemot, C Mayaud, N Moore, M Molimard. (France)

121 Exposures to Cough and Cold Preparations in Children Reported to U.S. Poison Control Centers [421]
Syed Rizwanuddin Ahmad, Ann McMahon. (United States)

122 Incidence Rate of Anaphylaxis in General Population and Asthma Patients in United Kingdom Using the Health Improvement Network (THIN) [422]
Zuleika Aponte, Antonio Gonzalez, Carlos Fernandez, Luis Garcia. (Spain)

123 Consumption of Beta-2-Agonists Used Supplementary to Steroids in Antiasthmatic Therapy Has Changed Significantly in Denmark [423]
Hans Klarskov Madsen. (Denmark)

124 Role of Age in Respiratory Syncycial Virus Infection Risk – Recommendations for Palivizumab Utilization [424]
Christian Hampp, Almut G Winterstein, Arwa Saidi. (United States)

125 Prevalence, Incidence and Persistence to Inhaled Anti-Asthma Medications in Individuals Aged < 30 Years in Norway [425]
Oystein Karlstad, Aage Tverdal, Svetlana Skurtveit, Per Nafstad, Kari Furu. (Norway)

126 Association between COPD and Selective Cardiovascular Diseases [426]
Cornelia Schneider, Susan S Jick, Christoph R Meier. (Switzerland)

RISK MANAGEMENT/COMMUNICATION

127 Drug Exposure and New Alerts for Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [427]
L Valeyrie-Allanore, C Haddad, M Mockenhaupt, L Naldi, JN Bouwes Bavinck, E Benedetti Placchesi, for the RegiSCAR-Study Group. (Germany)

128 TYSEDMUS: Cohort of Multiple Sclerosis Patients Treated with Tysabri® Using the French European Database for Multiple Sclerosis (EDMUS) – Methodological Aspects [428]
E Van Ganse, S Vukusic, L Zanetti, L Laforest, N Passante, I Achiti, B Frangoulis, F Rocher, C Ritleng, M Clanet, G Desamericq, A Castot, C Confavreux, Tysedmus Group. (France)

129 Does Written Standardized Information Improve Patient Understanding of DXA-Results? [429]
Dorthe Brask-Rasmussen, Suzanne M Cadarette, Peter C Eskildsen, Bo Abrahamsen. (Denmark)

130 The Impact of Patient Education and Physician Education on the Blood Pressure Control [430]
Fadia Shaya, Wallace Johnson, Anna Gu, Elijah Saunders. (United States)

131 Methodological Analysis of Post-Authorisation Safety Studies as Part of the First Cohort of Risk Management Plans: Small Molecules vs. Biologicals [431]
Thijs J Giezen, Aukje K Mantel-Teeuwisse, Sabine M Straus, Antoine C Egberts, Ingemar Persson, Hubert G Leufkens. (Netherlands)

132 Patients Treated with Insulin or Oral Blood Glucose Lowering Drugs and Risk of Road Traffic Accidents: A Registry-Based Cohort Study [432]
Svetlana Skurtveit, Hanne Strom, Torild Skriverhaug, Jorgen Bramness, Jorg Morland, Anders Engeland. (Norway)

133 Predictors of Isolated Systolic Hypertension in a Group of Inner City Minority Patients [433]
Fadia T Shaya, Wallace Johnson, Anna Gu, Elijah Saunders. (United States)

POSTER SESSION B: TUESDAY, AUGUST 19

134 Factors Predisposing an Abstract to be Accepted for Oral Presentation [434]

Anna K Jönsson, Ingela Jacobsson, Karolina Andersson, Staffan Hägg, Anders Sundström. (Sweden)

OBSERVATIONAL EFFECTIVENESS STUDIES

135 Developing and Leveraging a Patient-Centric Registry to Support Post-Marketing Safety Surveillance [435]

Elisa Cascade, Hugo Stephenson.

136 Survival of Women Treated with Trastuzumab for HER-2-Positive Metastatic Breast Cancer: Estimating Outcomes in Clinical Practice Using Administrative Data [436]

Clare Ringland, Sallie-Anne Pearson, Robyn L Ward. (Australia)

137 Drug Persistence on Anti-TNF-Agents in Psoriatic Arthritis [437]

Amr A Saad, Darren M Ashcroft, Kath D Watson, Kimme L Hyrich, Peter R Noyce, Deborah PM Symmons. (United Kingdom)

138 Internal and External Validity of Hermine French Cohort Study on 623 Metastatic Breast Cancer Patients Treated with Trastuzumab [438]

L Bergougnot, C Rembliez, F Campana, M-O Barbaza, C Cropet, M-C Le Deley. (France, Metropolitan)

139 Oral Isotretinoin and the Risk of Cardiovascular, Cerebrovascular and Thromboembolic Disorders [439]

Anick Bérard, Laurent Azoulay, Hamid Reza Nakhai-Pour. (Canada)

140 Factors Predictive of Institutionalization in a Population Based Cohort of Alzheimer's Disease Patients Dispensed Cholinesterase Inhibitors [440]

Joseph E Amuah, David B Hogan, Michael Eliasziw, Alison Supina, Patricia Beck, Winnane Downey, Colleen Maxwell. (Canada)

SUSTAINABLE ACCESS TO MEDICINES

141 A Cross-Sectional Survey of Drug-Company Sponsored Pharmacy Assistance Programs [441]

Niteesh K Choudhry, Joy L Lee, Jessica Agnew-Blais, Colleen P Corcoran, William H Shrank. (United States)

VACCINES

142 Influenza and Pneumococcal Vaccination Protect Against All Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease [442]

Stuart Schembri, Steve Morant, John Winter, Tom MacDonald. (United Kingdom)

143 Immunization of Pregnant Women with Tetanus-Diphtheria-Acellular Pertussis (Tdap) Vaccine: 29 Months of Data from the ADACEL Vaccine Pregnancy Registry [443]

Alena Khromava, Asif Mahmood, David R Johnson. (Canada)

144 Interim Estimation of Influenza Vaccine Effectiveness during the 2007-08 Season [444]

Edward Belongia, Burney Kieke, James Donahue, Laura Coleman, Jennifer Meece, Stephen Lindstrom, David Shay. (United States)

145 Idiopathic Acute Transverse Myelitis: Comparison of Patients with vs. without Receipt of a Vaccine within 30 Days Prior to Onset [445]

Yandong Qiang, Chitra Krishnan, Douglas A Kerr, Rosanna W Setse, Megan E Quigg, Neal A Halsey, CISA Network. (United States)

146 Influenza Vaccination Among Adults in Four North Carolina Counties, 2007-2008 [446]

Frank DeStefano, Douglas Currvan, Corliss Heath, Scott Wetterhall. (United States)

147 Surveillance of Adverse Events Following Immunization (AEFI) with Human Papillomavirus (HPV) Vaccine in Canada, (Sept. 2006 - Dec. 2007) [447]

Jean Nkanza. (Canada)

148 Comparison of Influenza Vaccine Effectiveness Estimates Using Clinician-Ordered Antigen Tests Versus Active Recruitment with PCR/Culture [448]

Laura Coleman, Burney Kieke, Stephanie Irving, David Shay, Mary Vandermause, Stephen Lindstrom, Edward Belongia. (United States)

End Session B



ICPE 2008



24th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

ANALGESICS/ ANTI-INFLAMMATORY AGENTS

- 1 New Incident Clinical Outcomes with Etoricoxib Use in the United Kingdom (UK) before and after the COX-2 Urgent Safety Restriction [485]**
Douglas J Watson, Bing Cai. (United States)
- 2 Adverse Drug Reactions to Local Anesthetics. A Review of the French Pharmacovigilance Database [486]**
Régis Fuzier, Maryse Lapeyre-Mestre, Jean-Louis Montastruc. (France)
- 3 The Feasibility of Linking the English Hospital Episode Statistics to the General Practice Research Database [487]**
Susan C Eaton, Tim J Williams, Shivani Puri, Tjeerd VanStaa. (United Kingdom)
- 4 Patterns of NSAID Prescribing in the UK: 2000-2005 [488]**
Suzie Seabroke, Lesley Wise. (United Kingdom)
- 5 Preadmission Use of Systemic Glucocorticoids and 30-Day Mortality Following Bleeding Peptic Ulcer - A Population-Based Cohort Study [489]**
Morten Olsen, Steffen Christensen, Anders Riis, Reimar W Thomsen, Henrik T Sorensen. (Denmark)
- 6 Outpatient Utilization of Non-steroidal Anti-Inflammatory Anti-rheumatic Drugs (NSAID) in the City of Zagreb 2001-2005 [490]**
Danijela Stimac, Josip Culig, Zvonimir Sostar, Mila Bicalic. (Croatia)
- 7 What Therapies Have Replaced Co-Proxamol in Ireland? [491]**
Mary Teeling, Kathleen Bennett, John Feely. (Ireland)
- 8 Predictors of High Cumulative Analgesic Use in Apparently Healthy Men [492]**
Tobias Kurth, Eunjung Kim, Robert J Glynn, J Michael Gaziano. (United States)
- 9 Less Gastrointestinal Risk, Similar Cardiovascular Risk among Users of Selective Compared to Non-Selective Non Steroidal Anti-Inflammatory Drugs [493]**
Michiel W van der Linden, Sjoukje van der Bij, Paco Welsing, Ernst J Kuipers, Ron M Herings. (Netherlands)
- 10 The Burden of Non-Steroidal Anti-Inflammatory Drug (NSAID) Utilization for Musculoskeletal Disorders in Blue-Collar Workers: A Population Cohort Study [494]**
Michel Rossignol, Abdelilah Abouelfath, Régis Lassalle, Cécile Droz, Bernard Bégaud, Fanny Depont-Hébert, Yola Moride, Patrick Blin, Nicholas Moore, Annie Fourier-Réglat. (Canada)
- 11 Are Traditional NSAIDs Prescribed Appropriately Among French Elderly? Results from the CADEUS Cohort [495]**
Sinem Ezgi Gulmez, Cecile Droz-Perroteau, Régis Lassalle, Nicholas Moore, Annie Fourier-Reglat. (France)
- 12 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs and the Risk of Hospitalization with Acute Kidney Injury [496]**
Jean-Philippe Lafrance, Donald R Miller. (United States)
- 13 Impact of the Rofecoxib Withdrawal on the Prescription Patterns of "Simple Analgesic Agents" [497]**
Marc Dorais, Jacques LeLorier. (Canada)
- 14 Changes in the Characteristics of Patients Prescribed Selective Cox-2 Inhibitors after the 2004 Withdrawal of Rofecoxib [498]**
Efrosini Setakis, Hubert GM Leufkens, Tjeerd P van Staa. (United Kingdom)
- 15 Low Utilization of Gastroprotection among New Chronic Users of Non-Steroidal Antiinflammatory Drugs in The Netherlands [499]**
Michiel W van der Linden, Ernst J Kuipers, Myrthe P Sukel, Bart J van den Bemt, Ron M Herings, Sabine Gaugris. (Netherlands)
- 16 Ex-Drinking May Add the Risk of Upper Gastrointestinal Bleeding (UGIB) in Patients Prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [500]**
Hikaru Watanabe, Yukari Kamijima, Tsugumichi Sato, David W Kaufman, Kiyoshi Kubota. (Japan)
- 17 The Use of Lumiracoxib in General Practice in England: Results of a Modified Prescription-Event Monitoring (PEM) Study [501]**
Deborah Layton, Vanessa Marshall, Saad Shakir. (United Kingdom)
- 18 Increased Risks of Hospitalization for Acute Non-Viral Hepatitis in Patients Treated with Celecoxib in Taiwan [502]**
Chang-Hsing Lee, Jung-Der Wang, Pau-Chung Chen. (Taiwan)
- 19 Low-Dose Aspirin and Risk of Subarachnoid Haemorrhage. A Population-Based Case-Control Study [503]**
Martin B Johansen, Steffen Christensen, Henrik T Sorensen. (Denmark)
- 20 Incidence of Hospitalization for Serious Hepatic Events Associated with NSAIDs Use [504]**
Benoit Panzini, Marc Dorais, Jacques LeLorier. (Canada)
- 21 Prevalence of Chronic Analgesic Use in Alzheimer's Disease in REAL.FR Study [505]**
A Gallini, V Gardette, S Gillette-Guyonnet, F Nourhashemi, B Vellas, M Lapeyre-Mestre, S Andrieu, C Brefel-Courbon, the REAL.FR Study Group. (France)

ANTI-INFECTIVES

- 22 Is Short Term Treatment with Pivmecillinam More Effective Than Sulfamethizole in Patients with Acute Uncomplicated Urinary Tract Infection? [506]**
Lars Bjerrum, Bente Gahrn-Hansen, Per Grinsted. (Denmark)
- 23 Results of Policy Implementation on Antibacterial Use [507]**
Ria Benko, Maria Matuz, Zoltan Peto, Peter Doro, Anna Molnar, Emese Csullog, Edit Hajdu, Gyongyver Soos. (Hungary)

POSTER SESSION C: WEDNESDAY, AUGUST 20

- 24 **Antibiotic Use and Microbiological Surveillance: An Ecological Study in an Italian University Hospital [508]**
M Chiara Silvani, Laura Bersaglia, Elisabetta Poluzzi, Domenico Motola, Anna Nanetti, Simone Ambretti, Ambrogio Bottoni, Alberto Vaccheri, Nicola Montanaro. (Italy)
- 25 **Antibiotic Drug Use of Children in the Netherlands from 1999 till 2005 [509]**
Josta de Jong, Paul B van den Berg, Tjalling W de Vries, Lolkje TW de Jong- van den Berg. (Netherlands)
- 26 **Antibiotic Use among Unskilled Veterinary Practitioners in India: Case Studies of Five Unskilled Animal Practitioners [510]**
Rajesh Kumar, Nilesch Kumar. (India)
- 27 **In-Depth Analyses of Systemic Antibacterial Monotherapy among Adult Outpatients [511]**
Maria Matuz, Ria Benko, Peter Doro, Edit Hajdu, Gyongyver Soos. (Hungary)

- 28 **Prevalence of Drug-Resistant Salmonella from Retail Chicken and Comparison with Human Clinical Isolates [512]**
Nkuchia M. Mikanatha, Carol H. Sandt, Russell Localio, Deepanker Tewari, Anthony Russo, Sean F. Altekruse, James Tait, Michael Hydock, Stanley Reynolds, Tom M. Chiller, Shelley Rankin, Ebbing Lautenbach, Patrick McDermott, for PA Antimicrobial Resistance Study Group. (United States)
- 29 **Utilization of Antibiotics among Patients with Diabetes [513]**
Peter Doro, Ria Benko, Maria Matuz, Gyongyver Soos. (Hungary)
- 30 **Could Changing Therapy Trends in the Use of Antibacterials in Norway Be Explained by Rational Prescribing? [514]**
Irene Lilleskare, Hege S Blix, Marit Ronning. (Norway)

BIRTH DEFECTS

- 31 **Anti-TNF Treatment during Pregnancy and Birth Outcomes – A Population Based Study [515]**
Helle Kieler, Fredrik Granath, Michael Fored, Olof Stephansson, Mette Norgaard, Lars Pedersen, Greg Keenan, Scott Chavers, Mirza Rahman. (Sweden)
- 32 **Vaccine Safety in Pregnancy: Can We Identify Exposures? [516]**
Carol Louik, Christina Chambers, Allen A Mitchell. (United States)
- 33 **Maternal Periconceptional Use of Dextromethorphan and Selected Birth Defects [517]**
PA Romitti, L Sun, AM Herring, CM Druschel, AA Mitchell, MM Werler, C Louik, RS Olney. (United States)

Procter & Gamble Pharmaceuticals

Committed to advancing
pharmacoepidemiological
research....

Committed to improving
patient health outcomes.

Touching lives, improving life. **P&G**™



POSTER SESSION C: WEDNESDAY, AUGUST 20

- 34 GPRD Study of Pregnancy Outcomes Following the Prescribing of DMARDs [518]**
Fokaline Vroom, Julia Snowball, Anita McGrogan, Lolkje de Jong-van den Berg, Corinne de Vries. (United Kingdom)
- 35 Last Menstrual Period Estimation Techniques Compared to Physician Recorded Last Menstrual Period Dates in the General Practice Research Database [519]**
Scott T Devine, Tarek A Hammad. (United States)
- 36 Value of Recruiting "100% Reporters" in a Pregnancy Registry: The Antiretroviral Pregnancy Registry Experience [520]**
Deborah Covington, Hugh Tilson, Heather Watts, Karen Beckerman, Sherry Zhang, Heidi Lehman. (United States)
- 37 Maternal Use of Erythromycin and Risk of Congenital Malformation and Infantile Hypertrophic Pyloric Stenosis: A Danish Population-Based Cohort Study [521]**
Kornigamon Rookkapan, Mette Norgaard, Pia Wogelius, Mette Gislum, Barbara E Mahon, Henrik T Sorensen. (Denmark)
- 38 Outcomes of Antenatal Corticosteroids in Preterm Infants [522]**
Lena K Eriksson, Bengt Haglund, Helle Kieler, Viveca L Odland. (Sweden)
- CARDIOVASCULAR DRUGS**
- 39 Antihypertensive Drugs Use in Italian General Practice [523]**
Francesco Salvo, Marco Golinelli, Domenico U Tari, Achille P Caputi, Vincenzo Arcoraci. (Italy)
- 40 History of Full-Paper Publication of Abstracts on Evaluation of Antihypertensive Therapies Presented at the 12th and 13th ESH Meetings [524]**
Maxim N Mily. (Belarus)
- 41 Albuminuria-Dependent Effect of Blood Pressure-Lowering Drugs in Preventing Cardiovascular Events [525]**
Cornelis Boersma, Maarten J Postma, Sipke T Visser, Paul E de Jong, Lolkje TW de Jong-van den Berg, Ron T Gansevoort. (Netherlands)
- 42 Rhabdomyolysis Reports Show Interaction between Simvastatin and CYP3A4 Inhibitors [526]**
Christopher G Rowan, Allen D Brinker, Parivash Nourjah, Jennie Chang, Andrew Moshholder, Mark Avigan. (United States)
- 43 Co-Medication of Statins and CYP3A4 Inhibitors before and after Introduction of New Reimbursement Policy, a Study with Data from the Norwegian Prescription Database (NorPD) [527]**
Helene Devold, Svetlana Skurtveit, Espen Molden, Kari Furu. (Norway)
- 44 Antidiabetic Treatments and Risk of Myocardial Infarction: A Population-Based Case-Control Study [528]**
Henriette T Horsdal, Flemming Sondergaard, Soren P Johnsen, Jorgen Rungby. (Denmark)
- 45 ??-Blocker Use and Risk of Fractures in the General Population Using National Health Insurance Database [529]**
Hong Ji Song, Hwa Jung Kim, Sun Young Jeong, Ju Young Kim, Byung-Joo Park. (Korea)
- 46 Risk of Chronic End Stage Renal Disease after Use of ACE Inhibitors Compared to Other Antihypertensives or No-Antihypertensive Use in a Cohort of Diabetic Patients in the United Kingdom [530]**
Jamie T Laudati, Stephen P Motosko, Judith K Jones. (United States)
- 47 Combination Use of ACE Inhibitors and Angiotensin Receptor Blockers Increases Risk of Life-Threatening Cardiac Dysrhythmias [531]**
Jennifer B Christian, Charles B Eaton, Anne L Hume, Peter D Friedmann, Lan Jiang, Kate L Lapane. (United States)
- 48 ACE-Inhibitor for Hypertension: Prescribing Practices and Predictors of Use Among Patients with Hypertension in Indonesia's Hospital [532]**
Jarir Atthobari, Iwan Dwiprahasto, Erna Kristin. (Indonesia)
- 49 Patients' Education and Incidence of Statin Prescriptions [533]**
Randi Selmer, Svetlana Skurtveit, Kari Furu, Aage Tverdal. (Norway)
- 50 Preadmission Use of Statins and Outcomes after Hospitalization with Pneumonia: A Population-Based Cohort Study of 29,900 Adult Patients [534]**
Reimar W Thomsen, Anders Riis, Jette B Kornum, Steffen Christensen, Soren P Johnsen, Henrik T Sorensen. (Denmark)
- 51 Impact of Adherence to Antihypertensive Agents on Health Care Costs among Patients in Primary Prevention of Cardiovascular Disease [535]**
Alice Dragomir, Sylvie Perreault, Robert Cote, Louise Roy. (Canada)
- 52 Type of Preadmission Antidiabetic Treatment and Prognosis Among Patients Hospitalised with Myocardial Infarction: A Nationwide Follow-Up Study [536]**
Henriette T Horsdal, Soren P Johnsen, Flemming Sondergaard, Jorgen Rungby. (Denmark)
- 53 History and Severity of Pre-Existing Heart Failure Categorized by Medication Regimen and Mortality from Hospitalized Pneumonia: Population-Based Cohort Study [537]**
Reimar W Thomsen, Nongyao Kasatpibal, Anders Riis, Mette Norgaard, Henrik T Sorensen. (Denmark)
- 54 Underuse of Clopidogrel Treatment in Heart Failure Patients and Women after Acute Myocardial Infarction with or without Percutaneous Coronary Intervention [538]**
Rikke Sorensen, Gunnar H Gislason, Steen Z Abildstrom, Jeppe N Rasmussen, Soren Rasmussen, Tina K Schramm, Morten L Hansen, Fredrik Folke, Lars Kober, Christian Torp-Pedersen. (Denmark)
- 55 Pharmacoepidemiological Evaluation of Antihypertensive Drugs Utilization in a Hospital Setting in Belarus [539]**
Maxim N Mily. (Belarus)

POSTER SESSION C: WEDNESDAY, AUGUST 20

- 56 **Diuretics and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [540]**
Adela C Boila, Kåre G Sunesen, Alin I. Nechifor, Jacob Jacobsen, Henrik T Sorensen, Mette Norgaard. (Romania)
**Student Award Receptient - Second Best Abstract*
- 57 **Patients' Characteristics and Choice of Statin - Influence of New Reimbursement Regulations in Norway in 2005 [541]**
Solveig Sakshaug, Randi Selmer, Hanne Strom, Aage Tverdal. (Norway)
- 58 **Pre-Admission Beta-Blocker Use and 30-Day Mortality Following Intensive Care - A Population-Based Cohort Study [542]**
Steffen Christensen, Martin B Johansen, Henrik T Sorensen. (Denmark)
- 59 **Factors Influencing Adherence to Antihypertensive Therapy in Italy [543]**
Elisabetta Poluzzi, Petar Strahinja, Alberto Vaccheri, Giampiero Mazzaglia, Giovanna Sini, Alessandro Filippi, Italo Paolini, Nicola Montanaro. (Italy)
- 60 **Effect of Clopidogrel Maintenance Dose on Occurrence of Intra-Stent Thrombosis after Percutaneous Coronary Intervention [544]**
Neda Tavassoli, Sophie Voisin, Didier Carrie, Jean Louis Montastruc, Maryse Lapeyre-Mestre, Atul Pathak. (France)
- 61 **Adherence Level of Antihypertensive Agents To Reduce Coronary Artery Disease in Primary Prevention [545]**
Sylvie Perreault, Alice Dragomir, Louise Roy, Michel White, Anick Berard, Lucie Blais, Lyne Lalonde. (Canada)
- 62 **Prevalence and Incidence of Cardiovascular Drug Use among Women and Men in Sweden [546]**
Michael Fored, Niklas Hammar, Andrejs Leimanis, Björn Wettermark. (Sweden)
- 63 **Use of Statins in Patients Receiving Oral Blood Glucose Lowering Drugs [547]**
Hanne Strom, Solveig Sakshaug, Svetlana Skurtveit. (Norway)
- 64 **Adherence to Statin or Aspirin or Both in Patients with Established Cardiovascular Disease: Exploring Healthy Behaviour Versus Drug Effects and Ten-Year Follow up of Outcome [548]**
Li Wei, Tom Fahey, Thomas M MacDonald. (United Kingdom)
- 65 **Abstract Withdrawn by Author [549]**

Roche is proud to support the

International Society for Pharmacoepidemiology

Roche PD Epidemiology plans to continue to expand in 2009; for further insights, please contact Jamie Robinson (jamie.robinson@roche.com).

www.rocheusa.com

We Innovate Healthcare



POSTER SESSION C: WEDNESDAY, AUGUST 20

66 Medication Use Pattern and Life Style Factors [550]

Mitsuyo Kinjo, Soko Setoguchi. (Japan)

67 Predicted Impact of Nesiritide on Dialysis and All-Cause Hospital Mortality in Cardiac Surgery Patients by Demonstrated Post-Operative GFR Change [551]

Jinghua He, Almut G Winterstein, Thomas M Beaver. (United States)

DATABASE (SIG)

68 Experiences with a Person-Related and Population Based Sickness Fund Sample (1997-2007) for Pharmacoepidemiology and Health Care Utilization Research [552]

Peter Ihle, Ingrid Koester, Jutta Kuepper-Nybelen, Ingrid Schubert. (Germany)

69 Zolpidem Use and the Risk of Motor Vehicle Crash Leading to Hospitalization [553]

Yao-Hsu Yang, Pau-Chung Chen, Jung-Der Wang. (Taiwan)

70 Risk of Myocardial Infarction (MI) and Non Aspirin Non Steroidal Anti-Inflammatory Drugs (NANSIDs): A Case-Control Study with the PGRx System [554]

Lamia Bensouda-Grimaldi, Denis Granados-Canal, Michel Rossignol, Florence Leclercq, Nicolas Danchin, Elisabeth Autret-Leca, Lucien Abenheim. (France)

71 Identification of Pulmonary Arterial Hypertension (PAH) Cases in Automated Claims Data: A Pilot Study [555]

Susan A Oliveria, Paola Primatesta, Marianne Ulcickas Yood, Feifei Wei, Scott Robinson, Karen Wells, Hector Cajigas. (United States)

72 Evidence for a Depletion of Susceptibles Effect in the Risk of Myocardial Infarction and Non Steroidal Anti-Inflammatory Drugs: A Case Control Study with the PGRx System [556]

Lamia Bensouda Grimaldi, Denis Granados-Canal, Michel Rossignol, Yves Cottin, Nicolas Danchin, Elisabeth Autret-Leca, Lucien Abenheim. (France)

73 Registration of Medicine Use at Individual Level for the Whole Danish Population Since 1994 [557]

Vibeke Dahl Jensen, Soren Henckel. (Denmark)

74 The Role of Systematic Reviews in Pharmacovigilance: A Case-Study of Carbamazepine Induced Severe Cutaneous Adverse Drug Reactions [558]

Ashish Shukla, Veeranjanyulu Addepalli, Preeti Sangave, Jyotsna Patwardhan. (India)

75 Analysis of Time Courses of Prescriptions and Hospitalisations from Two Different Health Insurances Providing Data for the German Pharmacoepidemiological Database [559]

Frank Andersohn, Sigrid Behr, Elke Scharnetzky, Ingo Langner, Edeltraut Garbe. (Germany)

76 Death Recording in a UK Primary Care Database [560]

Gillian C Hall. (United Kingdom)

77 Codispensing of Tadalafil and Other Phosphodiesterase Type 5 Inhibitors with Contraindicated Organic Nitrates [561]

Patricia M Eng, Mark Ma, Xiaochun Zhang, Timothy Costigan, Kenneth Hornbuckle, Alexander Walker. (United States)

78 Health Care Resources Utilisation by Patients with Psoriasis [562]

Jean Lachaine, Marie-Josée Martel, Yves P Poulin, Richard G Langley. (Canada)

79 Statistics on All Medicines Dispensed in Denmark Presented on the Web [563]

Hans Klarskov Madsen, Claudia Ranneries, Vibeke Dahl Jensen. (Denmark)

80 Assessing the Feasibility of Integrated Claims and Laboratory Databases for Observational Studies of Drug-Induced Liver Injury [564]

Zhiwen Liu, Patrick B Ryan, Suzanne L West, Henry J Krzywy. (United States)

81 Validation of the German Pharmacoepidemiological Database - Event Rates of Prescriptions, Hospitalisations, and Ambulatory Services in Two Northern German Health Insurances [565]

Frank Andersohn, Elke Scharnetzky, Ingo Langner, Edeltraut Garbe. (Germany)

82 Validation of Community-Acquired Pneumonia: High Positive Predictive Value for ICD-9 Codes [566]

Ewoudt MW van de Garde, Vera HM Deneer, Patrick C Souverein, Jules MM van den Bosch, Hubert GM Leufkens. (Netherlands)

83 Workload of Hospital Pharmacy in Taiwan: Analysis of National Claims Database [567]

Chia-Hsien Chang, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)

84 Routine Data for the Monitoring of National Prescribing Characteristics in Germany: The GEK-Arzneimittel-Report 2001-2007 [568]

Katrin Janhsen, Gerd Glaeske. (Germany)

85 Utilization and Costs of Drugs and Office Services among Recipients of Medicaid with Rheumatoid Arthritis with Versus without Comorbid Depression [569]

Rahul Khanna, Michael J Smith, Khalid M Kamal. (United States)

86 External Validity of Perinatal Pharmacoepidemiologic Studies Using Data from the RAMQ Administrative Database [570]

Anick Bérard, Anais Lacasse. (Canada)

87 The Importance of Defining Periods of Complete Mortality Reporting in Automated Patient Databases [571]

Andrew Maguire, Betina Blak, Mary Thompson, Gillian Hall. (United Kingdom)

88 Clinical Outcomes Associated with Anticoagulant Therapies in Patients with Incident Heart Failure: A Retrospective Analysis of a Population-Based Database [572]

Zhong Yuan, Rachel Weinstein, John Zhang, Mei Cheng, George A Griffin, Robert Zolynas, Mary S Lee, Leonard Oppenheimer, Paul Burton. (United States)

DEVICES

89 The Demographic Trends of the Patients Population Implanted Prosthetic Cardiac Valves in past 10 Years [573]

Xiaozheng Zhang. (United States)

POSTER SESSION C: WEDNESDAY, AUGUST 20

DISEASE EPIDEMIOLOGY/ BURDEN OF ILLNESS

- 90 Intravitreal (IVT) Injection-Related Ocular Adverse Events in the General Population of the United States of America [574]**
Alejandro Arana, Felix M Arellano, Elena Rivero, Marco Pavesi, Debashish Dey, Charles W Wentworth. (Spain)
- 91 Global Prevalence of Chronic Daily Headache – A Systematic Literature Review [575]**
Aubrey Manack, Jaime Natoli, Bonnie Dean, Qiana Butler, Catherine Turkel, Haley Kaplowitz. (United States)
- 92 Influence of Affluence: The Impact of Social Deprivation on Mortality Rates in THIN, a UK Primary Care Database [576]**
Betina Blak, Andrew Maguire. (United Kingdom)
- 93 Prevalence of Dyslipidemia and Its Risk Factors in US Children [577]**
Jie Li, Stephen P Motsko, Earl L Goehring, Jr, Judith K Jones. (United States)
- 94 Changes in the Incidence of Encephalitis in the UK [578]**
Gillis Carrigan, Alena Khromava, William Holden. (United States)
- 95 Unexpected Lower Prevalence of Depression in Patients with Diabetes: Potential for Selection Bias in a Waiting Room Population [579]**
Mirjam J Knol, Eibert R Heerdink, Antoine CG Egberts, Diederick E Grobbee, Mirjam I Geerlings. (Netherlands)
- 96 Characteristics of Patients with Anemia of Cancer [580]**
Sumitra Shantakumar, Monica G Kobayashi, Anna Dow. (United States)
- 97 Increased Risk of Acute Pancreatitis Observed in Patients with Type 2 Diabetes [581]**
Rebecca A Noel, Dan K Braun, Ruth Patterson, Gary Bloomgren. (United States)

- 98 Methodological Issues for Consideration in the Systematic Literature Review and Meta-Analysis of Pregnancy Registries [582]**
Matthew W Reynolds, Sheila Crean, Jenna Collins, Kevin Moschella. (United States)
- 99 Analysis of a Marker for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis among 167 Million Insured US Patients [583]**
Stephen P Motsko, Anna E Wallace, Mike Pollack, Earl L Goehring, Jr, Rhonda L Bohn, Judith K Jones. (United States)
- 100 Randomized Trial of the Effect of Questionnaire Length on Enrollment in a Web-Based Cohort Study in Denmark [584]**
Kenneth J Rothman, Ellen M Mikkelsen, Henrik T Sorensen, Lauren A Wise, Anders Riis, Elizabeth E Hatch. (United States)
- 101 Hepatitis C Virus Surveillance Study among Mexican Social Security Clients: A Public Health Intervention Opportunity [585]**
Ricardo Jimenez-Mendez, Carlos Conde, Vicente Madrid-Marina, Felipe Uribe, Y Juarez, S Diaz. (Mexico)
- 102 Global Incidence, Prevalence, and Survival of Soft Tissue Sarcomas in Adults [586]**
Sumitra Shantakumar, Page E Abrahamson, Monica G Kobayashi, J Arun, L Sreenivasulu, DS Anjan Kumar. (United States)
- 103 Incidence of Elevated Liver Enzymes in Rheumatoid Arthritis Patients [587]**
Tara Nazareth, Dina Gifkins, Zhiping Huang. (United States)
- 104 Multiple Sclerosis and Risk of Venous Thromboembolism: A 30-Year Population-Based Cohort Study [588]**
Steffen Christensen, Dóra Körmendiné-Farkas, Lars Pedersen, Montserrat Miret, Henrik T Sorensen. (Denmark)
- 105 The Incidence of Metabolic Syndrome and Its Reversibility in a Cohort of Patients with Psychotic Disorders Followed for One Year [589]**
Katja Taxis, Susanne G Schorr, Cees J Slooff, Richard Bruggeman. (Netherlands)

- 106 Use of Administrative Claims and Survey Data To Identify Asthma Severity and Control Status and Describe Disease Burden [590]**
Debra Wertz, Rhonda Bohn, Keith Rodgers, Patricia Sacco, Michael Pollack, Sean D Sullivan. (United States)
- 107 Estimating the Incidence and Prevalence of NIDDM in Belgium by Using Prescription Data [591]**
Johan De Haes, André De Swaef. (Belgium)
- 108 Smoking Cessation in the United States Workforce [592]**
Margaret McDonald, Robin P Hertz, Alan N Unger, Michael B. Lustik. (United States)

HORMONES/ REPRODUCTIVE AGENTS

- 109 Case-Control Study of Breast Cancer Risk for a Levonorgestrel-Releasing Intrauterine Device [593]**
Juergen Dinger, Sabine Moehner, Anita Assmann, Do Minh Thai, Lothar Heinemann. (Germany)
- 110 Oral Contraceptives and the Risk of Arrhythmia: Final Results from the EURAS-OC Study [594]**
Juergen Dinger, Anita Assmann, Doerthe Kuehl-Habich. (Germany)
- 111 Pregnancy-Related Outcomes Among Canadian Women Obtaining Two Regimens for Emergency Contraception [595]**
Vivian WY Leung, Judith A Soon, Marc Levine. (Canada)
- 112 Predictors of Cardiovascular Morbidity in Patients on Chronic Thyroxine [596]**
Robert W Flynn, Thomas M MacDonald, Roland J Jung, Andrew D Morris, Graham P Leese. (United Kingdom)
- 113 2D:4D Ratio Is Higher in Older People in Greece. May This Be Attributed to Environmental Influence? [597]**
Paraskevi Papaioannidou, Ioannis Kyriakidis. (Greece)

POSTER SESSION C: WEDNESDAY, AUGUST 20

MOLECULAR EPIDEMIOLOGY PHARMACOGENETICS (SIG)

- 114 Predicting Warfarin Maintenance Dose Requirements Using Genetic, Environmental, and Clinical Factors in Caucasians and African Americans [598]**
Hedi Schelleman, Jinbo Chen, Jason Christie, Craig W Newcomb, Colleen M Brensinger, Maureen Price, Alexander S Whitehead, Stephen E Kimmel. (United States)
- 115 The Monetary Value of a Genetic Test To Identify the Patients Susceptible To Develop Statin-Induced Muscular Side Effects [599]**
Elisabeth Martin, Odile Sheehy, Manon Choiniere, Jacques Le Lorier. (Canada)
- 116 Effectiveness of Statins in the Reduction of the Risk of Myocardial Infarction Is Modified by the GNB3 C825T Variant [600]**
BJM Peters, AH Maitland-van der Zee, B HCh Stricker, BMA van Wieren-de Wijer, A de Boer, AA Kroon, PW de Leeuw, P Schiffers, RG Janssen, CM van Duijn, OH Klungel. (Netherlands)
- 117 Appraising the Ability of Pharmacogenomic Clinical Studies To Detect Adverse Drug Reactions [601]**
Amalia M Issa, Kim Anh-Do. (United States)
- 118 Transcription Factor 7-Like 2 (TCF7L2) and Context-Specific Risk of Type 2 Diabetes Mellitus (T2DM) in African American and Caucasian Adults: The Atherosclerosis Risk in Communities Study [602]**
Yu Yan, Kari E North, Gerardo Heiss, Suzanne L West, Eric Boerwinkle. (United States)
- 119 Renin-Angiotensin-System Polymorphisms, Use of Angiotensin Receptor Blockers and the Risk of Diabetes [603]**
Ozlem Bozkurt, Anthonius de Boer, Diederik E Grobbee, Abraham A Kroon, Paul Schiffers, Peter W de Leeuw, Olaf H Klungel. (Netherlands)

PEDIATRIC PHARMACOEPIDEMIOLOGY

- 120 Consumption of Antibacterials for Systemic Use in Children in Denmark [604]**
Claudia Rannerries. (Denmark)
- 121 The Use of Anti-Asthmatic Drugs in Children in Northeast Brazil [605]**
Djanilson B Santos, Mauricio L Barreto, Helena LL Coelho. (Brazil)
- 122 SINCERE™: A New Multicenter Registry To Monitor Long-Term Safety of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Including Celecoxib in Juvenile Idiopathic Arthritis (JIA) [606]**
Rachel Sobel, Daniel Lovell, Edward Giannini, Neha Sheth, Staci Abramsky, Gail Cawkwell. (United States)
- 123 Unlicensed and Off-Label Drug Use in Hospitalized Children in Russia [607]**
Svetlana Ratchina, Anna Belokhvosova, Ludmila Konovalova, Ludmila Zharkova. (Russian Federation)
- 124 Prevalence of Reflux Disorders and Antireflux Medication in U.S. Children [608]**
Elaine H Morrato, David Partrick, Patrick Sullivan, Vahram Ghushchyan, Allison Kempe. (United States)
- 125 Counts and Period Prevalence of Gigantism among Children [609]**
Kandace L Amend, Najat Ziyadeh, Carles Blanch, Katarzyna Sablinska, John Seeger. (United States)

REGULATORY ISSUES/ DRUG POLICY

- 126 Types of Prescription Drugs Not Reimbursed by the Italian National Health System in Italy [610]**
M Chiara Silvani, Laura Bersaglia, Petar Strahinja, Domenico Motola, Chiara Biagi, Elisabetta Poluzzi, Alberto Vaccheri, Nicola Montanaro. (Italy)

- 127 144 Pharma Rep Meetings in Norwegian General Practice [611]**
Joerund Straand, Inger J Christiansen. (Norway)
- 128 Prior Authorization for Biologic DMARDs: A Description of United States Medicaid Programs [612]**
Michael A Fischer, Jennifer M Polinski, Amber D Servi, Jessica Agnew-Blais, Liljana Kaci, Daniel H Solomon. (United States)
- 129 Use of and Attitudes towards the Prescription Guidelines Booklet in Primary Health Care Doctors [613]**
Magnus AB Axelsson, Malin Spetz, Anders Mellén, Susanna M Wallerstedt. (Sweden)
- 130 Abstract Withdrawn by Author [614]**

STATE OF ART IN DRUG UTILIZATION

- 131 Trends in the Use of Lipid-Lowering Agents in an Indonesia's Hospital [615]**
Erna Kristin, Jarir Atthobari, Iwan Dwiprahasto. (Indonesia)
- 132 Drug Use in Population Screening: A Pharmacoepidemiological Aspects [616]**
Jarir Atthobari, Sipke TV Visser, Ron T Gansevoort, Paul E de Jong, Lolkje TW de Jong-van den Berg. (Indonesia)

WOMEN'S HEALTH

- 133 Cardiovascular Safety of Oral Hormone Replacement: Interim Results from the EURAS-HRT Study [617]**
Juergen Dinger, Anita Assmann, Ruediger Kolbeck. (Germany)
- 134 Patients Outcome after 18 Months Teriparatide Treatment: French Results from the EFOS Study [618]**
Gerald Rajzbaum, Soyi Liu-Leage, Isabelle Jamonneau, Florence Chartier, Stephanie Tcherny. (France)
- 135 Patterns of Use of the Levonorgestrel Intrauterine System – Data from a Large U.S. Health Plan [619]**
Wendy J Carman, Antonio C Costales, John D Seeger. (United States)

POSTER SESSION C: WEDNESDAY, AUGUST 20

MISCELLANEOUS

136 Risk of Type B Abnormal Complete Blood Count during Clinical Trials [620]

Isaac W Hammond, Xiaolei Li, Patricia E Fryar, Joli A Mammelle, Jessica O'Hara, Donna S Rich, Sophia M Goodison. (United States)

137 Human Insulin and Mortality in Patients with Type 1 Diabetes [621]

Laurent Azoulay, Alicia Schiffrin, Samy Suissa. (Canada)

138 Evaluation of Drug Prescribing in Nursing Homes Based on Explicit Indicators. The Bergen District Nursing Home (BEDNURS) Study [272]

Sabine Ruths. (Norway)

139 Adverse Events Associated with Pediatric Antibiotic Use [623]

Sharon B Meropol, Zhen Chen, Joshua P Metlay. (United States)

140 The Cancer Risk in Long-Term Users of Valproate: a Population-Based Case-Control Study [625]

Jesper Hallas, Lars Bjerrum, Henrik Stovring, Sverre Narverud, Thomas Heyerdahl, Kirsten Gronbaek, Soren Friis, Morten Andersen. (Denmark)

141 Risk of Acute Myocardial Infarction after CHOP-Like Chemotherapy +/- Rituximab among Older Pts with Diffuse Large B-Cell Lymphoma: A Population-Based Study in the U.S. [626]

Huei-Ting Tsai, Wyndham Wilson, Kieron Dunleavy, Ola Landgren. (United States)

142 Gene - Drug Interaction in Benzodiazepine Related Fall Risk [627]

Gijsbertus Ziere, Jeanne P Dieleman, Ron HN van Schaik, Tischa JM van der Cammen, Bruno HCh Stricker. (Netherlands)

143 Incidence of Coronary Heart

Disease Outcomes Among Chronic Opioid Users [628]

Wendy J Carman, Suzanne F Cook, John I Wurzelmann, Andrew T McAfee. (United States)

144 Osteoarthritis Treatment Prescriber Behavior: Survey in the United Kingdom [629]

Javier Cid Ruzafa, Marc A Hennebert, Teddy Nakpodia. (Spain)

145 Definition of Chronic Kidney Disease by Creatinine Based Methods May Be Strongly Misleading in Patients with Diabetes [630]

Dietrich Rothenbacher, Qiu-Li Zhang, Nuria Riera-Guardia, Wolfgang Koenig, Hermann Brenner. (Germany)

146 Cohort Effect or Selective Prescribing by Indication in the Prescription of New Atypical Antipsychotic in Schizophrenia? [631]

L Abenheim, B Astruc, H Verdoux, B Falissard, J Benichou, M Rossignol, P Blin, F Depont, F Rouillon. (France)

RTI(h)(s)

RTI HEALTH SOLUTIONS®

1400 YEARS
Combined
Experience



"Together, we offer you 330 years of epidemiology and risk management experience; our colleagues in other disciplines pitch in the rest of the 1400 years."

Visit us at Stand #A-14, Hall A

www.rtihs.org

LEADING RESEARCH...
MEASURES THAT COUNT

Top Row: Elizabeth Andrews, Jordi Castellsague, Carla Franzoni, Alicia Gilsenan, Lia Gutiérrez **Second Row:** Ceri Hirst, Christine Lankevich, Lee Lanza, Rebecca Martin, Kirk Midkiff **Bottom Row:** Susana Perez-Guthmann, Ken Rothman, Pat Tennis, Abenah Vanderpuije, Cristina Varas-Lorenzo **Not pictured:** Kay Johannes, Amy Ladner, Lisa McQuay

Research Triangle Park • Ann Arbor • Barcelona • Manchester • Ottawa • Waltham

Please visit PPD
at Booth 16.

OBSERVATIONAL STUDIES

RISK MANAGEMENT

LATE-STAGE TRIALS

EPIDEMIOLOGY

When you know what to look for,
the real opportunities are clear.

Count on PPD.

HEALTH OUTCOMES

PHARMACOVIGILANCE

MEDICAL INFORMATION

Post-Approval Services from PPD.

In Post-Approval, knowing what looms around every corner is critical to your success. You need an experienced partner who can empower you with a thorough understanding to make informed decisions.

For over a decade, our Post-Approval teams have been comprised of medical professionals. Our experts work passionately alongside your teams to rapidly identify actionable safety data, putting you in control of your product's lifecycle.

To learn more, please call Craig Eslinger at +1 919 456 4200 x4325
or visit www.ppdi.com/services/post_approval.

Helping you Advance the Science of Safety

PPD[®]

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 18				
1		10:30 AM	Auditorium 10	Oral
2		10:45 AM	Auditorium 10	Oral
3		11:00 AM	Auditorium 10	Oral
4		11:15 AM	Auditorium 10	Oral
5		11:30 AM	Auditorium 10	Oral
6		11:45 AM	Auditorium 10	Oral
7		10:30 AM	Auditorium 11	Oral
8		10:45 AM	Auditorium 11	Oral
9		11:00 AM	Auditorium 11	Oral
10		11:15 AM	Auditorium 11	Oral
11		11:30 AM	Auditorium 11	Oral
12		11:45 AM	Auditorium 11	Oral
13		10:30 AM	Auditorium 12	Oral
14		10:45 AM	Auditorium 12	Oral
15		11:00 AM	Auditorium 12	Oral
16		11:15 AM	Auditorium 12	Oral
17		11:45 AM	Auditorium 12	Oral
18		10:30 AM	Room 18/19	Oral
19		10:45 AM	Room 18/19	Oral
20		11:15 AM	Room 18/19	Oral
21		11:30 AM	Room 18/19	Oral
22		11:45 AM	Room 18/19	Oral
23		10:30 AM	Room 20	Oral
24		10:45 AM	Room 20	Oral
25		11:00 AM	Room 20	Oral
26		11:15 AM	Room 20	Oral
27		11:30 AM	Room 20	Oral
28		11:45 AM	Room 20	Oral
29		1:30 PM	Auditorium 10	Oral
30		1:45 PM	Auditorium 10	Oral
31		2:00 PM	Auditorium 10	Oral
32		2:15 PM	Auditorium 10	Oral
33		2:30 PM	Auditorium 10	Oral
34		2:45 PM	Auditorium 10	Oral
35		1:30 PM	Auditorium 11	Oral
36		1:45 PM	Auditorium 11	Oral
37		2:00 PM	Auditorium 11	Oral
38		2:15 PM	Auditorium 11	Oral
39		2:30 PM	Auditorium 11	Oral
40		2:45 PM	Auditorium 11	Oral
41		1:30 PM	Auditorium 12	Oral
42		1:45 PM	Auditorium 12	Oral
43		2:00 PM	Auditorium 12	Oral
44		2:15 PM	Auditorium 12	Oral
45		2:30 PM	Auditorium 12	Oral
46		2:45 PM	Auditorium 12	Oral
47		1:30 PM	Room 18/19	Oral
48		1:45 PM	Room 18/19	Oral
49		2:00 PM	Room 18/19	Oral
50		2:15 PM	Room 18/19	Oral
51		2:30 PM	Room 18/19	Oral
52		2:45 PM	Room 18/19	Oral
53		1:30 PM	Room 20	Oral

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 18 (CONTINUED)				
54		1:45 PM	Room 20	Oral
55		2:00 PM	Room 20	Oral
56		2:15 PM	Room 20	Oral
57		2:30 PM	Room 20	Oral
58		3:30 PM - 5:00 PM	Auditorium 10	Sympos.
59		3:30 PM - 5:00 PM	Auditorium 11	Sympos.
60		3:30 PM - 5:00 PM	Auditorium 12	Sympos.
61		3:30 PM - 5:00 PM	Room 18/19	Sympos.
62		3:30 PM - 5:00 PM	Room 20	Sympos.
Poster Session A				
Biologics (SIG)				
63	1	8:00 AM - 6:00 PM	Hall A1	Poster
64	2	8:00 AM - 6:00 PM	Hall A1	Poster
65	3	8:00 AM - 6:00 PM	Hall A1	Poster
66	4	8:00 AM - 6:00 PM	Hall A1	Poster
67	5	8:00 AM - 6:00 PM	Hall A1	Poster
68	6	8:00 AM - 6:00 PM	Hall A1	Poster
CNS/ Neurological				
69	7	8:00 AM - 6:00 PM	Hall A1	Poster
70	8	8:00 AM - 6:00 PM	Hall A1	Poster
71	9	8:00 AM - 6:00 PM	Hall A1	Poster
72	10	8:00 AM - 6:00 PM	Hall A1	Poster
73	11	8:00 AM - 6:00 PM	Hall A1	Poster
74	12	8:00 AM - 6:00 PM	Hall A1	Poster
75	13	8:00 AM - 6:00 PM	Hall A1	Poster
76	14	8:00 AM - 6:00 PM	Hall A1	Poster
77	15	8:00 AM - 6:00 PM	Hall A1	Poster
78	16	8:00 AM - 6:00 PM	Hall A1	Poster
79	17	8:00 AM - 6:00 PM	Hall A1	Poster
Cancer				
80	18	8:00 AM - 6:00 PM	Hall A1	Poster
81	19	8:00 AM - 6:00 PM	Hall A1	Poster
82	20	8:00 AM - 6:00 PM	Hall A1	Poster
83	21	8:00 AM - 6:00 PM	Hall A1	Poster
84	22	8:00 AM - 6:00 PM	Hall A1	Poster
85	23	8:00 AM - 6:00 PM	Hall A1	Poster
86	24	8:00 AM - 6:00 PM	Hall A1	Poster
87	25	8:00 AM - 6:00 PM	Hall A1	Poster
88	26	8:00 AM - 6:00 PM	Hall A1	Poster
89	27	8:00 AM - 6:00 PM	Hall A1	Poster
90	28	8:00 AM - 6:00 PM	Hall A1	Poster
91	29	8:00 AM - 6:00 PM	Hall A1	Poster
92	30	8:00 AM - 6:00 PM	Hall A1	Poster
93	31	8:00 AM - 6:00 PM	Hall A1	Poster
94	32	8:00 AM - 6:00 PM	Hall A1	Poster
Drug Utilization Studies (SIG)				
95	33	8:00 AM - 6:00 PM	Hall A1	Poster
96	34	8:00 AM - 6:00 PM	Hall A1	Poster
97	35	8:00 AM - 6:00 PM	Hall A1	Poster
98	36	8:00 AM - 6:00 PM	Hall A1	Poster
99	37	8:00 AM - 6:00 PM	Hall A1	Poster

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 18 (CONTINUED)				
100	38	8:00 AM - 6:00 PM	Hall A1	Poster
101	39	8:00 AM - 6:00 PM	Hall A1	Poster
102	40	8:00 AM - 6:00 PM	Hall A1	Poster
103	41	8:00 AM - 6:00 PM	Hall A1	Poster
104	42	8:00 AM - 6:00 PM	Hall A1	Poster
105	43	8:00 AM - 6:00 PM	Hall A1	Poster
106	44	8:00 AM - 6:00 PM	Hall A1	Poster
107	45	8:00 AM - 6:00 PM	Hall A1	Poster
108	46	8:00 AM - 6:00 PM	Hall A1	Poster
109	47	8:00 AM - 6:00 PM	Hall A1	Poster
110	48	8:00 AM - 6:00 PM	Hall A1	Poster
111	49	8:00 AM - 6:00 PM	Hall A1	Poster
112	50	8:00 AM - 6:00 PM	Hall A1	Poster
113	51	8:00 AM - 6:00 PM	Hall A1	Poster
114	52	8:00 AM - 6:00 PM	Hall A1	Poster
115	53	8:00 AM - 6:00 PM	Hall A1	Poster
116	54	8:00 AM - 6:00 PM	Hall A1	Poster
117	55	8:00 AM - 6:00 PM	Hall A1	Poster
118	56	8:00 AM - 6:00 PM	Hall A1	Poster
119	57	8:00 AM - 6:00 PM	Hall A1	Poster
120	58	8:00 AM - 6:00 PM	Hall A1	Poster
121	59	8:00 AM - 6:00 PM	Hall A1	Poster
122	60	8:00 AM - 6:00 PM	Hall A1	Poster
123	61	8:00 AM - 6:00 PM	Hall A1	Poster
124	62	8:00 AM - 6:00 PM	Hall A1	Poster
125	63	8:00 AM - 6:00 PM	Hall A1	Poster
126	64	8:00 AM - 6:00 PM	Hall A1	Poster
127	65	8:00 AM - 6:00 PM	Hall A1	Poster
128	66	8:00 AM - 6:00 PM	Hall A1	Poster
129	67	8:00 AM - 6:00 PM	Hall A1	Poster
130	68	8:00 AM - 6:00 PM	Hall A1	Poster
131	69	8:00 AM - 6:00 PM	Hall A1	Poster
132	70	8:00 AM - 6:00 PM	Hall A1	Poster
133	71	8:00 AM - 6:00 PM	Hall A1	Poster
134	72	8:00 AM - 6:00 PM	Hall A1	Poster
135	73	8:00 AM - 6:00 PM	Hall A1	Poster
136	74	8:00 AM - 6:00 PM	Hall A1	Poster
137	75	8:00 AM - 6:00 PM	Hall A1	Poster
138	76	8:00 AM - 6:00 PM	Hall A1	Poster
139	77	8:00 AM - 6:00 PM	Hall A1	Poster
140	78	8:00 AM - 6:00 PM	Hall A1	Poster
141	79	8:00 AM - 6:00 PM	Hall A1	Poster
142	80	8:00 AM - 6:00 PM	Hall A1	Poster
143	81	8:00 AM - 6:00 PM	Hall A1	Poster
144	82	8:00 AM - 6:00 PM	Hall A1	Poster
145	83	8:00 AM - 6:00 PM	Hall A1	Poster
146	84	8:00 AM - 6:00 PM	Hall A1	Poster
147	85	8:00 AM - 6:00 PM	Hall A1	Poster
148	86	8:00 AM - 6:00 PM	Hall A1	Poster
149	87	8:00 AM - 6:00 PM	Hall A1	Poster
150	88	8:00 AM - 6:00 PM	Hall A1	Poster
151	89	8:00 AM - 6:00 PM	Hall A1	Poster
152	90	8:00 AM - 6:00 PM	Hall A1	Poster

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 18 (CONTINUED)				
153	91	8:00 AM - 6:00 PM	Hall A1	Poster
154	92	8:00 AM - 6:00 PM	Hall A1	Poster
155	93	8:00 AM - 6:00 PM	Hall A1	Poster
156	94	8:00 AM - 6:00 PM	Hall A1	Poster
157	95	8:00 AM - 6:00 PM	Hall A1	Poster
158	96	8:00 AM - 6:00 PM	Hall A1	Poster
159	97	8:00 AM - 6:00 PM	Hall A1	Poster
160	98	8:00 AM - 6:00 PM	Hall A1	Poster
161	99	8:00 AM - 6:00 PM	Hall A1	Poster
162	100	8:00 AM - 6:00 PM	Hall A1	Poster
163	101	8:00 AM - 6:00 PM	Hall A1	Poster
164	102	8:00 AM - 6:00 PM	Hall A1	Poster
165	103	8:00 AM - 6:00 PM	Hall A1	Poster
166	104	8:00 AM - 6:00 PM	Hall A1	Poster
167	105	8:00 AM - 6:00 PM	Hall A1	Poster
168	106	8:00 AM - 6:00 PM	Hall A1	Poster
169	107	8:00 AM - 6:00 PM	Hall A1	Poster
170	108	8:00 AM - 6:00 PM	Hall A1	Poster
171	109	8:00 AM - 6:00 PM	Hall A1	Poster
172	110	8:00 AM - 6:00 PM	Hall A1	Poster
Drug Development				
173	111	8:00 AM - 6:00 PM	Hall A1	Poster
174	112	8:00 AM - 6:00 PM	Hall A1	Poster
Economics				
175	113	8:00 AM - 6:00 PM	Hall A1	Poster
176	114	8:00 AM - 6:00 PM	Hall A1	Poster
177	115	8:00 AM - 6:00 PM	Hall A1	Poster
178	116	8:00 AM - 6:00 PM	Hall A1	Poster
179	117	8:00 AM - 6:00 PM	Hall A1	Poster
180	118	8:00 AM - 6:00 PM	Hall A1	Poster
181	119	8:00 AM - 6:00 PM	Hall A1	Poster
Effectiveness Research				
182	120	8:00 AM - 6:00 PM	Hall A1	Poster
183	121	8:00 AM - 6:00 PM	Hall A1	Poster
184	122	8:00 AM - 6:00 PM	Hall A1	Poster
185	123	8:00 AM - 6:00 PM	Hall A1	Poster
186	124	8:00 AM - 6:00 PM	Hall A1	Poster
Gastrointestinal				
187	125	8:00 AM - 6:00 PM	Hall A1	Poster
188	126	8:00 AM - 6:00 PM	Hall A1	Poster
189	127	8:00 AM - 6:00 PM	Hall A1	Poster
190	128	8:00 AM - 6:00 PM	Hall A1	Poster
191	129	8:00 AM - 6:00 PM	Hall A1	Poster
Measurement Methods				
192	130	8:00 AM - 6:00 PM	Hall A1	Poster
193	131	8:00 AM - 6:00 PM	Hall A1	Poster
194	132	8:00 AM - 6:00 PM	Hall A1	Poster
195	133	8:00 AM - 6:00 PM	Hall A1	Poster
196	134	8:00 AM - 6:00 PM	Hall A1	Poster
197	135	8:00 AM - 6:00 PM	Hall A1	Poster
198	136	8:00 AM - 6:00 PM	Hall A1	Poster

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 18 (CONTINUED)				
199	137	8:00 AM - 6:00 PM	Hall A1	Poster
200	138	8:00 AM - 6:00 PM	Hall A1	Poster
Psychotropics				
201	139	8:00 AM - 6:00 PM	Hall A1	Poster
202	140	8:00 AM - 6:00 PM	Hall A1	Poster
203	141	8:00 AM - 6:00 PM	Hall A1	Poster
204	142	8:00 AM - 6:00 PM	Hall A1	Poster
205	143	8:00 AM - 6:00 PM	Hall A1	Poster
206	144	8:00 AM - 6:00 PM	Hall A1	Poster
207	145	8:00 AM - 6:00 PM	Hall A1	Poster
208	146	8:00 AM - 6:00 PM	Hall A1	Poster
209	147	8:00 AM - 6:00 PM	Hall A1	Poster
210	148	8:00 AM - 6:00 PM	Hall A1	Poster
211	149	8:00 AM - 6:00 PM	Hall A1	Poster
212	150	8:00 AM - 6:00 PM	Hall A1	Poster
213	151	8:00 AM - 6:00 PM	Hall A1	Poster
214	152	8:00 AM - 6:00 PM	Hall A1	Poster
215	153	8:00 AM - 6:00 PM	Hall A1	Poster
216	154	8:00 AM - 6:00 PM	Hall A1	Poster
217	155	8:00 AM - 6:00 PM	Hall A1	Poster
218	156	8:00 AM - 6:00 PM	Hall A1	Poster
219	157	8:00 AM - 6:00 PM	Hall A1	Poster
220	158	8:00 AM - 6:00 PM	Hall A1	Poster
221	159	8:00 AM - 6:00 PM	Hall A1	Poster
222	160	8:00 AM - 6:00 PM	Hall A1	Poster
223	161	8:00 AM - 6:00 PM	Hall A1	Poster
224	162	8:00 AM - 6:00 PM	Hall A1	Poster
Use of Indicators (Quality of Life, Patient's Perceptions, Quality of Care)				
225	163	8:00 AM - 6:00 PM	Hall A1	Poster
226	164	8:00 AM - 6:00 PM	Hall A1	Poster
227	165	8:00 AM - 6:00 PM	Hall A1	Poster
228	166	8:00 AM - 6:00 PM	Hall A1	Poster
229	167	8:00 AM - 6:00 PM	Hall A1	Poster
230	168	8:00 AM - 6:00 PM	Hall A1	Poster
231	169	8:00 AM - 6:00 PM	Hall A1	Poster
232	170	8:00 AM - 6:00 PM	Hall A1	Poster
233	171	8:00 AM - 6:00 PM	Hall A1	Poster
234	172	8:00 AM - 6:00 PM	Hall A1	Poster

Abstract #	Poster #	Presentation Time	Room	Format
TUESDAY, AUGUST 19				
235		11:00 AM	Auditorium 10	Oral
236		11:15 AM	Auditorium 10	Oral
237		11:30 AM	Auditorium 10	Oral
238		11:45 AM	Auditorium 10	Oral
239		12:00 PM	Auditorium 10	Oral
240		12:15 PM	Auditorium 10	Oral
241		11:00 AM	Auditorium 11	Oral
242		11:15 AM	Auditorium 11	Oral
243		11:30 AM	Auditorium 11	Oral
244		11:45 AM	Auditorium 11	Oral
245		12:00 PM	Auditorium 11	Oral
246		12:15 PM	Auditorium 11	Oral
247		11:00 AM	Auditorium 12	Oral
248		11:15 AM	Auditorium 12	Oral
249		11:30 AM	Auditorium 12	Oral
250		11:45 AM	Auditorium 12	Oral
251		12:00 PM	Auditorium 12	Oral
252		12:15 PM	Auditorium 12	Oral
253		11:00 AM	Room 18/19	Oral
254		11:15 AM	Room 18/19	Oral
255		11:30 AM	Room 18/19	Oral
256		11:45 AM	Room 18/19	Oral
257		12:00 PM	Room 18/19	Oral
258		12:15 PM	Room 18/19	Oral
259		11:00 AM	Room 20	Oral
260		11:15 AM	Room 20	Oral
261		11:30 AM	Room 20	Oral
262		11:45 AM	Room 20	Oral
263		12:00 PM	Room 20	Oral
264		12:15 PM	Room 20	Oral
265		11:00 AM - 12:30 PM	Hall A1	Wrkshp.
266		2:00 PM	Auditorium 10	Oral
267		2:15 PM	Auditorium 10	Oral
268		2:30 PM	Auditorium 10	Oral
269		2:45 PM	Auditorium 10	Oral
270		3:00 PM	Auditorium 10	Oral
271		3:15 PM	Auditorium 10	Oral
622		2:00 PM	Auditorium 11	Oral
273		2:15 PM	Auditorium 11	Oral
274		2:30 PM	Auditorium 11	Oral
275		2:45 PM	Auditorium 11	Oral
276		3:00 PM	Auditorium 11	Oral
277		3:15 PM	Auditorium 11	Oral
278		2:00 PM	Auditorium 12	Oral
279		3:15 PM	Auditorium 12	Oral
280		2:30 PM	Auditorium 12	Oral
281		2:45 PM	Auditorium 12	Oral
282		3:00 PM	Auditorium 12	Oral
283		2:15 PM	Auditorium 12	Oral
284		2:00 PM	Room 18/19	Oral
285		2:15 PM	Room 18/19	Oral
637		2:30 PM	Room 18/19	Oral
287		2:45 PM	Room 18/19	Oral

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
------------	----------	-------------------	------	--------

TUESDAY, AUGUST 19 (CONTINUED)

288		3:00 PM	Room 18/19	Oral
289		3:15 PM	Room 18/19	Oral
290		2:15 PM	Room 20	Oral
291		2:00 PM	Room 20	Oral
292		2:30 PM	Room 20	Oral
293		2:45 PM	Room 20	Oral
294		3:00 PM	Room 20	Oral
295		3:15 PM	Room 20	Oral
296		4:00 PM - 5:30 PM	Auditorium 10	Sympos.
297		4:00 PM - 5:30 PM	Auditorium 11	Sympos.
298		4:00 PM - 5:30 PM	Auditorium 12	Wrkshp.
299		4:00 PM - 5:30 PM	Room 18/19	Sympos.
300		4:00 PM - 5:30 PM	Room 20	Sympos.

Poster Session B

Analysis Methods

301	1	8:00 AM - 6:00 PM	Hall A1	Poster
302	2	8:00 AM - 6:00 PM	Hall A1	Poster
303	3	8:00 AM - 6:00 PM	Hall A1	Poster
304	4	8:00 AM - 6:00 PM	Hall A1	Poster
305	5	8:00 AM - 6:00 PM	Hall A1	Poster
306	6	8:00 AM - 6:00 PM	Hall A1	Poster
307	7	8:00 AM - 6:00 PM	Hall A1	Poster
308	8	8:00 AM - 6:00 PM	Hall A1	Poster
309	9	8:00 AM - 6:00 PM	Hall A1	Poster
310	10	8:00 AM - 6:00 PM	Hall A1	Poster
311	11	8:00 AM - 6:00 PM	Hall A1	Poster
312	12	8:00 AM - 6:00 PM	Hall A1	Poster
313	13	8:00 AM - 6:00 PM	Hall A1	Poster
314	14	8:00 AM - 6:00 PM	Hall A1	Poster
315	15	Abstract Withdrawn by Author		
316	16	8:00 AM - 6:00 PM	Hall A1	Poster
317	17	8:00 AM - 6:00 PM	Hall A1	Poster

Endocrine / Diabetes

318	18	8:00 AM - 6:00 PM	Hall A1	Poster
319	19	8:00 AM - 6:00 PM	Hall A1	Poster
320	20	8:00 AM - 6:00 PM	Hall A1	Poster
321	21	8:00 AM - 6:00 PM	Hall A1	Poster
322	22	8:00 AM - 6:00 PM	Hall A1	Poster
323	23	8:00 AM - 6:00 PM	Hall A1	Poster
324	24	8:00 AM - 6:00 PM	Hall A1	Poster
325	25	8:00 AM - 6:00 PM	Hall A1	Poster
326	26	8:00 AM - 6:00 PM	Hall A1	Poster
327	27	8:00 AM - 6:00 PM	Hall A1	Poster
328	28	8:00 AM - 6:00 PM	Hall A1	Poster
329	29	8:00 AM - 6:00 PM	Hall A1	Poster
330	30	8:00 AM - 6:00 PM	Hall A1	Poster
331	31	8:00 AM - 6:00 PM	Hall A1	Poster
332	32	8:00 AM - 6:00 PM	Hall A1	Poster
333	33	8:00 AM - 6:00 PM	Hall A1	Poster
334	34	8:00 AM - 6:00 PM	Hall A1	Poster

Abstract #	Poster #	Presentation Time	Room	Format
------------	----------	-------------------	------	--------

TUESDAY, AUGUST 19 (CONTINUED)

Error Prevention/Patient Safety

335	35	8:00 AM - 6:00 PM	Hall A1	Poster
336	36	8:00 AM - 6:00 PM	Hall A1	Poster
337	37	8:00 AM - 6:00 PM	Hall A1	Poster
338	38	8:00 AM - 6:00 PM	Hall A1	Poster
339	39	8:00 AM - 6:00 PM	Hall A1	Poster
340	40	8:00 AM - 6:00 PM	Hall A1	Poster

Gastrointestinal Drugs

341	41	8:00 AM - 6:00 PM	Hall A1	Poster
342	42	8:00 AM - 6:00 PM	Hall A1	Poster
343	43	8:00 AM - 6:00 PM	Hall A1	Poster
344	44	8:00 AM - 6:00 PM	Hall A1	Poster
345	45	8:00 AM - 6:00 PM	Hall A1	Poster

Hematological

346	46	8:00 AM - 6:00 PM	Hall A1	Poster
347	47	8:00 AM - 6:00 PM	Hall A1	Poster
348	48	8:00 AM - 6:00 PM	Hall A1	Poster
349	49	8:00 AM - 6:00 PM	Hall A1	Poster
350	50	8:00 AM - 6:00 PM	Hall A1	Poster
351	51	8:00 AM - 6:00 PM	Hall A1	Poster
371	52	8:00 AM - 6:00 PM	Hall A1	Poster

Medications in Pregnancy (SIG)

352	53	8:00 AM - 6:00 PM	Hall A1	Poster
353	54	8:00 AM - 6:00 PM	Hall A1	Poster
354	55	8:00 AM - 6:00 PM	Hall A1	Poster
355	56	8:00 AM - 6:00 PM	Hall A1	Poster
356	57	8:00 AM - 6:00 PM	Hall A1	Poster
357	58	8:00 AM - 6:00 PM	Hall A1	Poster
358	59	8:00 AM - 6:00 PM	Hall A1	Poster
359	60	8:00 AM - 6:00 PM	Hall A1	Poster
360	61	8:00 AM - 6:00 PM	Hall A1	Poster
361	62	8:00 AM - 6:00 PM	Hall A1	Poster
362	63	8:00 AM - 6:00 PM	Hall A1	Poster
363	64	8:00 AM - 6:00 PM	Hall A1	Poster
364	65	8:00 AM - 6:00 PM	Hall A1	Poster
365	66	8:00 AM - 6:00 PM	Hall A1	Poster
366	67	8:00 AM - 6:00 PM	Hall A1	Poster
367	68	8:00 AM - 6:00 PM	Hall A1	Poster
368	69	8:00 AM - 6:00 PM	Hall A1	Poster
369	70	8:00 AM - 6:00 PM	Hall A1	Poster
370	71	8:00 AM - 6:00 PM	Hall A1	Poster

Pharmacovigilance

372	72	8:00 AM - 6:00 PM	Hall A1	Poster
373	73	8:00 AM - 6:00 PM	Hall A1	Poster
374	74	8:00 AM - 6:00 PM	Hall A1	Poster
375	75	8:00 AM - 6:00 PM	Hall A1	Poster
376	76	8:00 AM - 6:00 PM	Hall A1	Poster
377	77	8:00 AM - 6:00 PM	Hall A1	Poster
378	78	8:00 AM - 6:00 PM	Hall A1	Poster
379	79	8:00 AM - 6:00 PM	Hall A1	Poster

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
TUESDAY, AUGUST 19 (CONTINUED)				
380	80	8:00 AM - 6:00 PM	Hall A1	Poster
381	81	8:00 AM - 6:00 PM	Hall A1	Poster
382	82	8:00 AM - 6:00 PM	Hall A1	Poster
383	83	<i>Abstract Withdrawn by Author</i>		
384	84	8:00 AM - 6:00 PM	Hall A1	Poster
385	85	8:00 AM - 6:00 PM	Hall A1	Poster
386	86	8:00 AM - 6:00 PM	Hall A1	Poster
387	87	8:00 AM - 6:00 PM	Hall A1	Poster
388	88	8:00 AM - 6:00 PM	Hall A1	Poster
389	89	8:00 AM - 6:00 PM	Hall A1	Poster
390	90	8:00 AM - 6:00 PM	Hall A1	Poster
391	91	8:00 AM - 6:00 PM	Hall A1	Poster
392	92	8:00 AM - 6:00 PM	Hall A1	Poster
393	93	8:00 AM - 6:00 PM	Hall A1	Poster
394	94	8:00 AM - 6:00 PM	Hall A1	Poster
395	95	8:00 AM - 6:00 PM	Hall A1	Poster
396	96	8:00 AM - 6:00 PM	Hall A1	Poster
397	97	8:00 AM - 6:00 PM	Hall A1	Poster
398	98	<i>Abstract Withdrawn by Author</i>		
399	99	8:00 AM - 6:00 PM	Hall A1	Poster
400	100	8:00 AM - 6:00 PM	Hall A1	Poster
401	101	8:00 AM - 6:00 PM	Hall A1	Poster
402	102	8:00 AM - 6:00 PM	Hall A1	Poster
403	103	8:00 AM - 6:00 PM	Hall A1	Poster
404	104	8:00 AM - 6:00 PM	Hall A1	Poster
405	105	8:00 AM - 6:00 PM	Hall A1	Poster
406	106	8:00 AM - 6:00 PM	Hall A1	Poster
407	107	8:00 AM - 6:00 PM	Hall A1	Poster
408	108	8:00 AM - 6:00 PM	Hall A1	Poster
409	109	8:00 AM - 6:00 PM	Hall A1	Poster
410	110	8:00 AM - 6:00 PM	Hall A1	Poster
411	111	8:00 AM - 6:00 PM	Hall A1	Poster
412	112	8:00 AM - 6:00 PM	Hall A1	Poster
413	113	8:00 AM - 6:00 PM	Hall A1	Poster
414	114	8:00 AM - 6:00 PM	Hall A1	Poster
415	115	8:00 AM - 6:00 PM	Hall A1	Poster
416	116	8:00 AM - 6:00 PM	Hall A1	Poster
Pulmonary/ Respiratory				
417	117	8:00 AM - 6:00 PM	Hall A1	Poster
418	118	8:00 AM - 6:00 PM	Hall A1	Poster
419	119	8:00 AM - 6:00 PM	Hall A1	Poster
420	120	8:00 AM - 6:00 PM	Hall A1	Poster
421	121	8:00 AM - 6:00 PM	Hall A1	Poster
422	122	8:00 AM - 6:00 PM	Hall A1	Poster
423	123	8:00 AM - 6:00 PM	Hall A1	Poster
424	124	8:00 AM - 6:00 PM	Hall A1	Poster
425	125	8:00 AM - 6:00 PM	Hall A1	Poster
426	126	8:00 AM - 6:00 PM	Hall A1	Poster
Risk Management/Communication				
427	127	8:00 AM - 6:00 PM	Hall A1	Poster
428	128	8:00 AM - 6:00 PM	Hall A1	Poster
429	129	8:00 AM - 6:00 PM	Hall A1	Poster

Abstract #	Poster #	Presentation Time	Room	Format
TUESDAY, AUGUST 19 (CONTINUED)				
430	130	8:00 AM - 6:00 PM	Hall A1	Poster
431	131	8:00 AM - 6:00 PM	Hall A1	Poster
432	132	8:00 AM - 6:00 PM	Hall A1	Poster
433	133	8:00 AM - 6:00 PM	Hall A1	Poster
434	134	8:00 AM - 6:00 PM	Hall A1	Poster
Observational Effectiveness Studies				
435	135	8:00 AM - 6:00 PM	Hall A1	Poster
436	136	8:00 AM - 6:00 PM	Hall A1	Poster
437	137	8:00 AM - 6:00 PM	Hall A1	Poster
438	138	8:00 AM - 6:00 PM	Hall A1	Poster
439	139	8:00 AM - 6:00 PM	Hall A1	Poster
440	140	8:00 AM - 6:00 PM	Hall A1	Poster
Sustainable Access to Medicines				
441	141	8:00 AM - 6:00 PM	Hall A1	Poster
Vaccines				
442	142	8:00 AM - 6:00 PM	Hall A1	Poster
443	143	8:00 AM - 6:00 PM	Hall A1	Poster
444	144	8:00 AM - 6:00 PM	Hall A1	Poster
445	145	8:00 AM - 6:00 PM	Hall A1	Poster
446	146	8:00 AM - 6:00 PM	Hall A1	Poster
447	147	8:00 AM - 6:00 PM	Hall A1	Poster
448	148	8:00 AM - 6:00 PM	Hall A1	Poster
WEDNESDAY, AUGUST 20				
449		8:30 AM	Auditorium 10	Oral
450		8:45 AM	Auditorium 10	Oral
451		9:00 AM	Auditorium 10	Oral
452		9:15 AM	Auditorium 10	Oral
453		9:30 AM	Auditorium 10	Oral
454		9:45 AM	Auditorium 10	Oral
455		8:30 AM	Auditorium 11	Oral
456		8:45 AM	Auditorium 11	Oral
457		9:00 AM	Auditorium 11	Oral
458		9:15 AM	Auditorium 11	Oral
459		9:30 AM	Auditorium 11	Oral
460		9:45 AM	Auditorium 11	Oral
461		8:30 AM	Auditorium 12	Oral
462		8:45 AM	Auditorium 12	Oral
463		9:00 AM	Auditorium 12	Oral
464		9:15 AM	Auditorium 12	Oral
465		9:30 AM	Auditorium 12	Oral
466		9:45 AM	Auditorium 12	Oral
467		8:30 AM	Room 18/19	Oral
468		8:45 AM	Room 18/19	Oral
469		9:00 AM	Room 18/19	Oral
470		9:15 AM	Room 18/19	Oral
471		9:30 AM	Room 18/19	Oral
472		9:45 AM	Room 18/19	Oral
624		8:30 AM	Room 20	Oral
474		8:45 AM	Room 20	Oral
475		9:00 AM	Room 20	Oral

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
WEDNESDAY, AUGUST 20 (CONTINUED)				
476		9:15 AM	Room 20	Oral
477		9:30 AM	Room 20	Oral
478		9:45 AM	Room 20	Oral
479		10:30 AM - NOON	Auditorium 10	Sympos.
480		10:30 AM - NOON	Auditorium 11	Wrkshp.
481		10:30 AM - NOON	Auditorium 12	Wrkshp.
482		10:30 AM - NOON	Room 18/19	Sympos.
483		10:30 AM - NOON	Room 20	Sympos.
484		2:30 PM - 4:00 PM	Auditorium 10-12	Plenary

Poster Session C

Analgesics/Anti-inflammatory Agents

485	1	8:00 AM - 1:45 PM	Hall A1	Poster
486	2	8:00 AM - 1:45 PM	Hall A1	Poster
487	3	8:00 AM - 1:45 PM	Hall A1	Poster
488	4	8:00 AM - 1:45 PM	Hall A1	Poster
489	5	8:00 AM - 1:45 PM	Hall A1	Poster
490	6	8:00 AM - 1:45 PM	Hall A1	Poster
491	7	8:00 AM - 1:45 PM	Hall A1	Poster
492	8	8:00 AM - 1:45 PM	Hall A1	Poster
493	9	8:00 AM - 1:45 PM	Hall A1	Poster
494	10	8:00 AM - 1:45 PM	Hall A1	Poster
495	11	8:00 AM - 1:45 PM	Hall A1	Poster
496	12	8:00 AM - 1:45 PM	Hall A1	Poster
497	13	8:00 AM - 1:45 PM	Hall A1	Poster
498	14	8:00 AM - 1:45 PM	Hall A1	Poster
499	15	8:00 AM - 1:45 PM	Hall A1	Poster
500	16	8:00 AM - 1:45 PM	Hall A1	Poster
501	17	8:00 AM - 1:45 PM	Hall A1	Poster
502	18	8:00 AM - 1:45 PM	Hall A1	Poster
503	19	8:00 AM - 1:45 PM	Hall A1	Poster
504	20	8:00 AM - 1:45 PM	Hall A1	Poster
505	21	8:00 AM - 1:45 PM	Hall A1	Poster

Anti-Infectives

506	22	8:00 AM - 1:45 PM	Hall A1	Poster
507	23	8:00 AM - 1:45 PM	Hall A1	Poster
508	24	8:00 AM - 1:45 PM	Hall A1	Poster
509	25	8:00 AM - 1:45 PM	Hall A1	Poster
510	26	8:00 AM - 1:45 PM	Hall A1	Poster
511	27	8:00 AM - 1:45 PM	Hall A1	Poster
512	28	8:00 AM - 1:45 PM	Hall A1	Poster
513	29	8:00 AM - 1:45 PM	Hall A1	Poster
514	30	8:00 AM - 1:45 PM	Hall A1	Poster

Birth Defects

515	31	8:00 AM - 1:45 PM	Hall A1	Poster
516	32	8:00 AM - 1:45 PM	Hall A1	Poster
517	33	8:00 AM - 1:45 PM	Hall A1	Poster
518	34	8:00 AM - 1:45 PM	Hall A1	Poster
519	34	8:00 AM - 1:45 PM	Hall A1	Poster
520	36	8:00 AM - 1:45 PM	Hall A1	Poster
521	37	8:00 AM - 1:45 PM	Hall A1	Poster
522	38	8:00 AM - 1:45 PM	Hall A1	Poster

Abstract #	Poster #	Presentation Time	Room	Format
WEDNESDAY, AUGUST 20 (CONTINUED)				
Cardiovascular Drugs				
523	39	8:00 AM - 1:45 PM	Hall A1	Poster
524	40	8:00 AM - 1:45 PM	Hall A1	Poster
525	41	8:00 AM - 1:45 PM	Hall A1	Poster
526	42	8:00 AM - 1:45 PM	Hall A1	Poster
527	43	8:00 AM - 1:45 PM	Hall A1	Poster
528	44	8:00 AM - 1:45 PM	Hall A1	Poster
529	45	8:00 AM - 1:45 PM	Hall A1	Poster
530	46	8:00 AM - 1:45 PM	Hall A1	Poster
531	47	8:00 AM - 1:45 PM	Hall A1	Poster
532	48	8:00 AM - 1:45 PM	Hall A1	Poster
533	49	8:00 AM - 1:45 PM	Hall A1	Poster
534	50	8:00 AM - 1:45 PM	Hall A1	Poster
535	51	8:00 AM - 1:45 PM	Hall A1	Poster
536	52	8:00 AM - 1:45 PM	Hall A1	Poster
537	53	8:00 AM - 1:45 PM	Hall A1	Poster
538	54	8:00 AM - 1:45 PM	Hall A1	Poster
539	55	8:00 AM - 1:45 PM	Hall A1	Poster
540	56	8:00 AM - 1:45 PM	Hall A1	Poster
541	57	8:00 AM - 1:45 PM	Hall A1	Poster
542	58	8:00 AM - 1:45 PM	Hall A1	Poster
543	59	8:00 AM - 1:45 PM	Hall A1	Poster
544	60	8:00 AM - 1:45 PM	Hall A1	Poster
545	61	8:00 AM - 1:45 PM	Hall A1	Poster
546	62	8:00 AM - 1:45 PM	Hall A1	Poster
547	63	8:00 AM - 1:45 PM	Hall A1	Poster
548	64	8:00 AM - 1:45 PM	Hall A1	Poster
549	65	<i>Abstract Withdrawn by Author</i>		
550	66	8:00 AM - 1:45 PM	Hall A1	Poster
551	67	8:00 AM - 1:45 PM	Hall A1	Poster

Database (SIG)

552	68	8:00 AM - 1:45 PM	Hall A1	Poster
553	69	8:00 AM - 1:45 PM	Hall A1	Poster
554	70	8:00 AM - 1:45 PM	Hall A1	Poster
555	71	8:00 AM - 1:45 PM	Hall A1	Poster
556	72	8:00 AM - 1:45 PM	Hall A1	Poster
557	73	8:00 AM - 1:45 PM	Hall A1	Poster
558	74	8:00 AM - 1:45 PM	Hall A1	Poster
559	75	8:00 AM - 1:45 PM	Hall A1	Poster
560	76	8:00 AM - 1:45 PM	Hall A1	Poster
561	77	8:00 AM - 1:45 PM	Hall A1	Poster
562	78	8:00 AM - 1:45 PM	Hall A1	Poster
563	79	8:00 AM - 1:45 PM	Hall A1	Poster
564	80	8:00 AM - 1:45 PM	Hall A1	Poster
565	81	8:00 AM - 1:45 PM	Hall A1	Poster
566	82	8:00 AM - 1:45 PM	Hall A1	Poster
567	83	8:00 AM - 1:45 PM	Hall A1	Poster
568	84	8:00 AM - 1:45 PM	Hall A1	Poster
569	85	8:00 AM - 1:45 PM	Hall A1	Poster
570	86	8:00 AM - 1:45 PM	Hall A1	Poster
571	87	8:00 AM - 1:45 PM	Hall A1	Poster
572	88	8:00 AM - 1:45 PM	Hall A1	Poster

ABSTRACT INDEX • FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
WEDNESDAY, AUGUST 20 (CONTINUED)				
Devices				
573	89	8:00 AM - 1:45 PM	Hall A1	Poster
Disease Epidemiology / Burden of Illness				
574	90	8:00 AM - 1:45 PM	Hall A1	Poster
575	91	8:00 AM - 1:45 PM	Hall A1	Poster
576	92	8:00 AM - 1:45 PM	Hall A1	Poster
577	93	8:00 AM - 1:45 PM	Hall A1	Poster
578	94	8:00 AM - 1:45 PM	Hall A1	Poster
579	95	8:00 AM - 1:45 PM	Hall A1	Poster
580	96	8:00 AM - 1:45 PM	Hall A1	Poster
581	97	8:00 AM - 1:45 PM	Hall A1	Poster
582	98	8:00 AM - 1:45 PM	Hall A1	Poster
583	99	8:00 AM - 1:45 PM	Hall A1	Poster
584	100	8:00 AM - 1:45 PM	Hall A1	Poster
585	101	8:00 AM - 1:45 PM	Hall A1	Poster
586	102	8:00 AM - 1:45 PM	Hall A1	Poster
587	103	8:00 AM - 1:45 PM	Hall A1	Poster
588	104	8:00 AM - 1:45 PM	Hall A1	Poster
589	105	8:00 AM - 1:45 PM	Hall A1	Poster
590	106	8:00 AM - 1:45 PM	Hall A1	Poster
591	107	8:00 AM - 1:45 PM	Hall A1	Poster
592	108	8:00 AM - 1:45 PM	Hall A1	Poster
Hormones/ Reproductive Agents				
593	109	8:00 AM - 1:45 PM	Hall A1	Poster
594	110	8:00 AM - 1:45 PM	Hall A1	Poster
595	111	8:00 AM - 1:45 PM	Hall A1	Poster
596	112	8:00 AM - 1:45 PM	Hall A1	Poster
597	113	8:00 AM - 1:45 PM	Hall A1	Poster
Molecular Epidemiology/Pharmacogenetics (SIG)				
598	114	8:00 AM - 1:45 PM	Hall A1	Poster
599	115	8:00 AM - 1:45 PM	Hall A1	Poster
600	116	8:00 AM - 1:45 PM	Hall A1	Poster
601	117	8:00 AM - 1:45 PM	Hall A1	Poster
602	118	8:00 AM - 1:45 PM	Hall A1	Poster
603	119	8:00 AM - 1:45 PM	Hall A1	Poster
Pediatric Pharmacoepidemiology				
604	120	8:00 AM - 1:45 PM	Hall A1	Poster
605	121	8:00 AM - 1:45 PM	Hall A1	Poster
606	122	8:00 AM - 1:45 PM	Hall A1	Poster
607	123	8:00 AM - 1:45 PM	Hall A1	Poster
608	124	8:00 AM - 1:45 PM	Hall A1	Poster
609	125	8:00 AM - 1:45 PM	Hall A1	Poster
Regulatory Issues/Drug Policy				
610	126	8:00 AM - 1:45 PM	Hall A1	Poster
611	127	8:00 AM - 1:45 PM	Hall A1	Poster
612	128	8:00 AM - 1:45 PM	Hall A1	Poster
613	129	8:00 AM - 1:45 PM	Hall A1	Poster
614	130	<i>Abstract Withdrawn by Author</i>		

Abstract #	Poster #	Presentation Time	Room	Format
WEDNESDAY, AUGUST 20 (CONTINUED)				
State of Art in Drug Utilization				
615	131	8:00 AM - 1:45 PM	Hall A1	Poster
616	132	8:00 AM - 1:45 PM	Hall A1	Poster
Womens Health				
617	133	8:00 AM - 1:45 PM	Hall A1	Poster
618	134	8:00 AM - 1:45 PM	Hall A1	Poster
619	135	8:00 AM - 1:45 PM	Hall A1	Poster
Miscellaneous				
620	136	8:00 AM - 1:45 PM	Hall A1	Poster
621	137	8:00 AM - 1:45 PM	Hall A1	Poster
272	138	8:00 AM - 1:45 PM	Hall A1	Poster
623	139	8:00 AM - 1:45 PM	Hall A1	Poster
625	140	8:00 AM - 1:45 PM	Hall A1	Poster
626	141	8:00 AM - 1:45 PM	Hall A1	Poster
627	142	8:00 AM - 1:45 PM	Hall A1	Poster
628	143	8:00 AM - 1:45 PM	Hall A1	Poster
629	144	8:00 AM - 1:45 PM	Hall A1	Poster
630	145	8:00 AM - 1:45 PM	Hall A1	Poster
631	146	8:00 AM - 1:45 PM	Hall A1	Poster
632	147	8:00 AM - 1:45 PM	Hall A1	Poster
633	148	8:00 AM - 1:45 PM	Hall A1	Poster
634	149	8:00 AM - 1:45 PM	Hall A1	Poster
635	150	8:00 AM - 1:45 PM	Hall A1	Poster
636	151	8:00 AM - 1:45 PM	Hall A1	Poster

ADVERTISERS INDEX

page #

Amgen.....	26
Degge Group.....	17
DrugLogic.....	22
Genetech.....	14
GSK.....	19
HealthCore.....	43
i3.....	27
Lilly.....	13
Mattson Jack.....	49
Merck.....	39
P & G.....	53
Pfizer.....	11
PPD.....	61
ProSanos/Phimap.....	44
Roche.....	55
RTI Health Solutions.....	59
UBC.....	35
Wiley.....	29
Wyeth.....	9

MEETING NOTES

A large rectangular area with a blue border, containing horizontal dashed lines for writing notes. The right side of this area is partially obscured by a decorative graphic of overlapping light blue circles.

MEETING NOTES

A large rectangular area with a blue border containing horizontal dashed lines for writing notes. The right side of the area is partially obscured by a light blue decorative graphic of overlapping circles.

ISPE TRAINING COURSES AT YOUR LOCATION

INTRODUCTION TO PHARMACOEPIDEMIOLOGY & DRUG SAFETY

An intensive, interactive, one-day workshop on common methodologies & techniques used in pharmacoepidemiological research.

Course description: Specifically designed for persons who are new to pharmacoepidemiology, therapeutic risk management and drug safety. A proven, practical introduction to this important discipline. Participants will work in teams on case studies and will present the results to other participants.

Who should attend: Anyone new to the field that is involved with the interpretation, critical appraisal and dissemination of pharmacoepidemiological studies and research findings. Work settings include pharmaceutical companies, government, academia, contract research organizations, legal firms, and media/public relations firms.

INTRODUCTION TO THERAPEUTIC RISK MANAGEMENT

Planning and evaluating the effectiveness of risk management programs.

Course description: The course is designed to meet the following objectives:

- Provide an overview of therapeutic risk management tailored to professionals in pharmacoepidemiology, pharmacovigilance, regulatory, and risk communication;
- Present requirements of risk management plans, with emphasis on systematic assessments of risk and the effectiveness of risk minimization interventions;
- Demonstrate methods of program evaluation, including Failure Mode and Effect Analysis;
- Afford an opportunity to explore risk management planning in more depth through a problem-solving workshop tailored to meet the needs of the on-site organization.

Who should attend: Anyone working in the fields of pharmacoepidemiology, pharmacovigilance, drug utilization review, regulatory affairs, outcomes research and risk communication and who are likely to be involved in products under special scrutiny due to safety concerns. Work settings include pharmaceutical companies, government, academia, contract research organizations, legal firms, and media/public relations firms.

FACULTY

Courses are taught by senior-level pharmacoepidemiologists – most of whom are Fellows of the International Society of Pharmacoepidemiology (FISPE).

WHERE CAN THE COURSE BE OFFERED:

At a location of your choice — conference center, university, hotel, or corporate conference room. ISPE faculty are available to teach this course in North America, Europe and Asia/Pacific Rim.


For further information contact:

Mark Epstein, ScD
ISPE Executive Secretary
301-718-6500 or
ISPE@paimgmt.com

OVERVIEW



GROUND FLOOR



24th Annual International Conference On
Pharmacovigilance & Therapeutic
Risk Management

ICPE 2008

EXHIBITION / CATERING

HALL A

SESSIONS

Auditorium 10-11-12

CONFERENCE ROOMS

- Meeting Room 5
- Meeting Room 6
- Meeting Room 7
- Meeting Room 16
- Meeting Room 17
- Meeting Room 18a
- Meeting Room 18b
- Meeting Room 18
- Meeting Room 19
- Meeting Room 20
- Meeting Room 21
- Meeting Room 23
- Meeting Room BV3
- Meeting Room BV4/BV5

